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T cell-based immunotherapies for melanoma have limited success so far. 
Complete clinical responses are rarely observed. T cell recruitment to tumors 
is one of the potential rate-limiting steps in effective anti-tumor response in 
melanoma therapies. Therefore, the aim of the present study is to identify the 
molecular cues that control T cell infiltration into cutaneous melanoma and to 
find treatments promoting T cell infiltration. For this purpose, we used the 
RETAAD model of spontaneous melanoma and samples from melanoma 
patients treated with chemotherapy. 
 
In the first part of the chemokine project, we show that the lack of T cell 
control of cutaneous melanoma in the RETAAD model of spontaneous 
melanoma is due to limited T cell infiltration into the tumors. This lack of T cell 
infiltration is not due to intrinsic defects in T cell migration to cutaneous sites. 
Rather, it is the result of lack of expression of T cell attracting chemokines 
within the local tumor microenvironment. We found that CXCR3 ligands 
(CXCL9 and CXCL10) and CCL5 synergize to attract T cells to cutaneous 
melanoma, and expression of these chemokines inhibits tumor growth. Most 
RETAAD skin tumors fail to express these chemokines and therefore escape 
T cell control. 
 
In the second part of the chemokine project, we demonstrate that the 
chemotherapeutic drugs (dacarbazine, temozolomide, and cisplatin) induce 
specific expression of T cell-attracting chemokines (including CXCL9, 
 IX 
CXCL10 and CCL5) in several human melanoma cell lines in vitro. This 
increase in chemokine expression is dose- and time-dependent, indicating a 
direct effect of chemotherapy drugs on chemokine expression. Using global 
transcriptome analysis, we analyze cutaneous metastases resected from 
melanoma patients before and after chemotherapy, and detect increased T 
cell infiltration into chemotherapy-sensitive tumors. Response to 
chemotherapy correlates with up-regulation of the same chemokines. 
Furthermore, patients exhibiting enhanced chemokine expression after 
chemotherapy survive longer.  
 
Collectively, our findings unravel a novel cell-extrinsic mechanism of action of 
common chemotherapy drugs by showing that chemotherapy works, in part, 
through the induction of chemokine expression in cancer cells and 
subsequent recruitment of effector T cells into the tumors. These findings may 
serve as a basis for new therapeutic strategies for the treatment of melanoma 
by identifying subgroups of patients with an increased chance of response to 
conventional chemotherapies. Furthermore, it suggests that screening for 
chemotherapy drugs that are able to induce the expression of T cell-attracting 
chemokines may improve conventional as well as immune-based therapies of 
cancer. 
 
To further validate our findings in future investigations, we have generated a 
new reporter mouse melanoma model (Melucie) that enables visualization of 
spontaneous tumor development by in vivo bioluminescence imaging (BLI). In 
vivo BLI was able to detect bioluminescent primary tumor and metastases, 
 X 
which were confirmed by ex vivo imaging and histology analysis. The Melucie 
model demonstrates a remarkable correlation between BLI signals and tumor 
weight, high sensitivity and positive predictive value, and enables longitudinal 
monitoring of disease progression in vivo. Taken together, this model will 
facilitate testing of future chemo-immunotherapeutic strategies against 
melanoma. 
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1.1.1 Melanoma incidence and etiological factors 
Metastatic melanoma is one of the deadliest types of skin cancer. Globally, 
there is an estimated 132,000 cases a year (World Health Organization), and 
it accounts for most skin cancer deaths. It is the sixth most common cancer 
type in men and the seventh in woman, with a median survival of 6-10 months 
and a 5-year survival rate of about 10% (Cummins et al., 2006). Genetic 
susceptibility and exposure to ultraviolet radiation are thought to be the two 
most important risk factors for the development of malignant melanoma 
(Brozena et al., 1993). Comprehensive strategies such as comparative 
genomic hybridization and mutation analysis by gene sequencing have 
identified several genetic alterations in metastatic melanoma. This includes 
genetic alterations in oncogenes (BRAF, C-KIT, NRAS, AKT3), tumor 
suppressor genes (CDKN2A, PTEN, APAF-1, and P53), cell cycle genes 
(CCND1), and transcription factors (MITF)i (Gajewski, 2011; Gray-Schopfer et 
al., 2007). 
 
1.1.2 Melanoma progression and the subtypes of cutaneous melanoma 
Melanoma arise from aberrant melanocytes, and mutations in critical growth 
regulatory genes, the production of autocrine growth factors and the loss of 
                                            
i
 BRAF – v-raf murine sarcoma viral oncogene homolog B1; C-KIT – v-kit Hardy-Zuckerman 4 
feline sarcoma viral oncogene homolog; NRAS – neuroblastoma RAS viral (v-ras) oncogene 
homolog; AKT3 – v-akt murine thymoma viral oncogene homolog 3 (protein kinase B, 
gamma); CDKN2A – cyclin-dependent kinase inhibitor 2A; PTEN – phosphatase and tensin 
homolog; APAF1 –  apoptotic peptidase activating factor 1; CCDN1 – cyclin D1; MITF – 
microphthalmia-associated transcription factor. 
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adhesion receptors have all been shown to contribute to disrupted intracellular 
signalling in melanocytes. This can result in the proliferation and spreading of 
melanocytes, thus, leading to the formation of a naevus or common mole. 
Melanocyte proliferation can be restricted to the epidermis (junctional naevus), 
the dermis (dermal naevus), or both (compound nevus). In general, naevi are 
benign but can progress to the radial-growth-phase (RGF) with some local 
invasion of the dermis, and subsequently, to the vertial-growth-phase (VGP) 
where invasion of the dermis and metastasis could occur. Not all melanomas 
will go through these sequential steps of progression – RGP or VGP can 
develop directly from benign melanocytes or naevi and can progress directly 



















Figure 1.1.1 – Progression of melanocyte transformation into melanoma. 
(A) In normal skin, normal melanocytes are evenly distributed within the basal layer 
of the epidermis. (B) Benign neavi can result from increased proliferation and 
spreading of aberrant melanocytes, and can be junctional, dermal or compound. 
Some neavi are dysplastic, characterized by morphologically atypical melanocytes. 
(C) Radial-growth-phase (RGP) is considered as the primary malignant stage. (D) 
Vertical-growth-phase (VGP) can lead directly to metastatic malignant melanoma. It 
is the most deadly stage, marked with infiltration of blood and lymphatic vessles. 
Pagetoid refers to upward spreading of melanocytes into the epidermis and is a 
histological characteristic of melanoma [adapted from (Gray-Schopfer et al., 2007)]. 
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There are four main clinical subtypes of melanoma: nodular melanoma (raised 
nodules without flat portions), acral lentiginous melanoma or ALM (commonly 
found on the palms, soles and nail bed, not associated with sun exposure), 
lentigo maligna (generally flat in appearance, associated with chronic sun 
exposure especially in elderly), and superficial spreading melanoma or SSM 
(usually flat with an intra-epidermal component, the most common form of 
melanoma in young people in the UK and USA) (Gray-Schopfer et al., 2007; 
Johansson et al., 2009). 
 
1.1.3 Melanoma diagnosis and treatment 
Diagnosis of melanoma has been based on pathology, but interestingly, 
Bastian and colleagues have demonstrated that genome wide alterations in 
DNA copy number together with individual somatic mutations have 70% 
accuracy in distinguishing the different subtypes of melanoma (Curtin et al., 
2005).  
 
Surgical excision is the mainstay therapy for early-stage melanoma. Non-
surgical modalities used in the treatment of advanced disease include 
cytotoxic chemotherapy, immunotherapy, a combination approach such as 
biochemotherapy, and novel investigational therapies (Gray-Schopfer et al., 
2007; Kadison and Morton, 2003; Keilholz and Gore, 2002; Kirkwood et al., 
2008; Rosenberg and Dudley, 2009; Sundaresan et al., 2009). To-date, there 
are three US FDA (Food and Drug Administration)-approved drugs available 
for the treatment of advanced metastatic melanoma. The first is the 
chemotherapy drug dacarbazine (DTIC, approved in 1976), the second is the 
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immune-modulatory cytokine interleukin-2 (IL-2, approved in 1998), and the 
third is the cytotoxic T lymphocyte antigen-4 (CTLA-4) blocker (Ipilimumab, 
approved in 2011).  
 
Dacarbazine (DTIC) is considered to be the most active drug for the treatment 
of metastatic melanoma, with a response rate of 20%, and a median duration 
of response of 4 to 5 months (Khayat et al., 2002; Nathan and Mastrangelo, 
1998). Other cytotoxic compounds, such as temozolomide (a DTIC analogue) 
(Middleton et al., 2000), cisplatin and carboplatin (Bajetta et al., 2002), vinca 
alkaloids (Khayat et al., 2002), taxanes (Bafaloukos et al., 2002) and 
nitrosoureas (Cure et al., 1999) are associated with response rates of less 
than 15% with significant adverse effects reported.  
 
Post-operative adjuvant therapies for malignant melanoma such as high dose 
IL-2 (a cytokine that stimulates T cell proliferation and function) demonstrated 
modest anti-tumor activity in clinical trials of metastatic melanoma patients. 
Responses were observed in approximately 15% of patients, with around 5% 
of patients achieving a durable complete response, and toxicity is a problem 
(Atkins et al., 1999; Dutcher et al., 1989; Rosenberg et al., 1989). Interferon-
alpha 2b (IFN-α2b) has also been approved by FDA, but only for the adjuvant 
treatment of stage IIb/III melanoma, and not for metastatic disease (Kirkwood 
et al., 2001). It is a type I IFN with pleiotropic functions in various 
malignancies, including immuno-modulatory, anti-proliferative, differentiation-
inducing, apoptotic, and anti-angiogenic properties (Kirkwood et al., 2008). 
High dose IFN-α2b demonstrated response rates of approximately 20% (as 
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single agent in a Phase II trial), with a slightly more durable response than 
DTIC (Dorval et al., 1986; Sertoli et al., 1989).  
 
Melanoma appears to be unique among human cancers due to its ability to 
induce anti-tumor lymphocytes during the natural course of tumor growth 
(Rosenberg and Dudley, 2009). Therefore, novel investigational 
immunotherapies for melanoma (both current and evolving), such as adoptive 
T cell transfer (ACT), cancer vaccines, bi-specific antibodies, and anti-
cytotoxic T lymphocyte antigen-4 (CTLA-4) antibody, are paving the way for 
exciting new areas for melanoma treatment (discussed in Section 1.3). 
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1.2 The role of the immune system in cancer 
The concept that the immune system may recognize and eliminate tumors is 
an established one. The long-standing theory of immunosurveillance, 
suggested by Thomas (Thomas, 1959) and Burnet, and developed by Burnet 
(Burnet, 1970), proposes that cells and tissues are constantly monitored by an 
ever-alert immune system, and that such immune surveillance is responsible 
for recognizing and eliminating the vast majority of incipient cancer cells and 
thus nascent tumors (Hanahan and Weinberg, 2011).  
 
Despite tumor immune surveillance, tumors can still develop in the presence 
of a functional immune system. Consequently, the theory of immune 
surveillance has gone through multiple phases of acceptance and discredit 
until a decade ago when an updated concept of tumor immunoediting was 
recognized as a more complete explanation for the role of the immune system 
in tumor development. According to this theory, the immune system not only 
suppresses tumor growth by eliminating cancer cells and preventing their 
outgrowth, but also interacts in a complex way with the tumor to shape its 
immune profile, resulting in cancer variants that escape immune control 
(Bourgault-Villada et al., 2011; Dunn et al., 2004; Schreiber et al., 2011; 
Smyth et al., 2006; Swann and Smyth, 2007). 
 
1.2.1 Natural killer cells and tumor immunosurveillance 
1.2.1.1 Natural killer cell subsets and effector mechanisms 
Natural killer (NK) cells, first identified in mice in 1975, are lymphocytes of the 
innate immune system that play important roles in the protection against viral 
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infections and the development of cancers (Biron, 1997; Trinchieri, 1989). In 
humans, NK cells constitute ~5-20% of peripheral blood lymphocytes and are 
mostly defined as CD3-CD56+ lymphocytes, which can be futher subdivided 
into two major subsets, namely CD56dimCD16+ and CD56brightCD16- 
populations (Waldhauer and Steinle, 2008). The CD56dim population exhibit 
high cytotoxic potential and broadly express MHC class I-specific inhibitory 
receptors, and these population is predominant in the blood (~95% of NK cells) 
and at sites of inflammation. On the other hand, the CD56bright population 
mainly produces cytokines upon activation. This NK population, considered to 
be the precursors of terminally differentiated CD56dim NK cells, is less 
cytotoxic and predominates in the lymph nodes (~75% of NK cells) 
(Waldhauer and Steinle, 2008). The CD56 molecule is absent in mouse NK 
cells and recent work has categorized mouse NK subsets according to the 
expression of CD27. Similar to CD56bright human NK cells, CD27high mouse NK 
cells produce large amounts of cytokines upon activation and are mostly 
found in the lymph nodes. However, in contrast to CD56bright human NK cells, 
the CD27high mouse NK cells are also potent cytolytic effectors (Waldhauer 
and Steinle, 2008). 
 
Various molecular mechanisms of NK cell cytotoxicity have been described. 
Firstly, activated NK cells can release cytotoxic granules containing perforin 
and granzymes, leading to target cells apoptosis. In addition to the 
perforin/granyzme pathway, interaction between tumor necrosis factor (TNF) 
receptor superfamily (TNFRSF) members, including Fas/CD95, TRAIL 
receptors, and TNFR1 on tumor cells with the corresponding ligands (FasL, 
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TRAIL and TNF) expressed or secreted by NK cells can lead to NK 
cytotoxicity under certain conditions. Furthermore, NK cells are also a potent 
source of a variety of cytokines and chemokines, including interferon-γ (IFN-γ), 
TNF, GM-CSF (granulocyte-macrophage colony stimulating factor), MIP-1α 
(macrophage inflammatory protein-1α) and RANTES (regulated upon 
activation, normal T cell expressed and secreted), which can promote the 
differentiation, activation and/or the recruitment of other immune cells. 
Moreover, NK cell-derived IFN-γ is crucial in priming T helper 1 (Th1) T cell 
responses (Waldhauer and Steinle, 2008). 
 
1.2.1.2 NK cells and tumor immunosurveillance 
Numerous studies have demonstrated the importance of NK cells in the 
eradication of tumors cells. Most of these studies were performed using 
syngeneic tumor cells implanted in mice deficient in NK cells (genetically or by 
antibody depletion) or with impaired NK cell functions. In these mice, tumors 
grew more aggressively and metastasize more frequently in the absence of 
NK cells (Hayakawa and Smyth, 2006; Kim et al., 2000; Smyth et al., 2002). 
Interestingly, Shreiber and colleagues have demonstrated that spontaneous 
tumors or tumors induced by methylcholanthrene (MCA) were higher in mice 
genetically deficient in key effector molecules of NK cells or their receptors, 
including perforin, IFN-γ, IFN-γR, or STAT1 (signal transducer of type I and 
type II IFN receptors) (Kaplan et al., 1998; Shankaran et al., 2001), 
suggesting that NK cells could play a role in controlling spontaneous tumor 
growth. Similarly, higher rates of spontaneous adenocarcinoma have been 
reported in mice deficient in both RAG2 (recombinase activating gene) and 
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STAT1 compared to mice deficient only for RAG2, implicating NK cells in 
tumor immunosurveillance. In humans, most evidences of NK cells in tumor 
immunosurveillance came from correlative studies. Low NK cell cytotoxic 
activity in the peripheral blood was correlated with increased risk of cancer 
(Imai et al., 2000). Furthermore, intra-tumoral infiltration of NK cells has been 
shown to represent a positive prognostic marker and improved survival in 
different human cancers (Chew et al., 2010; Ishigami et al., 2000). A more 
direct evidence for the role of NK cells in controlling malignancies is the 
transfer of alloreactive NK cells during allogeneic haematopoietic stem cell 
transplantion in leukaemic patients. Patients lacking HLA class I ligands for 
donor inhibitory killer cell Ig-like receptors (KIR) showed increased survival 
and protection from relapse (Hsu et al., 2005; Ruggeri et al., 2007). 
 
Tumor cell recognition by NK cells is based on their unique ability to recognize 
and attack cells with diminished levels of the cell surface major 
histocompatibility class I (MHC-I) molecules, which are present at normal 
levels in all cells of the body. Abnormal tumor cells or virally-infected cells 
often down-regulate MHC-I, allowing them to escape detection by cytotoxic T 
cells. However, this down-regulation of MHC-I (loss of self molecules) makes 
these cells sensitive to NK cell cytotoxicity, a concept known as “missing self” 
recognition (Algarra et al., 2000; French and Yokoyama, 2003). However, the 
“missing self” hypothesis failed to explain why autologous cells which lack 
MHC-I expression are spared (eg. erythrocytes) and why tumor cells with 
normal MHC-I expression are killed (Waldhauer and Steinle, 2008). The 
discovery and characterization of several activating NK receptors, eg. NKG2D 
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receptor which recognizes stress-induced self ligands on „dangerous‟ cells, 
led to the proposal of the “induced-self” recognition model (Bauer et al., 1999; 
Raulet, 2004). According to this model, NK cell triggering requires the 
expression of inducible ligands for activating NK receptors (Waldhauer and 
Steinle, 2008). It has since become clear that the activation of NK cells 
depends on an intricate balance between inhibitory and activating signals 
(Lanier, 2005). 
 
1.2.1.3 NK cells inhibitory and activating receptors 
NK cells make use of a large repertoire of germline-encoded inhibitory and 
activating receptors to sense „danger‟ in the form of „altered-self‟ cell surfaces 
(Waldhauer and Steinle, 2008). The main types of NK inhibitory receptors that 
recognize MHC class I molecules are the inhibitory killer cell Ig-like receptors 
(KIR) in humans, the Ly49 receptors in mice, and the heterodimeric 
NKG2A/CD94 receptor in both humans and mice. Inhibitory KIR and Ly49 
receptors bind to classical MHC class I molecules, while NKG2A/CD94 
detects the non-classical MHC class I molecule (HLA-E in humans and Qa-1b 
in mice) (Purdy and Campbell, 2009). Interaction between the inhibitory NK 
receptors with MHC class I molecules establishes NK cell tolerance towards 
normal cells. Upon binding MHC class I ligands on target cells, the inhibitory 
receptors‟ cytoplasmic immunoreceptor tyrosine-based inhibitory motifs (ITIM) 
undergo phosphorylation, leading to the recruitment of protein tyrosine 
phosphatases to the plasma membrane, which could counteract the activating 
receptor signals to inhibit cytotoxicity and cytokine production (Purdy and 
Campbell, 2009).  
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In contrast, the major NK cell activating receptors are the natural cytotoxicity 
receptors (NCR: NKp30, NKp44 and NKp46), the C-type lectin-like receptor 
(CTLR: NKG2D), the low affinity IgG receptor FcγRIII CD16, and the activating 
KIRs. The ligands for NCR have only just begun to be identified; NKG2D 
recognizes the non-classical MHC class I molecules MICA/MICB (MHC class I 
chain-related molecules A and B) and ULBP (UL16-binding proteins) in 
humans and Rae1 proteins, the minor histocompatibility protein H60, and the 
murine UL-16-binding protein-like transcript 1 (MULT1) in mice; while 
activating KIR seem to recognize classical MHC class I molecules (Purdy and 
Campbell, 2009; Waldhauer and Steinle, 2008). On the other hand, CD16 
binds to the Fc portion of IgG antibodies to mediate antibody-dependent 
cellular cytotoxicity (ADCC) (Ahmad and Menezes, 1996), thus allowing NK 
cells to recognize and kill target cells opsonized with antibodies. Activating 
receptors lack signaling motifs in their cytoplasmic sequences; instead, they 
associated with adaptor molecules via charged amino acids in the 
transmembrane domain (Waldhauer and Steinle, 2008). All these activating 
NK receptors promote cytotoxicity and cytokine production via the 
downstream activation of intracellular protein tyrosine kinase cascades. 
 
NKG2D is one of the most well characterized activating NK receptors. It is a 
type II transmembrane-anchored glycoprotein expressed as a disulfiled-linked 
homodimer on the surface of almost all NK cells (Ljunggren, 2008). The 
distinctive feature of NKG2D is the multitude of NKG2D ligands (NKG2DL) 
with varying receptor affinity. NKG2D ligands are frequently expressed on 
primary tumor cells, tumor cell lines, and cells infected with pathogens 
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(Ljunggren, 2008). NKG2DL is inducible by various forms of cellular stress, 
such as heat shock, viral infection, DNA damage or UV irradiation (Waldhauer 
and Steinle, 2008) and has been detected in various human cancers including 
melanoma (Vetter et al., 2002). Interestingly, the expression of NKG2DL has 
been shown to be regulated by genotoxic stress and the activation of the DNA 
damage response pathway, which has been reported to occur in 
precancerous lesions and in many human tumors (Gasser et al., 2005). 
Several reports have demonstrated the critical role of NKG2D in 
immunosurveillance not only for early epithelial tumors but also for lymphoid 
malignancies, however, they do not seem to be important in controlling 
carcinogen-induced sarcomas (Ljunggren, 2008). 
 
1.2.1.4 Tumor evasion strategies from NK surveillance 
While NKG2D-mediated tumor rejection can be effective at early stages of 
tumor growth, sustained expression of NKG2DL by late stage human tumors 
can negatively impact anti-tumor responses, leading to tumor immune evasion. 
In mice, persistent, ectopic expression of NKG2DL resulted in local and 
systemic downregulation of NKG2D expression, impairing anti-tumor immune 
responses (Ljunggren, 2008). In addition, chronic exposure of mouse NK cells 
to cell-bound NKG2DL affects NKG2D signalling and interferes with signalling 
from other activating receptors (Ljunggren, 2008). In humans, shedding of 
NKG2D ligands have been observed in patients with epithelial and 
hematopoetic malignancies (Waldhauer and Steinle, 2008). Shedding of 
soluble ligands critically affects tumor immunogenicity by reducing activating 
signals for NK cells. Furthermore, soluble NKG2D ligands has been shown to 
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downregulate NKG2D expression on tumor infiltrating T and NK cells and 
counteract recognition of cell-bound NKG2D ligands by NK cells (Ljunggren, 
2008; Nausch and Cerwenka, 2008). In addition, several immunosuppressive 
cytokines secreted by myeloid cells and/or tumor cells, such as TGF-β and L-
kynurenine (a tryptophan catabolite generated by indoleamine 2,3-
dioxygenase, IDO), have been shown to downregulate the expression of 
NKG2D receptor and its ligands, thus suppressing NKG2D-mediated 
immunosurveillance (Nausch and Cerwenka, 2008; Waldhauer and Steinle, 
2008). 
 
1.2.2 T cells and tumor immunosurveillance 
It is now well established that the adaptive arm of the immune system, in 
particular T lymphocytes, plays a critical role in controlling malignant 
progression (Pages et al., 2010). Several lines of evidence support this notion. 
For example, spontaneous cancer remissions in patients, although rare, have 
long been recognized in ovarian cancer, melanoma, renal cancer and 
neuroblastoma patients (Cole, 1974; Prestwich et al., 2008). For primary 
melanoma, partial regression is commonly reported, but complete 
spontaneous regression is rare. Histologically, regressing melanoma lesions 
are associated with a perivascular lymphocyte infiltrate, along with a clonal T 
cell expansion and an increase in T helper cells, all of which are suggestive of 
an immune-mediated mechanism (Prestwich et al., 2008). 
 
In mouse tumor models, carcinogen-induced tumors were more frequent 
and/or grew more rapidly in immunodeficient mice relative to 
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immunocompetent controls. In particular, there was an increase in tumor 
incidence in mice deficient in the development or function of CD8+ cytotoxic T 
lymphocytes (CTL) and/or CD4+ T helper 1 (Th1) cells (Kim et al., 2007; Teng 
et al., 2008). This data indicates the important contribution of the immune 
system, in particular T cells, in immune surveillance and tumor eradication.  
 
Further support from clinical epidemiological data demonstrates that T cell 
infiltration is a predictor of patient survival in several human solid cancers, 
including colorectal carcinoman (CRC), ovarian cancers, bladder cancer, non 
small cell lung  carcinomas (NSCLC), head and neck cancer, esophageal 
cancer, breast cancer, melanoma, renal cell carcinoma, prostrate 
adenocarcinoma, and hepatocellular carcinoma (HCC) (Clemente et al., 1996; 
Galon et al., 2006; Kawai et al., 2008; Pages et al., 2010; Sato et al., 2005; 
Schumann et al., 2010). For example, patients with colon and ovarian tumors 
that are heavily infiltrated with CTL and natural killer (NK) cells have a better 
prognosis than those that lack such infiltrates (Pages et al., 2010). In 
melanoma, melanoma-reactive T cells circulating in the blood, in contrast to 
tumor infiltrating lymphocytes (TIL), do not predict survival (Haanen et al., 
2006). This shows that T cell infiltration into tumors is a prerequisite for an 
effective anti-tumor response. However, the existence of tumor-reactive T 
cells is not sufficient to confer a favorable prognosis. Intra-tumoral T cell nests, 
as opposed to peri-tumoral T cells, are prognostic indicators in colorectal 
cancer (Naito et al., 1998) and ovarian carcinoma (Al-Attar et al., 2009), 
suggesting that the localization of T cell infiltrates is also an important 
determinant of the clinical outcome. 
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Taken together, this increasing body of evidence strongly support the notion 
that T cells are indeed one of the critical mediators of an effective anti-tumor 
immune response, and their density, distribution and quality are pivotal 
determinants of clinical outcome. 
 
1.2.3 Pathways of T cell-mediated killing of tumors 
Antigen recognition by T cells involves binding of the T cell receptor (TCR) to 
cognate major histocompatability complex (MHC)-peptide combinations on 
tumor cells, leading to tumor cell elimination. Much of our understanding of 
the mechanisms underlying lymphocyte-mediated cytotoxicity has come from 
in vitro studies. The dominant mechanisms of contact-dependent, lymphocyte-
mediated cytotoxicity that have been described are the perforin/granzyme-







Figure 1.2.1 – Mechanisms of T cell-mediated killing of tumor cells. 
Simplified view of the perforin/granzyme pathway (left) and the Fas/FasL pathway 
(right) in T cell-mediated killing of tumor cells. In the perforin/granzyme pathway, 
perforin forms a channel on the tumor cell membrane through which granzymes and 
other constituent granule proteins pass into the cell. The death receptor Fas on tumor 
cell can interact with its ligand, FasL, expressed on CTL. Both pathways lead to 
downstream activation of the caspase cascade, resulting in tumor cell apoptosis. 





Animal models with deficiencies in various T cell effector molecules have 
been instrumental in elucidating the roles of T cells during tumor regression 
(Breart et al., 2008). Several mechanisms of T cell action have been proposed, 
including: (1) direct killing of tumor cells, (2) recruitment of inflammatory cells 
by CD8+ T cell-derived interferon-gamma (IFN-γ), (3) IFN-γ-dependent 
increase in MHC class I expression on tumor cells, leading to lower activation 
threshold for T cell cytotoxic activity, (4) IFN-γ mediated inhibition of 
angiogenesis, and (5) inhibition of tumor cell proliferation (Breart et al., 2008; 
Eyles et al., 2010; Nelson and Ganss, 2006). In human cancers, intra-tumoral 
T cell infitlration has been correlated with increased tumor cell apoptosis 
(Dolcetti et al., 1999; Schumann et al., 2010) and decreased tumor cell 
proliferation (Schumann et al., 2010). 
 
A better understanding of how effector T cells survey cancer cells and 
eliminate tumors in vivo may provide clues as to how the local tumor 
microenvironment may subvert anti-tumor immune responses, and may offer 





1.2.4 Mechanisms of T cell trafficking to tumors 
Lymphocyte trafficking to lymphoid organs and to peripheral sites of injury, 
inflammation, infection and tumors is a multi-step process that involves 
distinct adhesive and activation steps (Johnston and Butcher, 2002). This 
includes: (1) primary tethering and rolling, (2) activation and secondary firm 
adhesion, (3) crawling, (4) transendothelial migration (TEM) (paracellular and 
transcellular), (5) extravasation, and (6) interstitial migration (Fisher et al., 
2006; Hiraoka, 2010) (Figure 1.2.2). The basic processes are common, but 
multiple molecular choices exist  at each step (i.e. adhesion molecules and 
chemokines) to provide a large degree of combinatorial diversity (Hiraoka, 
2010), which serves as the basis for different lymphocyte subsets with 
different functions and activation status being recruited in a site- and time-













































































































































































































































































































































































































































































































































1.2.4.1 Tethering and rolling 
Lymphocyte tethering and rolling along the endothelium is mostly mediated by 
the selectin family of adhesion molecules. L-selectin is constitutively 
expressed on most circulating lymphocytes, while P-selectin and E-selectin 
are inducibly expressed on activated endothelial cells. These selectins bind to 
ligands modified with specific carbohydrate epitopes, which are expressed on 
the endothelium of high endothelial venules (HEV) in secondary lymphoid 
organs (except spleen), and at peripheral sites of injury and inflammation 
(Hiraoka, 2010). This rolling process (due to hemodynamic shear forces) 
slows down circulating lymphocytes, thus enabling interactions to occur 
between G-protein-coupled chemokine receptors (GPCR) expressed on 
lymphocytes with chemokines or other chemoattractants displayed on the 
endothelium. 
 
1.2.4.2 Activation and firm adhesion 
It has been traditionally thought that leukocytes are directed by soluble 
chemoattractant gradients to migrate across the endothelium, and through the 
extracellular matrix into the tissue. However, it has been suggested that 
soluble chemokine gradients are unlikely to exist at the luminal endothelial 
surface, as soluble chemokines are exposed to continuous shear flow and are 
rapidly washed away from the apical surface (Middleton et al., 2002). 
 
There is an increasing body of evidence suggesting that many chemokines 
can bind to the surface of endothelial cells either by binding to heparin sulfate 
and other glycosylaminoglycans (GAG) or to the Duffy antigen receptor for 
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chemokines (DARC) (Johnston and Butcher, 2002). Activated endothelial 
cells can produce and bind to a number of such chemokines and mediate 
lymphocyte arrest (Johnston and Butcher, 2002). In addition, endothelial cells 
have been shown to transport chemokines from the basolateral to the luminal 
surface, indicating that chemokines secreted in the tissues can impact on the 
recruitment of intravascular lymphocytes (Middleton et al., 1997). 
 
Chemokines bound to the endothelium can transduce robust signals to 
lymphocytes mediating firm adhesion to immoblized integrin ligands. This 
occurs via upregulation of integrin affinity through conformational changes or 
an increase in integrin avidity through integrin clustering (Johnston and 
Butcher, 2002). Chemokine-induced activation of chemokine receptors 
triggers intracellular signalling pathways, resulting in the activation of guanine 
nucleotide exchange factors (GEF) mediated by local phosphoinositide 
production and kinase activity. GEF activates Rho and Ras guanosine 
triphosphatase (GTPases), leading to cytoskeletal rearrangements and 
conformational changes in integrin molecules which regulate firm adhesion of 
lymphocytes to endothelial ligands. Avidity changes occur via clustering of low 
affinity receptors, which requires protease-dependent release of integrins from 
cytoskeletal restraints in order to facilitate lateral mobility of integrins on the 
plasma membrane (Johnston and Butcher, 2002). Chemokines can induce 
rapid clustering of integrins, thus leading to strengthened adhesion to 
immobilized integrin ligands. The binding of β2-integrin, αLβ2 (or leukocyte-
function associated antigen-1, LFA1) to their endothelial ligands, ICAM1 and 
ICAM2 (intercellular adhesion molecule), and between α4 integrins, α4β1 (or 
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VLA4, very late antigen-4) and α4β7 with their ligands, VCAM1 (vascular cell 
adhesion molecule 1) and MADCAM1 (mucosal vascular addressin cell 




Lymphocyte crawling on endothelial cells requires the integration of three 
external signals: inside-out integrin activation signals from chemokine binding 
to GPCR, outside-in integrin activation signals, and chemokine-GPCR-
triggered signals to actomyosin-remodeling Rho GTPases (Rosenberg et al., 
2009). Migrating lymphocytes are flattened in shape, which is associated with 
polarization involving redistribution of intracellular signaling proteins, surface 
receptors, and adhesion molecules to specific sites of the cell (Hiraoka, 2010). 
Migrating lymphocytes form leading protrusions (or filopodia) and crawl along 
the endothelial surface supported by LFA1:ICAM1 interactions. Integrin 
ligands (such as ICAM1) clustered on the apical surface of endothelial cells 
trigger the activation of a variety of endothelial regulatory GTPases, including 
RhoA and RhoG, which may translate LFA1:ICAM1 focal contacts into 
endothelial invaginations surrounding lymphocyte filopodia, thus facilitating 
TEM (Rosenberg et al., 2009). Chemokines, cytokines and shear stress play 
major roles in lymphocyte crawling and triggering of additional promigratory 
actin remodeling machineries, leading to subsequent TEM under disruptive 
shear flow (Ascierto et al., 2011; Hiraoka, 2010).  
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1.2.4.4 Transendothelial migration (TEM) 
Two routes of TEM have been reported, namely the paracellular (majority of 
events) and transcellular (minority of events) routes (Hiraoka, 2010) (Figure 
1.2.2). In the paracellular route, leukocytes transmigrate between endothelial 
cells at cell junctions. This involves formation of a haptotactic gradient that 
guides lymphocytes to the junctional zones. The endothelial junctional 
molecules that actively mediate sequential steps in TEM includes CD31 
(platelet-endothelial cell adhesion molecule 1, PECAM1), ICAM1, ICAM2, 
CD99, members of the JAM family (such as JAM-A, JAM-B, and JAM-C), and 
endothelial cell-selective adhesion molecule (ESAM) (Hiraoka, 2010). In the 
transcellular route, lymphocytes cross the endothelial barrier by 
transmigrating directly through individual endothelial cells. This process 
involves translocation of apical ICAM1 to caveolae and F-actin-rich regions 
and the transport of caveolin-1 to the basal membrane, resulting in a channel 
through which the lymphocytes can migrate (Hiraoka, 2010). This pathway 
has been identified in various in vitro models and is reported to operate in the 




To extravasate into tumors, lymphocytes breach the vascular basement 
membrane and pericyte coverage of venular walls to reach the tumor 
parenchyma. Basement membranes are composed of tightly packed networks 
of laminins and type IV collagen inter-connected with perlecan and nigogens 
that are suggested to be more resistant than endothelium (Hiraoka, 2010). 
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There is no unifying theory on the exact molecular mechanisms whereby 
lymphocytes penetrate the basement membrane. However, it has been 
reported that the penetration involves binding of the integrin α6β1, the principal 
laminin receptor on lymphocytes, to the substrate. In addition, endothelial-
associated or lymphocyte-derived proteases have been implicated in cleaving 
the structural proteins of the basement membrane (Hiraoka, 2010).  
 
1.2.4.6 Interstitial migration 
Lymphocytes migrate within the interstitial environment in an amoeboid 
manner, consisting of the leading edge where short-lived pseudopods form by 
actin-mediated forward flow, the protruding membrane and surface receptors 
interact with the tissue substrate, followed by actomyosin-mediated 
contraction of the mid region of the cell body, and finally the posterior tail, 
known as the uropod, moves forward (Hiraoka, 2010; Weigelin et al., 2011). In 
contrast to other migration modes, amoeboid cell locomotion is independent 
of integrin-mediated adhesion (Hiraoka, 2010; Weigelin et al., 2011). The use 
of weakly adhesive and nonadhesive interactions and traction mechanisms 
allows T cells to move rapidly (up to 30µm/min) within tissues (Weigelin et al., 
2011).  
 
Besides its function in T cell trafficking, amoeboid migration of T cells 
contributes to enhanced capability to sense and respond to signals from the 
extracellular environment, including chemoattractant signals and cognate 
antigens expressed on tumor cells. The trailing uropod contains adhesion 
receptors, including ICAM1, integrins and the highly glycosylated surface 
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receptors CD43 and CD44, which likely regulate attachment to cell surfaces 
and extracellular matrix (ECM) during migration (Weigelin et al., 2011). Upon 
recognition of the cognate antigen, CD8+ T cells form long lasting contacts 
(30min to 6h) with target cells, resulting in tumor cell destruction. Some 
integrins, such as LFA-1, VLA-4 and αEβ7 promote adhesion and function as 
costimulatory molecules to enhance effector function by supporting interaction 
between T cells and tumor cells (Hiraoka, 2010). CD44, a receptor for ECM 
proteins and glycosaminoglycans, has been shown to maintain cell polarity 
during interstitial T cell migration and is critical for scanning of target cells 
needed for an efficient anti-tumor immune reaction (Mrass et al., 2008) .  
 
In conclusion, T cell effector functions are critically dependent on efficient 
trafficking of T cells from the blood into the tumors, which in turn is tightly 
regulated by a complex array of adhesion molecules and chemokine signals. 
Therefore, proper functions of the vasculature and the lymphocytes as well as 
the inflammatory state of the tissues are essential for lymphocyte trafficking 




1.3 T cell-based immunotherapies 
By analyzing the T cells that recognize tumors, many tumor-associated 
antigens (TAA) have now been identified and successfully cloned. In 
melanoma, examples of known TAA include gp100 (glycoprotein 100), melan-
A/MART-1 (melanoma-associated antigen recognized by T cells), tyrosinase, 
MAGEs, SSX-2 and -4 (synovial sarcoma X), NY-ESO-1 and others 
(Buonaguro et al., 2011; Jandus et al., 2009). In a single tumor, tumor-
infiltrating lymphocytes (TIL) directed towards multiple TAA can be identified 
(Prestwich et al., 2008). The identification of TAA that can be potentially 
targeted by anti-tumor T cells generated great interest for the establishment of 
T cell-based immunotherapies to treat cancer. This includes approaches that 
target T cells directly (such as adoptive T cell transfer or ACT, cancer 
vaccines, and bispecific antibodies) or indirectly (via suppression of T cell 
inhibitory mechanisms, such as CTLA-4 blockade). These T cell-based 
immunotherapies serve as novel treatments for patients with cancer, and has 
allowed for the design of new strategies to break immune tolerance in these 
patients (Lizee et al., 2007). 
 
1.3.1 Adoptive T cell transfer (ACT) 
T cell adoptive therapies are an attractive approach in treating cancers and 
have yielded some promising results in melanoma, however, complete clinical 
responses are only observed in a minority of patients (Rosenberg and Dudley, 
2009). ACT immunotherapy relies on ex vivo expansion and activation of 
tumor-specific lymphocytes followed by transfer of these cells into autologous 
tumor-bearing hosts (Figure 1.3.1). A significant breakthrough in the 
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development of effective ACT for the treatment of melanoma patients was the 
first demonstration in 1987 that tumor-infiltrating lymphocytes in metastatic 
melanoma could be grown in IL-2 and exhibit major histocompatability 
complex (MHC) restricted recognition of both fresh and cultured melanoma 




Figure 1.3.1 – Factors important for the success of ACT therapy against tumors. 
Several factors that can influence the efficacy of ACT include (1) the source of T cells 
(whether it is best to isolate from the tumor or from the peripheral blood), (2) ex vivo 
culture technique (bulk TIL, selected-TIL or young-TIL protocol) and manipulation 
[genetic modification to express either tumor-specific MHC-restricted T cell receptors 
(TCR) or non-MHC-restricted synthetic chimeric antigen receptors (CAR)], (3) host-
conditioning (to favour the survival/persistence and the activity of the readministered 
cells), and (4) post-transplant support (to favour the in vivo expansion and activation 
of TIL). CTLA-4 – cytotoxic T lymphocyte antigen-4; IL-2 – interleukin-2; TGFβ – 




1.3.1.1 Early ACT protocol 
The first ACT-based immunotherapy was described in 1988 for the treatment 
of metastatic melanoma patients, with increased number of patients reported 
in 1994. In this study, eighty-six patients were treated with autologous TIL with 
high dose IL-2 (720,000 IU/kg). The TIL single cell suspension was generated 
by enzymatic digestion of the bulk tumor and expanded in high concentration 
of IL-2 until at least 1011 TIL were generated (Hershkovitz et al., 2010). TIL 
and IL-2 were administered in two cycles separated by approximately 2 weeks. 
Twenty-eight patients received TIL without a preparative regimen and fifty-
eight patients receive an additional single low dose cyclophosphamide 
(25mg/kg) before the first TIL infusion (Hershkovitz et al., 2010). The overall 
objective response rate was 34% and was comparable to studies with high IL-
2 alone (31%), or IL-2 with a combination of cyclophosphamide (35%). 
Although objective anti-tumor responses were seen in these early trials, many 
of the responses were short-lived. Of the twenty-nine patients with an 
objective clinical response, only five patients experienced a complete 
response and the median survival of all partial responders was only four 
months. Lack of persistence of transfused cells was the major reason for 
treatment failure. In fact, less than 0.1% of the transfused cells survived in the 
circulation after one week of administration (Rosenberg and Dudley, 2009). 
 
Retrospective analyses revealed that objective clinical response was 
associated with cells with short period of culture, which exhibited high in vitro 
lysis of autologous tumor cells, and were able to traffic to the tumor targets in 
vivo. In addition, higher response rate was associated with patients receiving 
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TIL generated from subcutaneous tumors (49%) compared to those obtained 
from lymph nodes (17%), probably due to the presence of many non-tumor-
specific T cells within the lymph nodes (Hershkovitz et al., 2010). This initial 
study paved the way for further modifications which led to dramatic 
improvement in the effectiveness of TIL therapy (Rosenberg and Dudley, 
2009). 
 
1.3.1.2 Selected-TIL protocol 
Earlier trials involved the use of bulk TIL cultures that contained 
heterogeneous populations of lymphocytes, of which only some showed anti-
tumor activity. Studies of the T cell receptor rearrangements in TIL revealed 
the variability of T cells present in these cultures and pointed towards the 
need for modified culture techniques that select only anti-tumor reactive 
lymphocytes without the presence of any other bystander cells. Thus, 
modifications were made to culture TIL from multiple small tumor fragments 
instead of a single bulk tumor, and in vitro IFN-γ release assays were used to 
identify tumor-specific TIL (Hershkovitz et al., 2010). Despite being more labor 
intensive (at least 21-35 days before large-scale expansion), the Selected-TIL 
protocol had the advantage of specifically selecting lymphocytes with anti-
tumor activity. The potential disadvantage associated with this technique was 
the limited heterogeneity and polyclonality of the cells infused (Rosenberg and 
Dudley, 2009). 
 
The decisive improvement in the efficacy of ACT came in 2002 with the 
introduction of an immunodepleting preparative regimen given before adoptive 
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transfer. This followed the success in preclinical models demonstrating 
improved ACT efficacy by administration of either total body irradiation or 
lymphodepleting nonmyeloablative chemotherapy (NMC) before cell transfer. 
Lymphodepletion appears to act predominantly by suppressing Tregs and by 
eliminating competition for homeostatic cytokines such as IL-7 and IL-15 that 
are vital for the survival of the infused TIL (Rosenberg and Dudley, 2009). 
 
These results led researchers to explore the use of lymphodepleting 
strategies in patients before TIL transfer. Three consecutive studies involving 
93 metastatic melanoma patients were performed using increasing levels of 
lymphodepletion before cell transfer. In the first study, 43 patients received a 
nonmyeloablative, lymphodepleting chemotherapy regimen consisting of 
cyclophosphamide and fludarabine before infusion of expanded, tumor-
reactive, tumor-infiltrating lymphocytes and IL-2 therapy. In the following two 
consecutive studies, each cohort of 25 patients received an additional 200cGy 
or 1200cGy whole body irradiation before cell transfer. Preliminary results 
were promising with objective response rates of 49%, 52% and 72% 
respectively in these three consecutive protocols. Responses were often 
durable and clinical tumor regression was observed in all sites of the body 
with no long-term toxicities. Subsequently studies showed that clinical 
responses were highly correlated with in vivo persistence of the transferred 
cells, thus, highlighting the significant potential of lymphodepleting regimens 
to enhance the efficacy of ACT. Unfortunately, in the absence of a 
randomized clinical trial, it is not possible to determine how much 
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lymphoablative chemotherapy, high-dose IL-2 administration, and TIL therapy 
contributed to the promising results in these trials.  
 
Continual efforts to improve the efficacy of ACT led to extensive studies to 
identify both patient and cell factors associated with objective clinical 
responses. In addition to the persistence of the transfused cells, studies in 
both mouse models and human patients predicted that the state of 
differentiation of the transferred cells was repeatedly reported to have a 
significant association with clinical response. The two main characteristics of 
cells able to mediate an effective anti-tumor response are long telomere 
length and high expression of CD27, both of which are markers of less 
differentiated cells (Rosenberg and Dudley, 2009). These findings led to the 
generation of very “young” TIL for subsequent ACT trials.  
 
1.3.1.3 Young-TIL protocol  
The Young-TIL protocol utilizes bulk unselected TIL, which spend shorter time 
in culture. Single cell suspensions are generated from bulk tumor instead of 
multiple small fragments, and enables rapid large-scale expansion in just 10-
18d. This process simplified the laboratory procedures and significantly 
lowered the cost. Young TIL cultures were successfully established for 
approximately 90% of patients, making it more widely available for the 
treatment of more patients compared to the Selected-TIL procotol. Objective 
clinical response was 50%, including two ongoing complete responses (CR) 
and eight partial responses (PR). Dramatic improvement to the dropout rate 
(26% instead of 70% in the Selected-TIL protocol) was observed (Hershkovitz 
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et al., 2010). Toxicities related to the use of IL-2 and chemotherapy was 
similar to the Selected-TIL protocol. In short, the Young-TIL protocol provides 
a valuable tool to integrate ACT trials in more cancer centres worldwide for 
the treatment of more cancer patients (Hershkovitz et al., 2010). 
 
1.3.1.4 Genetically engineered T cells  
Technical issues with the production of tumor-specific lymphocytes present a 
formidable barrier to conducting ACT trials. Approximately 30-40% of biopsy 
samples yield satisfactory T cell populations and the procedure is labour-, 
cost- and time-intensive (Dudley et al., 2003). One of the methods vigorously 
pursued to improve the effectiveness of ACT therapy is the adoptive transfer 
of genetically modified peripheral blood lymphocytes instead of TIL. 
Autologous circulating blood lymphocytes can be genetically modified to 
express either MHC-restricted T cell receptors (TCR) or non-MHC-restricted 
synthetic chimeric antigen receptors (CAR) with defined antigen specificity. 
 
The TCR approach is accomplished by the direct transfer of the α and β TCR 
chains from an antigen-specific T cell clone into peripheral blood T cells via 
transduction of a retroviral construct, thus generating large numbers of tumor 
antigen-specific T cells (Morse et al., 2002; Schmitt et al., 2009). An initial trial 
was conducted in metastatic melanoma patients whereby genetically 
engineered lymphocytes encoding TCR with low affinity for melanoma-
associated antigen MART-1 was transfused to patients pre-conditioned with 
non-myeloablative chemotherapy (NMC) and IL-2. Although the response rate 
was low (13%), 2 out of 17 patients achieved full remission for more than a 
 34 
year (Morgan et al., 2006). This initial trial demonstrated the potential of using 
genetically engineered T cells for patients with low TIL count. Retroviruses 
encoding T cell receptors with higher avidity to melanoma antigens and a 
broad array of cancer antigens such as p53, gp100, carcinoembryonic antigen 
(CEA), and the cancer-testis antigen NY-ESO-1 are now being evaluated in 
clinical trials for the treatment of other types of cancer in addition to 
melanoma (Rosenberg and Dudley, 2009). 
 
Since the TCR for many antigens are not known and are difficult to generate, 
the chimeric antigen receptor (CAR) method was developed. This method 
utilizes the variable regions of the heavy and light chains of monoclonal 
antibodies recognising the tumor fused with T cell signalling chains derived 
from CD28, 41BB or CD3zeta (Hershkovitz et al., 2010). Clinical studies 
utilizing CAR to treat various cancers have induced modest responses, and 
many more clinical trials are underway to provide a more significant 
assessment of this approach. To date, no clinical trials involving the use of 
CAR have been reported. Nevertheless, several in vitro and preclinical studies 
have reported the feasibility of using lymphocytes encoding CAR for various 
melanoma tumor antigens such as ganglioside GD2, GD3 and MAGE-A1 
(Hershkovitz et al., 2010). Although still in its infancy, the ability to genetically 
modify autologous lymphocytes from patients‟ blood to recognize tumor 
antigens and mediate cancer regression in vivo has opened doors for 
enhancing and extending the ACT approach to patients with a wide variety of 
cancer types.  
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1.3.2 Vaccines  
Prophylactic vaccines have been proven to be clinically efficacious against 
infectious diseases, however, therapeutic cancer vaccines aimed at inducing 
effective anti-tumor activity are still unsatisfactory. The aim of cancer vaccines 
is to induce tumor regression by in vivo activation of tumor-specific T cells. 
Numerous strategies have been tested for therapeutic vaccination of cancer 
patients, including (1) whole cell-based vaccines: autologous and allogeneic 
whole tumor cells, (2) dendritic cell-based vaccines, and (3) antigen-based 
vaccines: peptides, proteins, plasmid DNA/mRNA, and viral vectors [reviewed 
in (Terando et al., 2007)]. Overall, the clinical results have been of limited 
impact (with some reported success as described below), even though tumor-
specific immune responses could be measured in the majority of cases 
(Palucka et al., 2011; Rosenberg et al., 2004; Speiser and Romero, 2010). 
 
1.3.2.1 Whole cell-based vaccines 
Whole cell-based vaccines consist of either autologous or allogeneic whole 
tumor cell vaccines. Autologous whole tumor cells vaccines are derived from 
tumor cells obtained from operative specimens or tissue cultures generated 
from autologous tissues. These cells are rendered replication deficient 
through irradiation, and readministered back to the patients usually with an 
immune adjuvant, and/or after conjugation to a hapten (Terando et al., 2007). 
The main advantage of this vaccination strategy is that all of the antigens 
within a patient‟s tumor, whether know or unknown, will be readminstered 
back to the patient to initiate an optimal immune response. However, 
adequate amounts and the accessibility of tumor tissues is a major issue. In 
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addition, vaccine preparation has been extremely challenging, laborious and 
time-consuming. The most extensively studied autologous vaccine for 
melanoma, M-Vax (AVAX technologies, MO, USA), was developed by Berd 
and colleagues (Berd, 2002). This vaccine consists of autologous melanoma 
cells that have been irradiated and then modified with the hapten, 
dinitrophenyl (DNP). Patients with resected stage III melanoma treated with 
this vaccine, together with BCG (Bacille Calmette Guérin) and pre-treatment 
cyclophosphamide, demonstrated improved disease-free and overall survival 
compared to controls (Terando et al., 2007). To-date, a phase III, randomized, 
placebo-controlled, double-blind, multi-centered trial of M-Vax in patients with 
stage IV melanoma has been initiated.  
 
Allogeneic whole tumor cell vaccines are generated from patients other than 
the intended recipient, and they consist of multiple tumor cell lines to 
maximize the antigen expression profiles (Terando et al., 2007). Two 
examples include Melacine (Corixa Corporation, Seattle, WA, USA) and 
Canvaxin (CancerVax Corporation, Carlsbad, CA, USA). Melacine is derived 
from two melanoma cell lines, and is rendered replication deficient through 
mechanical dissociation. A randomized trial to test the impact of Melacine in 
an adjuvant setting failed to demonstrate improved disease-free survival in 
vaccine-treated compared to non-treated melanoma patients (Sondak et al., 
2002). Canvaxin is derived from three melanoma cell lines and is rendered 
replication defective through irradiation. Although this vaccine demonstrated 
survival benefit in two phase II studies in patients with resected stage III and 
stage IV melanoma, two recent phase III studies of Canvaxin + BCG versus 
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placebo + BCG in stage III and stage IV melanoma patients failed to show any 
clinical benefit (Atkins et al., 2006).  
 
1.3.2.2 Dendritic cell-based vaccines 
Dendritic cell (DC) is the most potent antigen-presenting cell, and the only cell 
type able to initiate de novo antigen-specific T cell responses. Therefore, 
attempts have been made to generate DCs loaded with peptides, proteins, 
whole tumor cell lysates or mRNA (messenger RNA) for clinical trial purposes 
[reviewed in (Jandus et al., 2009)]. Although DC vaccination has been shown 
to induce potent anti-tumor immune responses in patients, clinical benefit 
remains scarce. A randomized phase III trial investigating the use of 
autologous peptide-pulsed vaccine versus dacarbazine in stage III/IV 
melanoma did not demonstrate superiority of the DC-based immunotherapy 
compared to chemotherapy. Several parameters have been considered to 
better improve DC-based vaccinations, including the type and maturation 
stage of DC to be administered, the optimal density of epitopes on DC cell 
surface, optimal protocol to generate DC in vitro, and alternative protocol to 
target antigens directly to DCs in vivo (Jandus et al., 2009). DC-based 
vaccines for the treatment of other types of cancers have yielded encouraging 
clinical outcomes. Sipuleucel-T (Provenge), a cellular vaccine based on 
enriched blood APCs briefly cultured with a fusion protein of prostatic acid 
phosphatase with GM-CSF, demonstrated a 4-mo prolonged median survival 
in patients in a Phase III clinical trial and was the first therapeutic cancer 
vaccine approved by the Food and Drug Administration for the treatment of 
metastatic prostate cancer (Kantoff et al., 2010).  
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1.3.2.3 Antigen-based vaccines  
Antigen-based vaccines that have been tested in clinical trials include 
peptides, proteins, plasmid DNA/mRNA, and viral vectors. Most cancer 
vaccine trials employ peptide vaccines derived from either cancer-testis 
antigens or differentiation TAAs (Buonaguro et al., 2011). For melanoma, 
peptide vaccines targeting melanocyte differentiation antigens (MART-1, 
gp100, tyrosinase) and cancer testis antigens (MAGE and NY-ESO) have 
been investigated alone, or in multi-peptide combinations, together with class 
II-restricted peptides, with or without cytokines (IL-2, IL-12, GM-CSF, IFN-α), 
and with a variety of adjuvants (incomplete Freund‟s adjuvant or IFA, Alum, 
ASO2B) (Terando et al., 2007). Peptide-based immunotherapies have been 
shown in some cases to elicit detectable anti-tumor T cells in the circulation, 
but clinical responses are rare (Jandus et al., 2009). The first prospective, 
randomized, multicenter, phase III clinical trial to demonstrate clinical benefit 
involved the treatment of 185 melanoma patients with gp100209-217 analogue 
peptide with high dose IL-2. Improved response rate and progression-free 
survival were observed in patients treated with peptide plus IL-2, compared to 
IL-2 alone (Schwartzentruber et al., 2009).  
 
One of the limitations in using peptides as immunogens is that each peptide-
based vaccine is limited to a subset of melanoma patients with defined HLA 
(human leukocyte antigen) haplotypes. In addition, most immunization 
protocols include MHC class I-restricted epitopes, which precludes targeting 
of tumor-specific CD4 helper T cells (Jandus et al., 2009). In this context, 
vaccination using recombinant proteins has the potential to target both CD4+ 
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and CD8+ T cells specific for a variety of epitopes of a TAA independently of 
the HLA haplotype (Jandus et al., 2009). Interestingly, vaccination of 
metastatic melanoma patients with a recombinant MAGE-A3 fusion protein, 
together with an adjuvant combination of monophosphoryl lipid A, QS-21, and 
CpG-ODNs (CpG oligodeoxynucleotides), improved clinical and immune 
responses compared to patients receiving the peptide plus vaccine 
formulation without CpG-ODNs (Kruit et al., 2008). A large phase III trial using 
MAGE-A3 vaccine with the same adjuvant is ongoing in resected NSCLC 
patients (Brichard and Lejeune, 2008). Several drawbacks of recombinant 
protein vaccines have been described, including the poor ability to cross-
prime MHC class I-restricted CD8+ T cells and high cost of production. A 
compromise between short peptides and full length recombinant proteins is 
the use of synthetic long peptides (20-30 amino acids long), and this has 
resulted in significant improvement in the immunogenicity of peptide vaccines 
(Jandus et al., 2009). 
 
Recombinant viral vectors (either recombinant adenovirus or fowlpox virus) 
encoding TAAs have demonstrated variable success in several phase I trials 
in melanoma patients. Recombinant viral vectors are commonly used to 
enhance gene transduction efficiencies. However, the presence of pre-
treatment anti-viral antibodies, or the induction of such antibodies following 
vaccination, can neutralize the effects of subsequent treatments (Terando et 
al., 2007). In addition, the immunodominance of viral antigens may dampen 
the generation of tumor antigen-specific responses (Jandus et al., 2009).  
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The shortcomings of recombinant viral vectors may be overcome with the use 
of naked DNA. Vaccination with DNA encoding melanoma antigens has 
shown some success in phase I trials (Terando et al., 2007). Administration of 
plasmid DNA has been performed by intramuscular or intradermal injections, 
or by intranodal infusion (Jandus et al., 2009; Terando et al., 2007). The main 
advantage of this technique is the continuous production of tumor antigens 
following gene transduction, in contrast to the short half-life of peptide 
vaccines. Heterologous prime-boost regimens, whereby the vector used for 
priming vaccinations (eg. plasmid DNA) is different from that used for booster 
vaccinations (eg. retroviral vector), may contribute to optimized cancer 
vaccine development. In addition to DNA, intradermal injection of total tumor 
mRNA has been shown to be feasible and immunogenic in a phase I trial 
(Jandus et al., 2009).  
 
In summary, although significant technical and scientific progress has been 
achieved in the field of cancer vaccines, the clinical benefit from such 
treatments are still lacking. As such, much remains to be accomplished in 
terms of efficacy and applicability. The identification of target antigen and 
route of delivery as well as immune-modulatory strategies to counter 
immunosuppression mechanisms within the tumor microenvironment are key 




1.3.3 Bi-specific antibodies 
An alternative approach to engage T cells for cancer therapy are antibodies, 
which are bispecific for a surface antigen on cancer cells and for T cell co-
receptor molecule CD3 on T cells. The concept of using bispecific antibodies 
to engage cytotoxic T cells to kill cancer cells was first demonstrated by 
Staerz and colleagues (Staerz et al., 1985). Further progress in the 
development of bispecific antibodies lead to a new subclass of bispecific 
antibodies called BiTE (for “bispecific T cell engager”).  
 
Generally, BiTEs are polypeptides of approximately 55 kDa composed of two 
single chain fragment variables (scFv) in tandem (Bird and Walker, 1991) 
(Figure 1.3.2). These antibodies are capable of binding any T cell to a cancer 
cell, independently of T cell receptor specificity, costimulation, or peptide 
antigen presentation (Baeuerle and Reinhardt, 2009). BiTEs have been 
shown to kill cancer cells by inducing immunological synapse between T cells 
and tumor cells (Offner et al., 2006), leading to BiTE-mediated T cell 
activation, and tumor cell killing via perforin-mediated membrane perforation 
and influx of granzyme proteases (Haas et al., 2009). Pioneering work by 
Kufer and colleagues demonstrated that these bispecific antibodies have high 
potency, and could engage both CD4+ and CD8+ T cells for redirected lysis of 
cancer cells at low effector to target (E:T) ratios (Mack et al., 1995). 
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Figure 1.3.2 – Redirected lysis of a tumor cell by a T cell using a bispecific T cell-
engager (BiTE) antibody. 
A BiTE antibody is generated from the variable domains of two distinct monoclonal 
antibodies. BiTEs simultaneously bind the CD3 subunit common to all TCRs and a 
surface antigen on tumors cells, triggering a tumor-specific, cytotoxic event. TCR – T 
cell receptor. TAA – tumor associated antigen. 
 
 
There are currently two BiTE antibodies being tested in clinical trials. 
Blinatumomab (MT103) is bispecific for CD3 and CD19. This bispecific 
antibody is now being tested in a phase I trial in patients with late-stage, 
relapsed non-Hodgkin‟s lymphoma (NHL) (Bargou et al., 2008) and in a phase 
II trial in patients with B-precursor acute lymphoblastic leukemia (B-ALL) 
having minimal residual (MRD) disease in their bone marrow (Topp et al., 
2011). The phase I study in NHL patients confirmed the remarkable potency 
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of blinatumomab for engaging T cells within cancer patients for redirected 
tumor cell lysis. All seven patients in the study who received continuous 
infusion with BiTE at 0.06mg/m2 per day reported objective tumor regression, 
including five partial responses and two complete responses with elimination 
of tumor cells from the blood, bone marrow and liver (Choi et al., 2011). 
Adverse events such as central nervous system (CNS) side effects were fully 
reversible and there was no dose-limiting cytokine release syndrome or 
autoimmune phenomena (Choi et al., 2011). However, this BiTE led to nearly 
complete depletion of CD19-expressing normal B cells. A recently completed 
phase II trial in B-ALL patients with MRD after therapy showed that 16 out of 
21 patients treated with Blinatumomab became MRD negative with probability 
for relapse-free survival of 78% at a median follow-up of 405 days (Topp et al., 
2011). An ongoing phase II trial with a second cohort of patients 
demonstrated complete remission or complete remission with only partial 
hematologic recovery in 9 of 12 patients with relapsed/refractory B-ALL in a 
small study (Topp, 2011). 
 
The second BiTE antibody being tested in clinical trial is MT110, which is 
bispecific for CD3 and epithelial cell adhesion molecule (EpCAM) (Brischwein 
et al., 2006). It is currently being tested in phase I trial on patients with lung, 
gastrointestinal, and colorectal cancers. Early results from this phase I study 
showed disease stabilization in 7 of 19 evaluable patients following infusion 
with clinically-tolerable doses of MT110, and clinical evaluation of higher 
doses is ongoing (Fiedler et al., 2010). BiTE antibodies have now been 
constructed to more than 10 different target antigens, including CD19, EpCAM, 
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Her2/neu, EGFR (epidermal growth factor receptor), CEA, CD33, EphA2 
(ephrin type-A receptor 2), and MCSP (melanoma chondroitin sulfate 
proteoglycan) (Baeuerle and Reinhardt, 2009; Choi et al., 2011).  
 
The advantages of BiTE technology compared to other T cell based therapies 
for cancer are that they are fully antibody-derived and thus, obviate the need 
for ex vivo enrichment and modification as well as in vivo maintenance. 
Furthermore, BiTE antibodies are able to maintain tumor lysis despite certain 
classical tumor escape mechanisms as they engage T cells without 
requirements for MHC presentation or TCR specificity (Choi et al., 2011). The 
challenges associated with BiTE technology are perhaps similar to other 
forms of cancer therapy including the identification of appropriate tumor-
specific targets, and the ability of BiTE-engaged T cells to overcome 
downstream barriers to T cell-mediated tumor rejection such as mechanical 
barriers, disorganized vasculature, and highly immunosuppressive 
microenvironments (Baeuerle and Reinhardt, 2009). 
 
In conclusion, BiTE antibodies may hold promise as a future cancer 
immunotherapy strategy. However, further investigations are needed to study 
the impact of other immune cell types such as Tregs on BiTE-activated T cells, 
the possible mechanisms to evade BiTE-engaged T cells, and the broader 
utility of BiTE antibodies to treat human malignancies (Baeuerle and 
Reinhardt, 2009). Strategies to improve the serum half-life of BiTE antibodies 
and to reduce the cost of production may ultimately advance this therapeutic 
platform for treating human cancers (Choi et al., 2011).  
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1.3.4 Anti-CTLA antibody 
CTLA-4 is a type I transmembrane glycoprotein that exhibits close homology 
to the costimulatory molecule CD28. T cell inhibition by CTLA-4 is mediated 
by two mechanisms: competitive antagonism of CD28 signals and direct 
negative signaling [reviewed in (Teft et al., 2006)]. During early T cell 
responses, engagement of CD28 molecules by B7 expressed on antigen 
presenting cells initiates a costimulatory signaling cascade required for 
optimal T cell activation via the TCR. CTLA-4 is upregulated on activated T 
cells, and competes with CD28 for binding to B7 molecules due to its higher 
affinity and avidity for the B7 molecules (Lizee et al., 2007). This competitive 
ligand binding will likely sequester B7 molecules, thus reducing the amount of 
CD28-dependent costimulation available and turning off the activated T cells. 
The second mechanism in which CTLA-4 leads to T cell inactivation is 
through direct delivery of an inhibitory signal through its cytoplasmic tail. The 
precise signals delivered by CTLA-4 and the level of action remain uncertain, 
but ultimately it leads to downregulation of cytokine production by inhibiting 
the accumulation of AP-1, NF-κB, and NFAT (nuclear factor of activated T 
cells) in the nucleus of activated T cells. CTLA-4 also inhibits early events of T 
cell proliferation by inhibiting cyclin D3, cyclin-dependent kinases 4 and 6, and 
the cell-cycle inhibitor p27kip1 [reviewed in (Teft et al., 2006)].  
 
CTLA-4 has been found to be progressively upregulated on chronically 
stimulated and exhausted T cells (Wherry et al., 2007). Using affymetrix gene 
expression profiling of metastatic melanoma, Gajewski and colleagues have 
observed minimal/absence of expression of the co-stimulatory molecules B7-1 
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and B7-2, suggesting that the melanoma tumor microenvironment may 
promote induction of classic T cell anergy (Gajewski, 2007; Gajewski et al., 
2010; Gajewski et al., 2006). CD4+ T cells have been shown to undergo 
anergy, leading to the failure to reject tumor in a mouse model in vivo 
(Sotomayor et al., 1999). Several preclinical studies confirmed that by 
blocking CTLA-4, anti-tumor T cell activity was enhanced and tumor 
recurrence was prevented [reviewed in (Kirkwood et al., 2008)]. This led to the 
development of CTLA-4-specific human monoclonal antibody (Ipilimumab or 
MDX-010, Medarex/Bristol-Myers Squibb) as a potential cancer 
immunotherapy. 
 
Ipilimumab is a recombinant human immunoglobulin G1κ monoclonal 
antibody that binds to CTLA-4 and blocks the interaction of CTLA-4 with CD80 
or CD86 (Figure 1.3.3). In patients, treatment with Ipilimumab showed 
moderate single-agent efficacy in mediating cancer regression in melanoma 
and renal cell carcinoma (Klebanoff et al., 2011). Interestingly, Ipilimumab 
(administered at 3mg/kg via intravenous infusion every 3 weeks for four doses) 
was shown to extend the overall survival in a recent phase III clinical trial that 
involved 676 melanoma patients with unresectable or metastatic melanoma 
who have failed one or more standard therapies (Hodi et al., 2010). The 
median overall survival was 10 months in the ipilimumab plus the peptide 
vaccine gp100 group, 10.1 months in the ipilimumab group, and 6.4 months in 
the gp100 group. Objective response rates in the ipilimumab plus gp100 arm, 
ipilimumab arm, and gp100 arm was 5.7%, 10.9%, and 1.5%, respectively. 
The median duration of response was 11.5 months in the ipilimumab plus 
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gp100 arm, and this was not reached in the ipilimumab alone or gp100 
alone arms (Balwit et al., 2011; Hodi et al., 2010). Common side effects 
include fatigue, diarrhea, skin rash, endocrine deficiencies (gland or hormone), 
and inflammation of the intestines (colitis), while severe to fatal autoimmune 
reactions were observed in 12.9% of patients. Consequently, Ipilimumab was 
approved by the FDA for the treatment of unresectable or metastatic 
melanoma, with a risk evaluation and mitigation strategy to ensure that 
treatment benefits outweigh risks (Balwit et al., 2011; Culver et al., 2011). 
Following the promising results of the anti–CTLA-4 anticancer therapy, 
monoclonal antibodies targeting other negative regulatory molecules such as 
PD-1 have been developed and Phase II/III trials are currently under 







Figure 1.3.3 – Mechanism of action of anti-CTLA-4 antibody, Ipilimumab. 
Ipilimumab binds to CTLA-4 and inhibits the interaction between B7 and CTLA-4. 
Thus, the inhibitory signal produced by B7 binding to CTLA-4 is blocked, and T cell 
activation is maintained. MHC – major histocompatibility complex; Ag – antigen; TCR 
– T cell receptor; CTLA-4 – cytotoxic T lymphocyte antigen 4; APC – antigen 
presenting cell. 
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1.4 Limitations of T cell-based immunotherapy 
The continual growth of tumors in the presence of functional anti-tumor 
immune responses, whether spontaneous or induced by immunotherapy, is 
indeed the most disturbing paradox of tumor immunology (Zitvogel et al., 
2006). The so far limited success of T cell based immunotherapies is largely 
due to our incomplete understanding of the mechanisms preventing the action 
of T cells locally. In order to generate an effective anti-tumor immune 
response, primed, activated T cells have to migrate into the tumor site and 
persist in the tumor tissues to execute their anti-tumor functions. This can 
explain largely why most T cell based immunotherapies fail: while large 
amounts of activated tumor-specific T cells can be detected in the circulation, 
many patients fail to benefit from these treatments. This argues for the 
importance of downstream barriers from the initial T cell priming step that 
needs to be addressed in order to translate immune responses into clinical 
tumor regressions. The obstacles faced by activated T cells include defective 
T cell migration to tumor site, tumor-induced T cell suppression mechanisms, 
and active immune evasion strategies employed by the tumor cells. 
 
1.4.1 Defective T cell migration to tumor sites 
The efficacy of immunotherapy strategies relies on the capacity of functional 
anti-tumor T cells to traffic effectively to sites of tumor development. Therefore, 
T cell recruitment to the tumor is one of the potential rate-limiting steps in 
immunotherapy. In melanoma patients, approximately one-third have tumor 
metastases with significant TIL infiltration. However, the majority of metastatic 
lesions lack TIL, demonstrating that proper T cell trafficking into tumors might 
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not occur in these patients (Gajewski et al., 2006). Furthermore, infusion of 
radiolabeled TIL in cancer patients did not lead to tumor localization (Chin et 
al., 1993), suggesting that there might be impaired trafficking of TIL to tumors, 
or there may be specific exclusion of T cells from the tumors. 
 
The migration of T cells is dependent on the expression of a combination of 
selectins, chemokine receptors and integrins that regulate the trafficking and 
extravasation of T cells in different tumor microenvironments [reviewed in 
(Mondino et al., 2010)]. Thus, failure of T cell migration to tumor sites may be 
attributed to several factors, including low levels of T cell chemoattractants at 
the tumor site, active repulsion, lack of expression of chemokine receptors on 
T cells, and/or improper vascularisation. These factors are discussed in the 
following sections together with the therapeutic strategies aimed at interfering 
each of these factors to improve effector T cell trafficking into tumors. 
 
1.4.1.1 Low levels of T cell chemoattractants 
Little is known of the molecular cues critical for the recruitment of effector T 
cells into the tumor microenvironment. Intra-tumoral chemokines are likely to 
have a major impact on tumor-infiltrating T cells (Balkwill, 2003; Mantovani et 
al., 2004). Most information regarding the role of chemokines in effector T cell 
recruitment was derived from transduction of chemokine genes into 
transplantable tumor cell lines. To date, several chemokines have been 
suggested as potential recruiting factors for T cells into tumors, including 
XCL1 (lymphotactin) (Huang et al., 2005; Huang et al., 2002), CCL2 (Mcp-1) 
(Brown et al., 2007; Zhang et al., 2006), CCL3 (Mip-1α) (Crittenden et al., 
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2003; Maric and Liu, 1999), CCL4 (Mip-1β) (Schall et al., 1993; Taub et al., 
1993), CCL5 (Rantes) (Mule et al., 1996), CCL8 (Mcp-2) (Proost et al., 1996), 
CCL16 (LEC) (Giovarelli et al., 2000), CCL20 (LARC) (Crittenden et al., 2003), 
CCL21 (SLC) (Kirk et al., 2001; Sharma et al., 2000; Yang et al., 2004), 
CXCL12 (SDF-1α) (Bleul et al., 1996; Williams et al., 2010), CX3CL1 
(fractalkine) (Tang et al., 2007; Xin et al., 2005), and the non-ELR-CXC 
chemokines, CXCL9 (Mig), CXCL10 (IP-10), and CXCL11 (I-TAC) (Ben-
Baruch, 2006). In contrast to the known T cell attracting properties of these 
chemokines, several reports have also demonstrated T cell chemorepulsive 
activity mediated by high concentrations of CXCL12 (Poznansky et al., 2000; 
Vianello et al., 2006), even though at low concentrations CXCL12 has been 
shown to attract T cells.  
 
In addition to preclinical data, clinical pathological data have shown 
correlation between chemokine expression and the levels of T cell infiltration 
in human tumors. For example, the expression of CXCL9 and CXCL10 was 
associated with heavy T cell infiltration in primary melanoma lesions (Kunz et 
al., 1999). Furthermore, gene expression profiling studies in metastatic 
melanoma demonstrated that intra-tumoral expression of chemokines indeed 
correlate with T cell infiltration (Harlin et al., 2009). However, since T cells are 
also an important source of chemokines, the significance of such a correlation 
is unclear. Therefore, the expression of chemokines within a tumor has to be 
analyzed in relation to T cell infiltration, tumor responses and patient survival. 
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Given the critical roles of chemokines in T cell recruitment, it is likely that the 
failure of activated T cells to cause tumor regression is due to the lack of 
inflammation within the tumor microenvironment, which fails to express the 
appropriate proinflammatory chemokines necessary for T cell attraction. 
Consequently, researchers have used intratumoral delivery of chemokines or 
other immunostimulatory cytokines to recruit selected leukocyte populations to 
tumors as initiators or effectors of antitumor immune responses in preclinical 
models [reviewed in (Ruffini et al., 2007)] and in human cancers (Sangro et al., 
2004). 
  
1.4.1.2 Lack of expression of chemokine receptors 
The migration of effector T cells into a proinflammatory tumor 
microenvironment is dependent on the expression of corresponding 
chemokine receptors that recognize tumor-derived chemokines. IFN-γ-
producing T-helper type 1 (Th1) cells express the chemokine receptors CCR2, 
CCR5 and CXCR3, while T-helper type 2 (Th2) cells express CCR3, CCR4, 
CCR8 and CXCR4, suggesting that a partially distinct set of chemokines are 
involved in recruiting T cells with different polarization/differentiation state. 
Activated CD8+ cytotoxic T lymphocytes (CTL) are believed to respond to a 
similar set of chemokines as do Th1 cells (Gajewski et al., 2006). However, it 
has been shown that tumor-reactive T cells often lack the appropriate 
chemokine receptors to migrate in respond to the chemokines produced by 
the tumors (Berry et al., 2009). Hence, T cells engineered to express defined 
chemokine receptors have been shown to improve migration of T cells to 
tumor sites. For example, T cells genetically modified to express the 
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chemokine receptor CXCR2 migrated towards the ligand CXCL1 in vitro 
(Kershaw et al., 2002); while forced expression of CCR4 on T lymphocytes 
improved homing to Hodgkin‟s lymphoma expressing the corresponding 
chemokines CCL17 and CCL22 in vivo (Di Stasi et al., 2009). These reports 
demonstrate the potential application of using T cells engineered to express 
defined chemokine receptors to redirect tumor-reactive T cells to tumor sites. 
 
1.4.1.3 Improper vascularization 
Tumor tissues can be segregated into distinct microanatomical regions based 
on differences in vascular parameters. The blood vessels in peritumoral 
regions, in contrast to intratumoral regions often have a high endothelial 
venule (HEV)-like morphology and express high levels of primary and 
secondary adhesion molecules. Thus, the peritumoral areas are frequently 
associated with dense lymphocyte infiltrates (Fisher et al., 2006). Intratumoral 
vessels express low levels of adhesion molecules or chemokines, which 
prevents efficient interaction with circulating lymphocytes and thus, limits 
lymphocyte trafficking through tumor-associated blood vessels. Several in 
vitro and in vivo studies have suggested that angiogenic factors or anti-
inflammatory cytokines produced within the tumor microenvironment can 
negatively impact lymphocyte trafficking by preventing the expression of 
endothelial adhesion molecules (Hiraoka, 2010). 
 
In addition, tumor-associated blood vessels in various human cancers are 
often morphologically aberrant, characterized by dilated and fragile vessels, 
increased permeability, intensive vessel sprouting, delayed maturation and 
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loss of hierarchical architecture (Hamzah et al., 2008; Hiraoka, 2010). 
Constant vessel remodeling leads to spontaneous haemorrhages and 
increased interstitial fluid pressure in the tumour environment and represents 
a major barrier to successful T cell migration into the tumor parenchyma 
(Hamzah et al., 2008). Therefore, strategies aimed at “normalizing” tumor 
blood vessels to promote T cell infiltration and improve anti-tumor responses 
have been adopted. G-protein signalling 5 (Rgs5), for example, has been 
identified as a master gene responsible for the abnormal tumour vascular 
morphology in mice and loss of Rgs5 improved spontaneous T cell infiltration 
into tumors (Hamzah et al., 2008). In a recent study, Shrimali et al 
demonstrated that normalization of tumor vasculature through disruption of 
the VEGF (vascular endothelial growth factor)/VEGFR-2 axis can increase 
extravasation of adoptively transferred T cells into the tumor and improve 
ACT-based immunotherapy (Shrimali et al., 2010). 
 
1.4.2 T cell suppressive mechanisms after successful T cell recruitment 
into tumors 
Even when effector T cells have successfully migrated into the tumor tissues, 
they have to persist within the tumor microenvironment and maintain their 
cytotoxic functions for effective tumor cell killing. However, T cells that 
infiltrated the tumors are often faced with many immunosuppressive cues 
within the tumor microenvironment that prevent the action of T cells locally. 
The immunosuppressive mechanisms that have been described include T cell 
inhibitory ligands, negative regulation by other suppressor cells, activation-
induced T cell death, and metabolic inhibition. 
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1.4.2.1 T cell inhibitory ligands 
T cells that have migrated into the tumors may be progressively impaired or 
„exhausted‟ with respect to their functional and proliferative capacities. A 
diverse array of negative regulatory molecules expressed on T cell surface 
correlated with this „exhausted‟ phenotype, including CTLA-4, programmed 
cell death-1 (PD1/CD279), lymphocyte-activation gene 3 (LAG3/CD223), and 
T cell Ig- and mucin-domain-containing molecule-3 (TIM-3), among others 
(Klebanoff et al., 2011). Apart from being markers of T cell exhaustion, 
signaling through these molecules has been demonstrated to actively 
suppress cytokine secretion and T cell proliferation (Klebanoff et al., 2011). 
Strategies to overcome such inhibitory mechanisms have been discussed 
previously (Section 1.3.4). 
 
1.4.2.2 Negative regulation by other suppressor cells 
Regulatory immune cells including Tregs, Tr1 cells, Th3 cells and myeloid 
derived suppressor cells (MDSC) have all been described to contribute to 
immune suppression within the tumor microenvironment. The 
immunosuppressive cytokines IL-10 and TGF-β secreted by regulatory T cells 
inhibit the activation of professional antigen-presenting cells and directly 
suppress the function of effector T cells and B cells. Moreover, regulatory T 
cells constitutively express cell surface CTLA-4, which binds to B7 molecules 
on APC, indirectly suppressing T cell activation (Du and Wang, 2011). Several 
studies in cancer patients have demonstrated that the prevalence of Treg 
cells is significantly higher in cancerous lesions compared to those in healthy 
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controls, and the percentage of Treg cells among tumor-infiltrating immune 
cells correlates with lower survival rate (Du and Wang, 2011).  
 
Myeloid-derived suppressor cells (MDSC) represent a heterogeneous 
population of immunosuppressive cells with the expression of variable surface 
markers, such as CD11c+, CD11b+, CD33+, CD34+ and CD15+ (in human) and 
CD11b+, Gr1+ (in mouse). Increasing numbers of MDSC have been detected 
in the blood and/or in intratumor lesions in patients with different types of 
cancer. In addition, the frequency of MDSC is also positively correlated with 
the incidence of recurrence or metastatic disease in patients (Du and Wang, 
2011). Experimental studies have shown that MDSC can function as potent 
suppressors of cytotoxic activity of effector CD8+ T cells via various 
mechanisms including the expression of arginase and/or reactive oxygen 
species, the induction of Foxp3+ Treg cells, sequestration of cysteine 
necessary for T cell activation, and down-regulation of L-selectin on T cells 
(Du and Wang, 2011; Ostrand-Rosenberg, 2010). Interestingly, MDSC can 
also promote early cancer cell dissemination from primary melanoma tumor 
by inducing epithelial-mesenchymal transition (EMT) (Toh et al., 2011). 
 
Clinical trials using denileukin diftitox (Ontak), a CD25-directed diphtheria 
toxin to eliminate Tregs, have already been initiated in renal cell carcinoma or 
melanoma patients and preliminary results are promising (Dannull et al., 2005; 
Rasku et al., 2008). Sunitinib, a receptor tyrosine kinase inhibitor, has been 
shown to reduce the levels of MDSC in the blood of renal cell carcinoma 
patients. However, no changes in tumor burden, response to treatment or 
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survival have been reported (Ko et al., 2009). Chemotherapeutics such as 
gemcitabine is also known to inhibit Tregs in humans (Correale et al., 2005) 
and interestingly, MDSCs in mouse (Le et al., 2009; Suzuki et al., 2005). 
   
1.4.2.3 Activation-induced T cell death 
Several reports indicated that Fas (CD95/Apo-1) ligand (FasL) expression on 
various types of tumor cells may induce apoptosis of T cells in vitro (Hahne et 
al., 1996; O'Connell et al., 1996; Strand et al., 1996) and in vivo (Cefai et al., 
2001), and may promote tumor escape from immune attack. FasL is 
expressed by many human tumors and is associated with poor prognosis in 
breast, liver, and ovarian cancers, supporting the immunosuppressive 
“counterattack” hypothesis (Jansen et al., 2010). Several studies using gene 
therapy strategies to knockdown FasL expression on tumor cells 
demonstrated reduced T cell apoptosis (Zhang and Xu, 2007) and improved 
anti-tumor immune responses (Jansen et al., 2010). Nevertheless, the exact 
role of FasL in tumor escape mechanism is still controversial. Tumor-specific 
T cells have been shown to utilize the Fas/FasL system to kill tumor cells in 
vivo (Arai et al., 1997). Therefore, much remains to be done to investigate 
whether FasL knock-down therapy has the potential to enhance current 
immunotherapies, including interleukin delivery and tumor vaccines, to 
achieve tumor regression in a clinical setting. 
 
Although less well studied, chemokine-induced T cell death has also been 
reported in melanoma. In melanoma, the binding of melanoma-induced 
expression of CCR5 ligands to CCR5 on CD8+ T cells activates an apoptotic 
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pathway involving cytochrome c release into the cytosol and activation of 
caspase-9 and -3 (Mellado et al., 2001a). Further studies are needed to 
confirm whether this phenomenon can be broadly applicable to other 
chemokines known to activate T cells and are normally expressed within the 
tumor microenvironment.  
 
1.4.2.4 Metabolic inhibition 
Three metabolic enzymes have been identified to mediate 
immunosuppression within the tumor micronenvironment, including 
indoleamine 2,3-dioxygenase (IDO), arginase, and inducible nitric oxide 
synthase (iNOS). IDO can be produced by tumor cells and/or dendritic cells in 
the tumor microenvironment and it suppresses T cell responses through 
tryptophan depletion via the production of proapoptotic metabolites (Fallarino 
et al., 2002). Uyttenhove et al demonstrated that inhibition of IDO expression 
using 1-methyltryptophan (1-MT) can improve T cell mediated tumor control in 
vivo (Uyttenhove et al., 2003). In addition to IDO, arginase has been shown to 
inhibit T cell activation by degrading another essential amino acid, arginine. In 
advanced cancer patients and in preclinical models, defective T cell activation 
has been associated with arginase-mediated downregulation of CD3zeta 
expression on T cells. Another arginine-metabolizing enzyme, iNOS, can lead 
to the production of nitric oxide, which has detrimental effects on T cell 
priming, proliferation, and cytotoxicity (Lizee et al., 2007). iNOS expression in 
human melanoma is associated with poor clinical prognosis (Ekmekcioglu et 
al., 2006) and targeted inhibition of iNOS inhibited human melanoma growth 
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in mouse models (Sikora et al., 2010), suggesting that targeting iNOS could 
be attractive for clinical application.  
 
1.4.3 Defects at the level of the cancer cell 
Cancer cells have been shown to actively evade immune attack and 
elimination by the immune system, leading to enhanced tumor development 
and progression. In fact, the concept of avoiding immune destruction has 
been proposed as one of the two emerging hallmarks of cancer in Weinberg‟s 
latest revision of the classical hallmarks of cancer (Hanahan and Weinberg, 
2011). Several immune escape strategies utilized by cancer cells that are 
commonly described includes downregulation or loss of tumor antigens or 
MHC class I molecule and defects in apoptotic machinery. 
 
1.4.3.1 Down-regulation or loss of tumor antigens/MHC class I molecule 
Tumor cells are known to escape immune control by losing the expression of 
tumor antigens or down-regulating multiple components of the MHC class I 
antigen presentation machinery including proteasome components, 
transporter associated with antigen processing-1 (TAP1) or TAP2, MHC class 
I molecule or β2-microglobulin. Loss of MHC class I expression has been 
documented more frequently on aggressive and metastatic cancers compared 
to early-stage or more differentiated cancers (Du and Wang, 2011). 
Conversely, higher class I expression in bladder carcinoma has been 
associated with longer patient survival (Du and Wang, 2011). Tumors with 
altered expression of class I molecule contain few CD8+ T cells in both renal 
cell carcinomas and cervical carcinomas (Du and Wang, 2011). This 
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deficiency is also associated with diminished sensitivity to CTL-mediated lysis, 
but increased susceptibility to NK cell destruction. The frequency of class I 
deficiencies is dependent on the tumor type and varies from 15 to 95% 
(Seliger, 2008). Therefore, the assessment of MHC class I antigen processing 
machinery components might identify patients able to respond to 
immunotherapy. Prospective studies have to be performed to validate the 
value of identifying MHC class I abnormalities for prognosis and therapeutic 
purposes. 
 
1.4.3.2 Defects in apoptotic machinery 
Evasion of endogenous cell death processes via defects in normal cell death 
pathways contribute to cancer progression by permitting progressively 
aberrant cell behaviours and desensitizing tumor cells to immune-mediated 
attack, radiation, and chemotherapy. The mechanisms responsible for this 
deficiency have been attributed to constitutive NF-κB activation, expression of 
anti-apoptotic Bcl-2 family members, defective signalling by Fas or TRAIL 
(tumor necrosis factor–related apoptosis-inducing ligand), active Notch 
signalling, expression of survivin, among others (Gajewski et al., 2006). 
Several apoptosis-based therapies have been developed to trigger tumor 
apoptosis and clinical trials are underway. These include gene therapies by 
down-regulation of anti-apoptotic genes/over-expression of pro-apoptotic 
genes, small molecule inhibitors of IAP, nutlins to increase levels of p53, 
chemical inhibitors of c-AKT that targets several apoptosis-regulating proteins, 
and compounds that reduce activation of NF-κB family transcription factors 
(Reed, 2006). 
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1.5 Chemotherapy and anti-tumor immune responses  
Chemotherapy drugs were originally selected for their direct cytotoxic effect 
on tumor cells. The clinical success of chemotherapy to treat tumors is still 
very limited and varies considerably with tumor types. Tumors that are usually 
cured by chemotherapy include childhood leukemia, Hodgkin‟s disease, 
testicular cancer, choriocarcinoma, Burkitt‟s lymphoma, and nephroblastoma 
(Kaye), whereas most solid tumors respond poorly to chemotherapy. For 
example, the use DTIC as a single agent can induce objective tumor 
regression in 15%–20% of metastatic melanoma patients. However, the 
median response duration is 5 to 6 months with a negligible complete 
response rate and no significant effect on survival (Hershkovitz et al., 2010). 
 
Accumulating evidence indicates that chemotherapy drugs could also 
indirectly promote tumor cell killing by effector components of the immune 
system (Nardin et al., 2011) (Figure 1.5.1). Certain chemotherapeutic drugs 
may contribute to anti-tumor immune responses by eliciting specific cellular 
responses that render tumor cell death immunogenic (Zitvogel et al., 2011). 
This includes the production of “eat-me signals” via calreticulin translocation 
to the plasma membrane, which stimulates antigen uptake by dendritic cells 
and antigen presentation to T cells. The release of danger signals such as 
high mobility group box 1 (HMGB1) protein, stimulates TLR4 (toll-like receptor 
4) and regulates antigen processing and presentation, and thereby influences 








Figure 1.5.1 – Activation of the immune system by chemotherapy agents. 
Chemotherapy drugs have been shown to contribute to anti-tumor responses via the 
induction of immunogenic cell death mechanisms, upregulation of immune 
recognition molecules on tumor cells, inhibition of immunosuppressive cells, and non-
specific activation of innate immune cells (see text for details). CRT – calreticulin; 
HMGB1 – high-mobility group protein B1; DR4,5 – death receptor 4 and 5 [adapted 
from (Menard et al., 2008)].  
  
 
Other chemotherapy drugs may have side effects that stimulate the immune 
system, either directly or indirectly. Chemotherapy can induce stress signals 
leading to increased susceptibility of cancer cells to immune attack (Fine et al., 
2010), including upregulation of NK stimulatory ligands (eg. NKG2D ligands 
after DNA damage) and/or death receptors (eg. Fas and TRAIL receptor) on 
tumor cells, leading to increased tumor cell killing. In addition, 
chemotherapeutic drugs could indirectly stimulate the immune system through 
transient lymphocyte depletion followed by more rapid homeostatic 
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proliferation, and subversion of immunosuppression mechanisms. For 
example, low dose cyclophosphamide (CPM) decreases the number and 
inhibitory function of CD4+ CD25+ Tregs by downregulating the expression of 
forkhead box P3 (FoxP3) and glucocorticoid-induced TNF-receptor-related 
protein (GITR) (Zitvogel et al., 2008), while gemcitabine reduces the 
frequency of CD11b+ Gr1+ MDSCs (Suzuki et al., 2005). Furthermore, 
chemotherapy may exert a direct effect on the activation of immune effector 
cells. For example, the vascular disrupting agent, 5,6-dimethyl-xanthenone-4-
acetic acid (DMXAA) has been shown to activate tumor-associated 
macrophages (Jassar et al., 2005) or DC (Wallace et al., 2007), leading to 
increased tumor infiltration by CTL and myeloid cells. In addition, the taxane 
paclitaxel (Taxol; Bristol-Myers Squibb) can activate mouse macrophages and 
DCs by binding directly to TLR4, and has been shown to enhance T cell and 
NK cell activity in breast cancer patients (Zitvogel et al., 2008). 
 
Recently, chemotherapeutic drugs have been shown to increase cytokine 
production in a variety of cell types in vitro. The significance of tumor-derived 
cytokine production in the therapeutic effectiveness or side effect profile of 
chemotherapeutic agents is unknown (Darst et al., 2004). However, significant 
levels of cytokines, including IL-8, TNF-α (tumor necrosis factor alpha), and 
others have been detected in the serum of patients undergoing chemotherapy 
for a variety of tumors (Darst et al., 2004). Another open question is whether T 
cell infiltration is a prognostic factor or predicts response to chemotherapy 
(Halama et al., 2009). While the presence of T cell infiltrates does not predict 
response to neoadjuvant chemotherapy in advanced laryngeal cancer 
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patients (Wolf et al., 2002), T cell infiltration after neoadjuvant chemotherapy 
in breast cancer patients is predictive of survival (Demaria et al., 2001; 
Ladoire et al., 2011).  
 
In melanoma, mixed responses to chemotherapy are frequently observed 
(Bajetta et al., 2002). Systemic events such as improved induction of an 
immune response are unlikely to account for this variability, as this would 
most likely impact all lesions similarly. Tumor heterogeneity or differences in 
the tumor microenvironment is a more plausible explanation. It is not known 
whether differential T cell trafficking contributes to mixed responses after 
chemotherapy, and importantly, whether local factors controlling the 
recruitment of T cells into tumors could be affected by chemotherapy and 
therefore influence the clinical outcome.  
 
Taken together, the ability of chemotherapy drugs to stimulate an anti-tumor 
immune response suggests that improved patient outcomes might be 
achieved using rational combinations of chemotherapy and immunotherapies 
(Nardin et al., 2011). Indeed, impressive clinical responses have been 
reported in patients treated with a combination of monoclonal antibodies (mAb) 
and chemotherapeutic drugs (Zhang and Herlyn, 2009). This raises great 
expectations for combination therapies using either vaccine or adoptive T cell 
transfer with chemotherapy, which have been shown to be promising in 
animal models and early clinical trials (Zhang and Herlyn, 2009). 
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1.6 Preclinical models in tumor immunotherapy studies 
Mouse models of cancer have been instrumental in defining the mechanisms 
of tumor development and for the assessment of putative cancer therapeutics. 
The most widely used models are transplantation models, including murine 
tumors grown in syngeneic hosts or human tumor xenografts grown in 
immunodeficient mice. Autochthonous tumor models including carcinogen-
induced tumor models and spontaneous tumor models (also known as 
genetically-modified mouse models, GEMM) are more recent developments 
that mirror defined steps of human carcinogenesis.  
 
1.6.1 Transplanted tumor model 
In transplanted tumor models, tumor cell lines implanted subcutaneously, 
intraperitoneally, or orthotopically into syngeneic mice generally grow rapidly 
(average doubling time < 2 days) and thus do not mimic the much slower 
doubling times of most human cancers. Extensive culturing of tumor cells will 
inadvertently select for cells with optimal growth and survival in vitro, and 
these tumor cells grow rapidly in vivo independent of the complex 
stroma/immune interactions (Tham and Abastado, 2011). The high 
proliferative capacity of these cells renders the tumors more sensitive to 
chemotherapeutic drugs that target actively dividing cells.  
 
In the case of human tumor xenograft models, human tumor cells are grown 
in immune-deficient mice, therefore the role of the immune system cannot be 
evaluated. It is also unclear whether the tumor cells implanted at ectopic sites, 
which is a standard methodology, will respond to therapy the same way as 
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tumors grown at orthotopic site (i.e. in their organ of origin). In addition, 
studies of metastatic cancer therapy often involve artificial injection of tumor 
cells into the circulation. Therefore, transplanted tumor models are not suited 
for studying the early events of metastasis. Furthermore, large numbers of 
cells are required to induce tumor formation, which does not reflect the 
physiological condition of spontaneous tumor growth in vivo (Tham and 
Abastado, 2011). Despite these disadvantages, transplanted tumor models 
are still extensively used to study the immune response to tumor development 
and for the development of anticancer immune therapies, especially for 
advanced cancers.  
 
1.6.2 Spontaneous tumor model 
Carcinogen-induced models rely on administration of specific chemicals to 
generate cellular changes that rapidly lead to carcinogenesis. Several 
examples of widely used and studied models are the 7,12- 
dimethylbenzanthracene (DMBA) or N-methyl-N-nitrosourea (MNU) or 
hormonal 17b-estradiol (E2) induced mammary tumor models. In healthy 
female mice, these carcinogens induce a high incidence of mammary 
adenocarcinomas (MACs) that express similar histology and biomarker 
expressions to the human disease within 2–5 months (Ting et al., 2007).  
 
Genetically-modified mouse models (GEMM) are generated through 
alterations in the level of expression (over-expression or deletion) of 
oncogenes or tumor suppressor genes. Examples of GEMM include the 
spontaneous models of breast cancers (including MMTV-PyMT and MMTV-
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Erbb2) and pancreatic islet carcinoma (RIP-Tag). The main advantage of 
autochthonous models is that they can faithfully recapitulate key aspects of 
the human disease progression, including tumor initiation, local progression 
and distant metastases (Tham and Abastado, 2011). The tumors mostly 
develop at orthotopic sites, often reflect their respective human tumor 
histotypes, and contain a stroma and vasculature. As tumors develop over a 
long period of latency, there is sufficient time for tumor-host immune system 
interactions. While both of these autochthonous tumor models have been 
successful in predicting toxicity issues in humans, their value in predicting 
clinical results remains slow to progress (Walrath et al., 2010). This is, in part, 
due to low penetrance, long tumor latency, low incidence of distant metastasis, 
and asynchronous tumor development (Francia et al., 2011). 
 
1.6.3 RETAAD model of spontaneous melanoma 
To better mimic human disease, we are working on RETAAD mice, a recently 
characterized model of spontaneous melanoma that displays many critical 
features of the human disease (Lengagne et al., 2008). RETAAD mice are 
transgenic for the activated human RET oncogene and the chimeric 
mouse/human MHC antigen AAD (α1-α2 domains of HLA-A2 linked to α3 
domain of H-2Dd). The RET oncogene, which encodes a receptor tyrosine 
kinase, is driven by the metallothionein-I (MT) promoter (Kato et al., 1998). In 
RETAAD mice, the RET oncogene is expressed by melanocytes (Iwamoto et 
al., 1991), driving enhanced melanogenesis, leading to skin melanosis and 
oncogenic transformation (Eyles et al., 2010).  
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In RETAAD mice, melanoma tumor development occurs step-wise starting 
with exophthalmos (i.e. bulging of the eye), followed by the development of 
spontaneous uveal melanoma (~28d), facial tumors (61d), neck/trunk tumors 
(135d), and eventually metastatic spread to various visceral organs (~250d), 
with each organ displaying a unique kinetic of tumor onset and tumor growth. 
SNP (single nucleotide polymorphism) analyses of 102 tumors derived from 
five mice revealed that most tumors arising in the same mouse share a 
common clonal origin. Consequently, most lesions (including cutaneous 
tumors) represent metastases and not independently transformed primary 
tumors (Eyles et al., 2010). 
 
The expression of natural tumors antigens and the chimeric MHC molecule 
AAD in RETAAD mice facilitate the analysis of CD8+ T cell responses against 
immunodominant HLA-A2-restricted human melanoma epitopes. Lengagne 
and co-workers have previously demonstrated that in the RET transgenic 
mice, a strong and broad anti-melanoma CD8+ T cell response could be 
detected in the periphery as tumor grows (Lengagne et al., 2008; Lengagne et 
al., 2004). Using tyrosinase-related protein 2 (TRP2) as a model antigen, 
Umansky and colleagues showed that Trp2-specific CD8+ T cells (mostly of 
the effector memory phenotype) could be detected in the bone marrow and 
tumors of transgenic mice (Umansky et al., 2008). Interestingly, these tumor-
specific effector memory CD8+ T cells were also found in the bone marrow of 
transgenic mice without macroscopic tumors but showing microscopic lesions 
in the lymph nodes. 
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Recently, we have shown that tumor cells disseminate early to various organs 
in the RETAAD mice even before clinical detection of the primary eye tumor 
(Eyles et al., 2010). These early disseminated tumor cells (DTC) remain 
dormant for varying periods of time depending on the organ/tissue. CD8+ T 
cells are required for the maintenance of tumor cell dormancy in visceral 
organs but not in the skin, as depletion of CD8+ T cells significantly 
accelerated visceral tumor outgrowth and decreased survival in these mice, 
but had no effect on skin tumor development (Eyles et al., 2010; Lengagne et 
al., 2008).  
 
The growth of immunogenic tumors in the presence of a functional anti-tumor 
immune response is clearly the most disturbing paradox of tumor immunology. 
The commonly proposed mechanisms to explain the paradoxical growth of 
tumors, including systemic ignorance, anergy, or tumor immunoediting alone 
cannot explain the growth of cutaneous tumors in the RETAAD mice, since 
most mice develop a strong tumor-specific CD8+ T cell response and that 
these T cells have been shown to efficiently recognize tumor cell lines derived 
from cutaneous nodules (Lengagne et al., 2008). Local alteration of the 
immune system is a plausible explanation. In fact, several studies have 
focused on the role of immunosuppressive cells in cutaneous tumor 
development in the RET model. Increased frequencies of regulatory T cells 
(Treg) and myeloid-derived suppressor cells (MDSC) have been detected in 
cutaneous tumors and have been proposed to impair anti-tumor T cell 
responses in these tumors. However, depletion of Tregs had no effect on skin 
melanoma development (Kimpfler et al., 2009). While the depletion of MDSCs 
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led to partial restoration of T cell function in cutaneous tumors and increased 
survival in these mice (Meyer et al., 2011), we have found no effect of MDSC 
depletion on cutaneous tumor growth (Toh et al., 2011). Therefore, the 
escape of cutaneous tumors from the immune system involves other local 
suppression mechanism(s) that deserve futher exploration. 
 
Taken together, the RETAAD model recapitulates many distinctive features of 
human disease, including natural progression of the disease, the paradoxical 
growth of immunogenic tumors in an immunocompetent host, and mixed 
efficacy of T cells, Therefore, the RETAAD model represents a unique model 
to investigate the basis of tumor escape from anti-tumor T cell responses, 
which could help to better understand and improve the efficacy of current T 
cell-based immunotherapies to treat cancers. 
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1.7 In vivo imaging to monitor tumor responses to immunotherapies 
The two main objectives in modelling human diseases in animal models are (1) 
to recapitulate the pathophysiological characteristics of the human disease in 
the presence of a complete immune system to facilitate understanding of the 
complex molecular mechanisms underlying tumor development; and (2) to 
use these models to develop or test new targeted therapies. Since the growth 
and progression of spontaneous tumors varies widely from animal to animal, 
post-mortem tissue analysis of large cohorts of animals is often required to 
derive statistically meaningful data. Autopsy is often the most effective way to 
evaluate treatment efficacy and longitudinal studies examining the dynamics 
of tumor response and relapse to treatment is almost impossible. 
 
The recent development of non-invasive imaging techniques has made it 
possible to follow tumor progression in mice with spontaneous tumor 
development. These include nuclear techniques such as magnetic resonance 
imaging (MRI) (Nelson et al., 2003), single-photon emission computed 
tomography (CT) and positron emission tomography (PET) (Mankoff et al., 
2000; Mankoff et al., 2005; Ray et al., 2003; Yang et al., 2003), and optical 
techniques such as fluorescence imaging (FLI) (Hoffman and Yang, 2006) 
and bioluminescence imaging (BLI) (Rehemtulla et al., 2000). Detailed 
comparison of these molecular imaging techniques for tumor detection in vivo 
has been extensively reviewed (Koo et al., 2006; Lyons, 2005). For molecular 
imaging to be adapted more widely and to be complementary to other types 
molecular measurements, the read-out needs to meet certain criteria, i.e. it 
should be reliable, quantitative, high throughput, sensitive, high resolution, 
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longitudinal (allow imaging over time), and allow assessment of tumor burden 
in the whole animal. 
 
We have previously compared the performances of various imaging 
modalities for whole body tumor imaging in transplanted and autochthonous 
melanoma models. Our data showed that BLI enables high-throughput, 
sensitive (detecting even non-palpable tumors), and quantitative whole-body 
tumor imaging for skin tumors and visceral metastases, and is suited for the 
determination of tumor burden in longitudinal studies. FLI is less sensitive 
than BLI and can only detect palpable tumors (≥2mm). Moreover, FLI signal is 
more subjected to tissue attenuation (3-fold vs 14-fold) and the presence of 
hair (70-fold vs 400-fold). Therefore, deep tissue imaging is unlikely due to the 
increased optical path through the tissues (Puaux et al., 2011). For nuclear 
imaging techniques, MRI and 18FDG-PET allow early detection of small 
tumors and exhibit good sensitivity (81% and 70%) and positive predictive 
value (95% and 86%) compared to necropsy. In addition, MRI and 18FDG-
PET are not limited by the depth of the tumor, and both were able to provide 
precise locations of small nodules. For whole-body metabolic imaging, 18FDG-
PET is a better option for longitudinal follow-up of tumor burden. However, the 
high background observed in some organs (e.g. brain, heart and bladder) 
prevent tumor detection in these organs. MRI provides good contrast and 
anatomical information related to location, volume, vascularization and 
invasion. However this method is more challenging for whole-body tumor 
detection. Furthermore, both MRI and 18FDG-PET scans are time-consuming 
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(low throughput), costly and require expertise for data analysis (Puaux et al., 
2011). 
 
Taken together, while each imaging modality has its own advantages, BLI is 
by far most suited for whole body detection of spontaneous tumor growth and 
for the purpose of evaluating preclinical therapies. BLI has been extensively 
validated in multiple transplanted and xenograft tumor models and its use in 
spontaneous tumor model is beginning to gain much attention. 
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1.8 Aims of the project 
The success of T cell-based immunotherapies to treat cancers is still lacking. 
Therefore, the goal of the present study is to identify local factors that 
determine tumor control by T cells. We address this question using both the 
RETAAD mouse model of spontaneous melanoma and samples obtained 
from melanoma patients.  
 
In RETAAD mice, CD8+ T cells control visceral tumor outgrowth but have no 
effect on cutaneous tumors (Eyles et al., 2010; Lengagne et al., 2008), 
suggesting mixed T cell efficacy in the RETAAD mice. In melanoma patients 
treated with chemotherapy, mixed T cell responses were similarly observed. 
Using global transcriptome analysis on cutaneous melanoma metastases 
resected from melanoma patients before and after chemotherapy, increased T 
cell infiltration was identified specifically in chemotherapy-sensitive tumors 
(Nardin et al., 2011). Therefore, the aim of this study is to identify molecular 
cues that control T cell infiltration into cutaneous melanoma tumors in both 
human and mouse, and to evaluate the impact of therapeutic strategies on 
modulating the expression of such molecular cues in promoting T cell 
infiltration into tumors.  
 
In addition, we addressed the need for a reliable imaging technique to follow 
disease progression and to evaluate responses to future chemo-
immunotherapeutic treatments in spontaneous tumor models. This leads to 
the second aim of this study, i.e. to improve our current model of spontaneous 
mouse melanoma by developing a new transgenic mouse model that allows 
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longitudinal monitoring of disease progression and therapeutic responses by 
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2 MATERIALS AND METHODS 
 
2.1 Development of a new spontaneous bioluminescent mouse 
melanoma model to monitor tumor growth and treatment 
responses 
2.1.1 Tumor cell lines 
The B16-F10 mouse melanoma cell line was from American Type Culture 
Collection (Cat Nr CRL-6475). B16-F10-luc cells (Xenogen, Alameda, CA) 
express firefly luciferase (sequence from pGL3, Promega) under the control of 
the SV40 promoter. 
 
2.1.2 Animals 
Animal care and experimental procedures were approved by the Institutional 
Animal Care and Use Committee of the Biological Resource Center, A*STAR, 
Singapore. RETAAD mice were generated as previously described (Kato et 
al., 1998).  
 
2.1.3 Development of Melucie mouse 
2.1.3.1 Gene expression analysis 
RETAAD tumor samples were homogenized and RNA extraction was 
performed using NucleoSpin® RNA II kit (MACHEREY-NAGEL). Reverse 
transcription was performed and the expression of five melanocyte-specific 
genes relative to Gapdh was measured by quantitative real-time PCR (qRT-
PCR) with SYBR green as previously described (Eyles et al., 2010). 
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2.1.3.2 Cloning of the Dct promoter 
The mouse dopachrome tautomerase (Dct) promoter sequences with two 
different lengths were amplified from a BAC (bacterial artificial chromosome) 
probe (CHORI), denoted Dct1 (-3181 to +445) and Dct2 (-3181 to +63). Both 
Dct promoter sequences were individually cloned into the multiple cloning site 
(MCS) region of a pGL4.17 plasmid (Promega). Briefly, the pGL4.17 plasmid 
was digested with NheI and XhoI, dephosphorylated, and the Dct promoters 
were ligated separately with the luciferase vector to generate the final 
constructs, pGL4.17-Dct1 and pGL4.17-Dct2.  
 
2.1.3.3 Luciferase reporter assay 
The pGL4.17-Dct1 and -Dct2 constructs were transfected into B16-F10 
mouse melanoma cells using Lipofectamine™ 2000 (Invitrogen) according to 
the manufacturer‟s protocol.  The pGL4.13 vector (luc2 gene under the control 
of SV40 promoter) was used as a positive control. For luciferase assays, the 
cells were harvested 24h after transfection, and the luciferase activity was 
measured using a Dual Luciferase Reporter Assay kit (Promega) according to 
the manufacturer‟s protocol and firefly luciferase activity was normalized by 
renilla luciferase activity. Total protein content of the cell extracts was 
measured using BioRad Protein Assay Solution. Data was expressed as the 
relative light unit (RLU) per mg protein.  
 
2.1.3.4 Transgenesis and founder screening 
To generate the transgenic mouse, Dct-Luc, the pGL4.17-Dct2 construct was 
digested using SacII and StuI. Of the two resulting fragments, the larger 
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fragment (6341bp) containing the Dct promoter and luc2 gene was gel-
purified. This linear DNA preparation was microinjected into fertilized C57BL/6 
oocytes at the one-cell stage. Resulting mouse embryos were then implanted 
into pseudo-pregnant females. Pups were screened for transgene insertion by 
PCR. Luciferase expression was confirmed by in vivo BLI using a protocol 
described previously (Puaux et al., 2011) and the number of luciferase 
integration site(s) was determined by fluorescence in situ hybridization (FISH). 
Briefly, mouse chromosomes were prepared from mouse tail fibroblasts. To 
detect the transgene DNA, transgene-specific probes (300 bases to 2kb in 
size) were generated from the luciferase construct used for micro-injection. 
Cells were co-denatured with the probes during hybridization. Finally, two out 
of five luciferase founders were selected and independently crossed with MT-
ret transgenic mice to generate double-transgenic Melucie mice. 
 
2.1.4 Characterization of Melucie mouse 
In vivo BLI of tumors was performed as previously described (Puaux et al., 
2011). Ex vivo BLI of isolated organs was performed immediately after 
euthanasia of the animals. Dissected organs were plated into 48-well plates 
and imaged by IVIS after addition of 15mg/ml luciferin substrate. The 
presence of tumors in dissected organs was confirmed by hematoxylin and 




2.1.5 Data analysis and statistical analysis 
BLI data were analyzed using Living Image Software (Xenogen, MA). Data 
was presented as relative light unit (RLU) (or photons per second, p/s). 
Correlation analyses was perfomed on log transformed values using Pearson 
correlation, one-tailed. The positive predictive value (PPV) was defined as: 
(number of tumors detected by imaging and confirmed at necropsy) / (total 
number of tumors detected by imaging); the sensitivity for tumor identification 
was defined as: (number of tumors detected by imaging and confirmed at 
necropsy) / (total number of tumors observed at necropsy). 
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2.2 Chemokines and intra-tumoral T cell trafficking in cutaneous 
mouse melanoma  
2.2.1 Mouse melanoma cell lines 
The B16-F10 (Cat Nr CRL-6475) cell line was from ATCC. The Melan-ret cell 
line, derived from a cutaneous tumor of a RET+ mouse, was previously 
described (Lengagne et al., 2004). 
 
2.2.2 Mice 
Animal care and experimental procedures were approved by the Institutional 
Animal Care and Use Committee of the Biological Resource Center, A*STAR, 
Singapore. 
 
2.2.3 Gene expression analysis 
RETAAD tumor samples were homogenized and RNA extraction was 
performed using NucleoSpin® RNA II kit (MACHEREY-NAGEL). Reverse 
transcription was performed and the expression of various immune genes 
relative to Gapdh (for mouse) and ACTB (for human) was measured by qRT-
PCR with SYBR green as previously described (Eyles et al., 2010). 
 
To measure the expression of chemokine and chemokine receptor genes, 
reverse transcription was first carried out using RT2 first strand kit 
(SABiosciences) with 1μg of RNA. The inflammatory cytokine-chemokine “RT2 
profiler PCR array” (SABiosciences) was used to measure the transcript 
levels of 40 inflammatory chemokines and their receptors. Data analysis was 
conducted according to the manufacturer's instructions. 
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2.2.4 Immunofluorescence 
Formalin-fixed paraffin-embedded sections (5μm) were immunolabeled for 
CD3ε to identify T cells. Briefly, sections were heat-treated with Target 
Retrieval Solution (Dako S1699), blocked with 10% (v/v) normal goat serum 
(Dako) in PBS for 2h and Avidin/Biotin blocking solution (Dako X0590) for 
10min, before overnight incubation at 4°C with rat monoclonal anti-CD3 
antibody (Acris SM1754P; diluted 1:50 in PBS with 10% [v/v] normal goat 
serum). Anti-CD3 antibody binding was revealed with biotinylated donkey 
polyclonal anti-rat antibody (Jackson Lab; AffiniPure F(ab‟)2 Fragment; diluted 
1:300) and AF594-conjugated strepavidin (Invitrogen S-11227; diluted 1:500 
in PBS with 10% [v/v] normal goat serum). Nuclei were counterstained with 
DAPI. CD3 labeling was visualized using ImagePro Analyzer 6.2 software 
(Media Cybernetics Inc.). 
 
2.2.5 Flow cytometry analyses 
Single cell suspensions were obtained by digestion with Collagenase A 
(1mg/ml) and DNase I (0.1mg/ml) (Roche) in RPMI for 20min. After red blood 
cell lysis, Fc receptors were blocked with anti-mouse CD16/CD32 monoclonal 
antibodies (mAbs) for 30min before incubation with antigen-specific antibodies 
with a 1:50 dilution. 
 
For the quantification of CD3+ T cells, a total of 22 cutaneous and 4 visceral 
tumors were collected from tumor-bearing RETAAD mice. Tumors were 
dissociated and labeled with PerCP-Cy5.5-conjugated anti-CD45 mAb and 
PE-conjugated anti-CD3 mAb (Biolegend) for 20min. 
 83 
For the characterization of chemokine receptors expressed on the surface of 
T cells subsets, whole blood was obtained from RETAAD mice and peripheral 
blood mononuclear cells (PBMC) were isolated. PBMC were incubated with 
PE-conjugated anti-CD3E mAb, PerCP-Cy5.5-conjugated anti-CD4 mAb, 
eFluor450-conjugated anti-CD8A mAb, PE-Cy7-conjugated anti-CD44 mAb, 
FITC-conjugated anti-CD62L mAb, and APC-conjugated anti-(human) CCR1 
(R&D Systems) or anti-CCR2 (R&D Systems) or anti-CCR3 mAb. For CCR5, 
cells were labeled with FITC-conjugated CD3E mAb, PerCP-Cy5.5-
conjugated anti-CD4 mAb, eFluor450-conjugated anti-CD8 mAb, PE-Cy7-
conjugated anti-CD62L mAb, APC-Cy7-conjugated anti-CD44 mAb, and PE-
conjugated anti-CCR5 mAb (R&D Systems). For CXCR3, cells were labeled 
with PE-conjugated anti-CD3E mAb, PerCP-Cy5.5-conjugated anti-CD4 mAb, 
eFluor450-conjugated anti-CD8 mAb, FITC-conjugated anti-CD62L mAb, 
APC-Cy7-conjugated anti-CD44 mAb, and PE-Cy7-conjugted anti-CXCR3 
mAb. Corresponding isotype-matched control mAbs were used in control 
samples. All antibodies were from Biolegend unless otherwise stated. The 
same labeling protocol was used to characterize chemokine receptors on TIL. 
The markers for naïve, effector memory and central memory T cells were 
defined as CD62L+ CD44- (naïve), CD62L- CD44+ (effector memory) and 
CD62L+ CD44+ (central memory) for both CD4+ and CD8+ T cells. 
 
All samples were acquired on a multicolor FACS LSRII and data analysis was 
performed using FlowJo software (Becton Dickinson). 
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2.2.6 Construction of chemokine expression plasmids 
Total RNA from LPS-activated murine peritoneal macrophages was reverse 
transcribed then PCR amplified using specific primers for Ccl5 (5‟ primer 
TACCGAGCTCGGATCCATGAAGATCTCTGCAGCTG; 3‟ primer AAACGGG 
CCCTCTAGAGCAGGGTCAGAATCAAGAAACC), and Cxcl9 (5‟ primer 
TACCGAGCTCGGATCCGCCACCATGAAGTCCGCTGTTC; 3‟ primer GCCC 
TCTAGACTCGAGCTCTTATGTAGTCTTCCTTG). The 5‟ end of each primer 
contains 15 bases homologous to the 5‟ end of each cloning site in the vector 
and the 3‟ end of each primer is gene-specific. The Ccl5 5‟ primer contains a 
BamHI site, and the 3‟ primer contains a NheI site; the Cxcl9 5‟ primer 
contains a BamHI site, and the 3‟ primer contains a XhoI site. Specific 
chemokine bands were cloned into pcDNA3.1 Hygro(+) (Invitrogen) using the 
In-Fusion® Advantage PCR Cloning Kits from Clontech. Each construct was 
confirmed by restriction digestion and sequencing to generate pcDNA3.1(+)-
CCL5 and pcDNA3.1(+)-CXCL9. Chemokine production was confirmed using 
commercially available ELISA kits for mouse CCL5 and CXCL9 following the 
manufacturer‟s instructions (R&D systems). 
 
2.2.7 In vivo experiments 
2.2.7.1 RETAAD T cell migration to skin tumor site 
Five tumor-bearing RETAAD mice per group (aged between 30 to 40 weeks) 
were injected subcutaneously in the right flank with 200,000 B16-F10luc cells 
in 100μL of PBS. Mice were euthanized when the B16 tumor diameter 
reached 1cm. The B16 transplanted skin tumor and one to two RETAAD skin 
tumors were collected from the same mouse. Tumors were excised and 
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divided into two parts. One part was stored in RNALater for qRT-PCR of 
chemokine/cytokine expression, while the other was dissociated with 
Collagenase A and DNase I (Roche) for analysis of T cell infiltration by flow 
cytometry. 
 
2.2.7.2 In vivo transfection of cutaneous tumors 
Five to ten RETAAD tumor-bearing mice per group (aged 30 to 50 weeks) 
were used. For each mouse, 2 to 7 cutaneous tumors were transfected with 
5ug of pcDNA3.1(+)-CCL5 or -CXCL9 or empty plasmid using in vivo JetPEI 
transfecting reagent (Polyplus Transfection). Three injections were performed 
on alternate days for 5 days. On day 6, the mice were euthanized and the 
tumors were excised, weighed and divided into two parts. One part was 
stored in RNALater in preparation for RNA extraction and qRT-PCR analysis 
of intra-tumoral mRNA expression of Ccl5, Cxcl9, Cxcl10, Ifng, Gzma, and 
Gzmb; the other was dissociated and analyzed for immune cell infiltration by 
flow cytometry. For Ccl5 and Cxcl9 co-injection studies, 2.5ug of 
pcDNA3.1(+)-CCL5, -CXCL9, empty plasmid or a combination of 5ug of 
pcDNA3.1(+)-CCL5 and -CXCL9 were injected into cutaneous RETAAD 
tumors using the protocol described above. On day 6, the mice were 
euthanized and tumors were excised, weighed and stored in RNALater. 
mRNA expression of Cd3g, Ccl5 and Cxcl9 was analyzed by qRT-PCR. 
 
2.2.7.3 Transfection of Melan-ret cells 
Melan-ret cells were seeded into 6-well plates and transfected with plasmid 
DNA encoding Cxcl9 using Lipofectamine™ 2000 (Invitrogen) according to 
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the manufacturer‟s protocol. Six hours later, Cxcl9-transfected Melan-ret cells 
and control cells were harvested and injected subcutaneously into alternate 
flanks of C57 BL/6 mice with 200,000 cells per dose. Tumor growth was 
monitored by palpation every two to three days starting on day five after tumor 
cell injection. 16 days later, the mice were euthanized, and tumors were 
collected, weighed and Cd3g expression was analyzed by qRT-PCR. The 
same experiment was repeated using Rag1-/- mice. 
 
2.2.8 Statistical analyses 
Gene expression data were normalized, log-transformed and compared using 
Student‟s t-test or ANOVA. P values for multiple comparisons were adjusted 
using Bonferroni correction. Other parameters (tumor weight, tumor area, 
percentage of tumor-infiltrating cells) were compared using non-parametric 




2.3 Chemokines and intra-tumoral T cell trafficking in cutaneous 
human melanoma 
2.3.1 Human melanoma cell lines 
The HTB-71 cell line was from ATCC. The other four human melanoma cell 
lines (M88, M102, M131, and M134) were kindly provided by J-B Latouche 
and P. Musette. 
 
2.3.2 Chemotherapeutic drugs 
Temozolomide, cisplatin, and dacarbazine were purchased from Sigma-
Aldrich. Stock solutions of temozolomide were prepared in DMSO (20mg/ml), 
cisplatin in DMF (10mg/ml) and dacarbazine in 0.6N HCl (10mg/ml). 
 
2.3.3 Patient samples 
Tumor samples were prospectively obtained from 13 stage III and IV 
melanoma patients recruited at the Cochin Hospital, Paris, France, between 
2006 and 2009. The study was approved by the Ethics Committee of Ile de 
France. The Declaration of Helsinki protocols were followed and the patients 
gave their written, informed consent. Demographics and clinical 
characteristics of the patients, and microarray data analysis can be found in 
(Nardin et al., 2011). 
 
2.3.4 Chemotherapy drug treatment and chemokine gene expression   
Human melanoma cells were seeded into 12-well plates. After 48h, drugs 
were added at indicated concentrations. For dose-response studies, cells 
were incubated with escalating concentrations of drugs for three days before 
being harvested, while the supernatants were collected and frozen. RNA 
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extraction and cDNA conversion were performed as described previously, and 
the expression of CCL5, CXCL9 and CXCL10 relative to ACTB was analyzed 
by qRT-PCR. For kinetic studies, cells were incubated with a fixed dose of 
drug and were harvested at 6, 12, 24, 48 and 72h after addition of the drug. 
The expression of chemokines was determined using qRT-PCR at various 
timepoints. 
 
2.3.5 Multiplex analysis of chemokine and cytokine production by 
tumor cells   
Concentrations of various cytokines/chemokines in the supernatant of drug-
treated cells were analyzed using multiplex bead-based assays based on 
xMAP technology, combining both the 21-plex (MF0-005KMII) and 27-plex 
(M50-0KCAF0Y) kits from Biorad. A total of 48 secreted factors were 
measured, including 28 cytokines (IL-1α, IL-2Rα, IL-3, IL-12 (p40), IL-16, IL-
18, IL-1b, IL-1rα, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12 (p70), IL-13, 
IL-15, IL-17, IFN-α, IFN-α2, IFN-γ, LIF, MIF, TNFα, TNFβ, TRAIL), 10 
chemokines [CTACK, CXCL1 (GROα), CXCL10 (IP-10), CCL2 (MCP-1), 
CCL7 (MCP-3), CXCL9 (MIG), CCL3 (MIP-1α), CCL4 (MIP-1β), CCL5 
(RANTES) and CXCL12 (SDF-1α)], and 10 growth factors (basic-FGF, β-NGF, 
G-CSF, GM-CSF, HGF, M-CSF, PDGF-BB, SCF, SCGF-β and VEGF). 
Analyses of tumor supernatants were performed in a 96-well microplate 
format according to the manufacturer‟s protocol. 
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2.3.6 Statistical analyses 
Gene expression data were normalized, log-transformed and compared using 
Student‟s t-test or ANOVA. P values for multiple comparisons were adjusted 
using Bonferroni correction. Other parameters (tumor weight, tumor area, 
percentage of tumor-infiltrating cells) were compared using non-parametric 
tests (Mann-Whitney or Kruskal-Wallis). Patient survival was analyzed by the 



































3.1 Development of a new spontaneous bioluminescent mouse 
melanoma model to monitor tumor growth and treatment 
responses 
3.1.1 Generation of the ret+/- luc+/- transgenic mouse 
In order to generate a unique model that allows non-invasive imaging of 
spontaneous melanoma tumor development and drug response, the 
advantages of both BLI and the spontaneous melanoma model, MT-ret, were 
exploited to develop a new transgenic mouse model called Melucie. The 
Melucie mouse is double-transgenic for the activated human RET oncogene 
and the luciferase reporter gene and is expected to develop spontaneous 
bioluminescent melanoma tumors and metastases.  
 
To achieve melanocyte-specific transgenic expression, many laboratories use 
regulatory sequences of the tyrosinase family genes, such as tyrosinase (Tyr), 
tyrosinase-related protein 1 (Trp1) and tyrosinase-related protein 2 (Trp2) (or 
dopachrome tautomerase, Dct) (Murisier and Beermann, 2006) [reviewed in 
(Larue and Beermann, 2007)]. To determine the optimal promoter to drive 
luciferase expression in melanoma tumors, the relative expression of five 
different melanocyte-specific genes, including Tyr, gp100, melan-A/Mart-1, 
Trp1, and Trp2 were analyzed in RETAAD tumors. Among the five genes 
analyzed, Trp2 was found to be the most highly expressed melanocyte-
specific gene in the tumors (Table 3.1.1). Therefore, the promoter of mouse 
dopachrome tautomerase (DCT), i.e. the homolog of human tyrosinase 
related protein 2 (Trp2), was chosen the melanocyte-specific promoter to 
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drive luciferase expression specifically in melanocytes. Consequently, 
melanoma tumors, which are enriched in melanocytes, are expected to 
express high levels of luciferase activity, thus allowing tumor detection via BLI.  
 
Table 3.1.1 – Quantitative real-time PCR analysis of the expression of melanocyte-
specific genes in RETAAD tumors. 
 
Melanocyte-specific gene Mean Ct 
Tyrosinase related protein 2 (Trp2) 19 
Tyrosinase (Tyr) 20.2 
Melan-A/MART-1 22 
Glycoprotein 100 (gp100) >22 
Tyrosinase related protein 1 (Trp1) >22 
 
Table shows the mean ct values of the expression of five melanocyte-specific genes 




The Dct promoter has been used previously to drive lacZ expression to study 
melanocyte differentiation during embryonic development (Mackenzie et al., 
1997). Based on this earlier report, two constructs were generated: one 
containing the exact sequence of Dct promoter used by Mackenzie (-3181 to 
+445, denoted Dct1) and another one with a shortened 5‟ end (-3181 to +65, 
denoted Dct2) (Figure 3.1.1A).  Both promoter sequences were cloned next to 
a codon-optimized luciferase reporter gene to generate the plasmids 
pGL4.17-Dct1 and pGL4.17-Dct2 respectively (Figure 3.1.1B). Transfection of 
these constructs into B16 mouse melanoma cell line confirmed the 
functionality of the enzymes after luciferin addition. In addition, higher 
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luciferase activity was observed for the construct with shorter non-coding 
sequence, i.e. pGL4.17-Dct2 (Figure 3.1.1C). Therefore, this construct was 























Figure 3.1.1 – Generation of luciferase construct for transgenesis.  
(A) Mouse dopachrome tautomerase (Dct) promoter sequences used to drive 
luciferase transgene expression. Promoter sequences with two different lengths were 
amplified from a BAC (bacterial artificial chromosome) probe (CHORI), denoted Dct1 
(-3181 to +445) and Dct2 (-3181 to +63). Both Dct promoter sequences were 
individually cloned into the multiple cloning site (MCS) of the pGL4.17 plasmid 
(Promega). NC = Non-Coding. (B) Vector map of the pGL4.17 plasmid (Promega) 
used for cloning. Red line indicates the position of insertion of the Dct promoter 
sequences within the multiple cloning site (MCS) of the pGL4.17 plasmid. (C) The 
two transgene constructs, pGL4.17-Dct1 and pGL4.17-Dct2 were individually 
transfected into B16-F10 mouse melanoma cells. Luciferase assay was performed 
24h after transfection. The pGL4.17 vector and the pGL4.13 vector (luc2 gene under 
the control of SV40 promoter) were included as a negative and positive control, 
respectively. Total protein content of the cell extracts was measured using Bradford 






In general, for the development of a transgenic mouse, two methods of 
transgenesis are available. The first one is the knock-in approach, which 
involves homologous recombination of the gene of interest in the mouse 
genome of embryonic stem cells (ESC). This method allows specific targeting 
of the luciferase gene to the chosen locus, i.e. adjacent to a melanocyte-
specific promoter. There is only a single transgene integration site and thus, 
only one transgenic line is necessary. This method is precise (targeted to the 
locus) but requires working with ESC (Smithies et al., 1985). The second 
approach is random insertion of a target construct containing both coding and 
regulatory elements. This requires having a construct containing the chosen 
promoter adjacent to the luciferase gene. The copy number of the transgene 
in the genome is unknown and may be high (usually 1-50 copies but can be 
up to 1000 copies). For random insertion, the presence of multiple copies of 
the transgene may lead to the formation of concatamers, i.e. they are joined 
to each other in a head-to-tail configuration. The precise location of the 
transgene in the genome is unknown. Therefore, “position effects” or “founder 
effect” may occur, making it necessary to analyze several transgenic lines 
derived from independent founders. This implies the need to screen large 
numbers of animals. This method is less precise, but it obviates the need to 
work with ESC. Most importantly, this method can lead to high levels of gene 
expression due to integration of multiple copies of the transgene (Gordon and 
Ruddle, 1981; Ittner and Gotz, 2007). 
 
In our case, the level of the transgene expression is an important 
consideration because the level of luciferase expression in melanoma will 
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directly influence the sensitivity of tumor detection. This is especially important 
for early detection of both cutaneous and visceral tumors. Random insertion, 
therefore, was our method of choice for transgenesis because it may select 
for high expressors (with multiple copies of transgene). Furthermore, it allows 
selection of a transgenic line giving the best signal to noise ratio. In order to 
generate the luciferase transgenic mouse, the linearized luciferase construct 
pGL4.17-Dct2 (transgene sequence is shown in Appendix 1) was 
microinjected into pronuclear embryos from C57BL/6 mice and integration of 
the target construct into the mouse genome occurred by random insertion. 
Five independent transgenic founders denoted Dct-1-5 was generated.  
 
The number of transgene insertion site(s) in each luciferase founder was 
determined by fluorescence in situ hybridization (FISH). As shown in Figure 
3.1.2, only a single transgene insertion site was identified in each of the 
founders. In addition, BLI was performed to confirm the in vivo functionality of 
the luciferase enzyme after luciferin injection (Figure 3.1.3). Two out of five 
luciferase founders (Dct-1 and Dct-2, one low expressor and one high 
expressor) were subsequently selected and crossed independently with MT-
ret transgenic mouse to obtain double-transgenic Melucie lines [which we 
refer to here as Centromeric Melucie (low expressor) and Telomeric Melucie 





Figure 3.1.2 – Identification of transgene integration site by fluorescence in situ 
hybridization (FISH).  
Briefly, mouse chromosomes were prepared from mouse tail fibroblasts isolated from 
five different luciferase founders, denoted Dct-1 to Dct-5. To detect the luciferase 
transgene DNA, FISH probes (300bases to 2kb in size) labelled with spectrum green-
dUTP were generated by nick translation of the luciferase construct used for micro-
injection. The chromosomes were co-denatured with the FISH probes during 
hybridization. Hybridization signal is indicated by white arrow and two single dots (in 
green). Only a single transgene integration site is detected for all the luciferase 





















































































































































































































































































































































































































































































































































































































































































































































































3.1.2 Bioluminescence imaging of spontaneous melanoma tumor 
development in ret+/- luc+/- mice 
The sensitivity and positive predictive value (PPV) of BLI in the detection of 
autochthonous melanoma tumors in vivo were evaluated in tumor-bearing 
Telomeric and Centromeric Melucie mice. For Telomeric Melucie, high 
background of luciferase expression was observed in vivo after intraperitoneal 
injection of the luciferin substrate (Figure 3.1.4A). Therefore, this Melucie line 
was excluded from further analysis, and we focused on the Centromeric 
Melucie for further characterization. In vivo BLI in Centromeric Melucie 
successfully detected luciferase expression from melanoma tumors with 
minimal/no background observed (Figure 3.1.4B). The overall sensitivity and 
PPV for tumor detection via BLI was 80% and 100%, respectively. For skin 
tumor detection, the sensitivity and PPV was 88% and 100%; while for 
visceral metastases detection, the values were 33% and 100% respectively. 
Taken together, this data indicates that the Melucie model is suited for whole-

























Figure 3.1.4 – Spontaneous melanoma tumor detection in Melucie mice by in vivo 
BLI.  
(A) In vivo BLI of a tumor-bearing Telomeric Melucie mouse. High background of 
bioluminescent signal was observed throughout the whole animal. Images are 
representative of at least 10 mice. Exposure = 40s, Binning = 8. (B) In vivo detection 
of primary uveal melanoma (left panel), multiple cutaneous tumors (middle panel) 
and visceral metastases (reproductive tract tumor; right panel) in a Centromeric 
Melucie mouse by BLI. The BL signal was tumor-specific with no/low background 








Back Left flank Right flank 
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The specificity of a reporter strain depends on the luminescence signal to 
noise ratio and consequently, on the background level of expression of the 
luciferase gene. Therefore, the ex vivo bioluminescence signal from selected 
organs were compared between ret+/- luc+/- Melucie mice [n=4] and ret-/- luc+/- 
littermate controls [n=3] after in vivo administration of luciferin. The 
background luminescence in all the organs tested from control mice was 
negligible. Higher emitted light was detected from the eyes, lungs and 
reproductive tract in the Centromeric Melucie compared to control mice, even 
in the absence of macroscopic tumors (Figure 3.1.5A). Interestingly, the 
presence of tumor cells in these organs was confirmed by histology (Figure 
3.1.5B). No difference in signal was observed in the spleen, which serves as 
the control organ. The levels of emitted light from macroscopic tumors were 
comparatively higher (Figure 3.1.5A). This was expected as tumors are 











Figure 3.1.5 – Detection of melanoma tumors in individual organs from Centromeric 
Melucie by ex vivo imaging and histology.  
Tumor-bearing Centromeric Melucie [n=4] and age-matched littermate controls ret-/- 
luc+/- [n=3] were injected intraperitoneally with 150mg/kg body weight of luciferin. 
Mice were sacrificed 15mins post-luciferin injection and selected organs were 
harvested, weighed and placed into 24-well plates. Ex vivo imaging was performed 
and the bioluminescence signal was quantified using the Living Image Software 
(Xenogen). (A) Comparison of ex vivo BL signals from multiple organs of tumor-
bearing Centromeric Melucie [n=4] and ret-/- luc+/- control mice [n=3]. Higher BL signal 
was observed in the eyes, lungs and reproductive tract, consistent with the presence 
of tumors in these organs. Macroscopic tumor nodules and spleens were included as 
positive and negative controls, respectively. High level of BL signal was detected in 
the tumors, as tumors are enriched in melanocytes and are expected to express high 
level of the luciferase enzymes. Data is shown as relative light unit (RLU) per mg 
tissue. (B) The presence of tumors in the eyes, lung and reproductive tract of 
Centromeric Melucie was confirmed on tissue sections by hematoxylin and eosin 




BLI of orthotopic xenografts in mice has demonstrated a linear correlation 
between tumor bioluminescence signal and tumor volume. To investigate 
whether such a correlation was also maintained during oncogene-driven 
tumor formation in our model, the luciferase activity of various tumors at 
different stages of growth was measured in several tumor-bearing Melucie 
mice. The tumors were imaged 15 minutes after i.p. injection of luciferin into 
the anaesthetized animals, and the signals were plotted against the wet tumor 
weights at necropsy. A remarkable correlation was observed between the 
detected photons and tumor weights (Pearson r = 0.7426, p-value = 4.72e-08) 
(Figure 3.1.6A). Furthermore, there was a good correlation between ex vivo 
and in vivo signals (Pearson r = 0.5340, p-value = 0.0063) (Figure 3.1.6B), 
and the in vivo signals correlated strongly to wet tumor weight (Pearson r = 
0.602, p-value = 0.002) (Figure 3.1.6C). Our data indicates that the Melucie 
model is capable of volumetric detection of tumor growth in vivo.  
 
We also followed melanoma tumor development in the Melucie by measuring 
bioluminescence from cutaneous tumors starting at 17 weeks of age when the 
tumor was first detected until the mice became moribund at 40 weeks. BLI 
was performed at three different time points, i.e. on day 121, 177, and 273 
after birth. The mouse in Figure 3.1.6D showed an almost doubling of the 
signal every 30 days throughout the 150 day period, indicating exponential 























Figure 3.1.6 – Longitudinal monitoring of tumor growth by in vivo BLI.  
Tumor bioluminescent signals were measured in vivo and ex vivo and correlation 
analyses were performed between in vivo BL signals, ex vivo BL signals, and wet 
tumor weight. Data demonstrates volumetric detection of tumor growth by BLI. (A) 
Correlation between ex vivo BL signals and wet tumor weight in 38 tumors collected 
from 3 Centromeric Melucie mice. (B-C) Correlation between in vivo and ex vivo BL 
signals (B), and between in vivo BL signals and wet tumor weight (C), in a total of 21 
tumors collected from a tumor-bearing Centromeric Melucie. All correlation analyses 
were performed on log transformed values using Pearson correlation, one-tailed. (D) 
BL images of a Centromeric Melucie followed over a period of 39 weeks. Signal 
intensity was measured from a region of interest drawn around a cheek tumor. The 
numbers represent the BL signal intensity from a cheek tumor (indicated by an arrow) 
in photons per second (p/s). 
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In addition, we investigated whether BLI could detect early primary eye tumor 
growth in young Melucie mice. The development of primary eye tumors starts 
approximately at 3 weeks of age and is mostly confined within the choroid 
layer of the eye. Subsequently, tumors undergo distant metastases to the 
surrounding areas of the eye, together with local metastases leading to the 
development of multi-lobular nodules. These primary eye tumors are virtually 
non-palpable at early stages and their detection relies on clinical examination 
of exophthalmia (or bulging of the eye). Therefore, the ability of BLI to detect 
young primary eye tumors will provide a useful means to determine early 
events of tumor development and to assess response to therapy in our 
spontaneous mouse model.  
 
In this study, young Melucie mice were analyzed at two different age groups, 
2 weeks or 4 weeks, by in vivo imaging and ex vivo imaging. The presence of 
tumors was confirmed by histology. As shown in Figure 3.1.7A, no differences 
were detected between signals emitted in vivo and ex vivo from both eyes of 
the mice at 2 weeks of age. Histology confirmed the absence of uveal tumors 
at this age (Figure 3.1.7B). However, at 4 weeks of age, there was 
consistently higher signal from one eye compared to the contralateral eye 
within the same mouse both in vivo and ex vivo (Figure 3.1.7C). Most 
importantly, a higher BLI signal correlated with a higher number of tumor 
nodules as shown by histology (Figure 3.1.7D). 
 
Altogether, we report the successful development of a new transgenic mouse 
model that permits non-invasive monitoring of spontaneous melanoma tumor 
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growth in live animals using in vivo BLI. Our data clearly demonstrates that 
the Melucie can be used to detect early events of tumor development and it 
represents a convenient model for longitudinal monitoring of primary tumor 
growth and metastases in vivo. Furthermore, we believe that the development 
of Melucie will invariably be an asset for the testing of future chemo-




























Figure 3.1.7 – Early detection of spontaneous uveal melanoma tumor development 
by in vivo BLI.  
To determine the sensitivity of BLI to detect early primary eye tumor development, 
BLI was performed on contralateral eyes of young Centromeric Melucie mice (2 
weeks old, n=2). BL signals were quantified from both the left eye (LE) and right eye 
(RE) after in vivo (A) and ex vivo (B) imaging. No difference was observed between 
the two contralateral eyes both by in vivo and ex vivo imaging. H&E staining confirm 
the absence of tumors in the eyes of 2-week old mice. (C) In vivo and ex vivo BL 
signals were similarly compared between contralateral eyes in 4 week-old Melucie 
[n=2]. The presence of tumors in these eye samples was confirmed by H&E staining. 
Interestingly, higher BL signal detected in right eye from a  
Centromeric Melucie (denoted #007) was associated with higher number of tumor 





3.2 Chemokines and intra-tumor T cell trafficking in cutaneous mouse 
melanoma 
3.2.1 Distinct immune milieu in cutaneous metastases compared to 
visceral metastases in RETAAD mice 
In the RETAAD mouse model of spontaneous melanoma, CD8+ T cells have 
been shown to control the outgrowth of visceral metastases and disease 
progression but have no effect on cutaneous tumors (Eyles et al., 2010; 
Lengagne et al., 2008). The hypotheses on the lack of control of cutaneous 
tumors by T cells results from either the absence of T cell infiltration or from 
the loss of function of infiltrating T cells.  
 
To understand why functional T cells fail to control cutaneous tumors, the 
tumor microenvironment of both cutaneous [n=19] and visceral metastases 
[n=10] from tumor-bearing RETAAD mice [n=5] were compared by qRT-PCR 
for the expression of 35 immune-related genes coding for various cytokines 
(Ifng, Il6, Csf1, Csf2, Il1rn, Il10, Mif, Tnfa, Tgfb1, Vegfa, Mmp9), chemokines 
(Ccl2, Ccl3, Ccl5, Cxcl10, Cxcr4), immune mediators (Fizz1, Prf1, Gzma, 
Nos2, Arg1, Ltb4, Mpo, Anxa1, Cd274) and lineage markers (Cd3, Cd4, Cd8, 
Lck, Foxp3, Klrk1, Ly6g, Emr1, Mgl1, Ela2).  
 
Non-supervised hierarchical clustering revealed two distinct clusters, one for 
cutaneous tumors and a separate cluster for visceral metastases (Figure 
3.2.1). In the cluster consisting of all the cutaneous tumors analyzed, no 
particular organization was observed between tumors collected from different 
parts of the body (eg. facial tumors or body tumors) or between different types 
of tumors (eg. attached to the skin or embedded within muscle). For visceral 
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metastases, the majority of the tumors (8 out of 10) cluster together. In 
particular, all the lung tumors formed a separate sub-cluster, which was 
distinct from visceral metastases collected from other organs.  
 
Overall, this data demonstrates that cutaneous melanoma metastases display 
a distinct immune profile compared to visceral metastases and suggests that 
heterogeneity within the tumor microenvironment might play a role in the 







































































































































































































































































































































3.2.2 Low T cell infiltration in cutaneous metastases 
To further identify the immune genes whose expressions are significantly 
different between cutaneous and visceral metastases, differential gene 
expression (DGE) analysis was performed. In general, there was a trend for 
lower expression of immune-related genes in cutaneous tumors compared to 
visceral metastases (Figure 3.2.2). Among the list of genes analyzed, five 
immune genes (Cd3g, Csf2, Nos2, Il1rn, and Anxa1) were differentially 
expressed between cutaneous and visceral metastases (p-value < 0.05). All 
of these genes, with the exception of Anxa1, were higher in visceral tumors 
compared to cutaneous tumors. Interestingly, Cd3g was the most differentially 
expressed gene (p-value = 0.012), suggesting that cutaneous tumors 







































Figure 3.2.2 – Cutaneous tumors expresses low levels of immune-related genes 
compared to visceral metastases. 
The expression of 35 immune-related genes relative to gapdh was measured by 
qRT-PCR in RETAAD cutaneous (n=19) and visceral (n=10) tumors. The relative 
expression of each gene was normalized against the median expression value of that 
particular gene, log transformed, and differential gene expression (DEG) analysis 
was performed using GEPAS 4.0 web-based software. The p-value between groups 
is indicated by FDR Indep. Most of the immune-related genes analyzed were more 
highly expressed in visceral metastases compared to cutaneous metastases. Data 
are color-coded gene expression compared to the median expression of each gene 
in all samples. Red – up-regulated; Blue – downregulated; White – no data.  
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To confirm this observation, the expression of other T cell markers (including 
Cd4, Cd8a and Lck) as well as T cell effector molecules (including Ifng, Prf1b, 
and Gzmb) were analyzed by qRT-PCR and their expression were found to 
be significantly lower in cutaneous metastases compared to visceral tumors 
(Figure 3.2.3A). The expression of both Cd4 and Cd8a was lower in 
cutaneous tumors (p-values = 0.026 and 0.023), suggesting that both 
compartments were affected.  
 
To measure T cell infiltration at the protein level, 22 cutaneous tumors and 4 
visceral metastases were collected from tumor-bearing RETAAD mice and 
were compared for the presence of CD3+ T cells by flow cytometry. The 
median percentage of CD3+ T cells was 2.7 times lower (2-tailed Mann-
Whitney test: p-value = 0.04) in cutaneous tumors compared to visceral 
tumors (Figure 3.2.3B). Immunofluorescent staining of cutaneous tumor 
sections confirmed that T cells were mostly confined to the peritumoral stroma 
with little or no infiltration into the tumor nest (Figure 3.2.3C, left). In contrast, 






























Figure 3.2.3 – Low T cell infiltration in cutaneous metastases. 
(A) The relative expression of T cell markers (Cd3g, Cd4, Cd8a) and effector 
molecules (Ifng, Prf1b, Gzmb) to gapdh was measured in cutaneous (n=20) and 
visceral (n=10) tumors. Cutaneous tumors express significantly less T cell-related 
genes compared to visceral tumors. Unpaired t-test, two-tailed. (B) To measure T cell 
infiltration at the protein level, cutaneous (n=22) and visceral (n=4) tumors were 
collected from 9 RETAAD mice and analyzed for the presence of CD3+ cells by flow 
cytometry. Data represents the percentage of CD3+ cells among total live immune 
cells (CD45+DAPI-). Mann-Whitney U test, two-tailed. (C) Immunofluorescence 
labeling of CD3 (pink) in RETAAD cutaneous (left panel) and visceral (right panel) 
tumor. A representative reproductive tract tumor is shown. CD3+ cells were low or 
absent in the cutaneous tumor bed and were more abundant in visceral tumor. 
Images are representative of 3 tumors analyzed in each group. Scale bar = 50μm. 
Statistical significance between groups is represented by * p<0.05; ** p<0.01; *** 
p<0.001; Cut – Cutaneous; Vis – Visceral. 
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In some cutaneous tumors, a few infiltrating T cells was observed. To 
determine whether the few T cells that infiltrated cutaneous tumors retained 
their functionality, the tumors weights were compared between tumors with 
different T cell densities. The results demonstrated an inverse correlation 
between tumor weights and the percentages of CD3+, CD4+ and CD8+ 
infiltrating cells (Pearson‟s r coefficient=-0.67; -0.58; -0.64; p-values=0.009; 
0.02; 0.01, respectively), suggesting that the few infiltrating T cells were able 
to control tumor growth (Figure 3.2.4A). In addition, the ratios of Ifng to Cd4 
and Cd8a, as well as the ratios of Gzmb and Prf1 to Cd8a were not 
significantly different between cutaneous and visceral tumors (Figure 3.2.4B), 
implying that there was no gross alteration in the functionality of infiltrating T 
cells in cutaneous tumors. 
 
Taken together, these data demonstrate that both CD4+ and CD8+ T cells 
poorly infiltrate cutaneous tumors in RETAAD mice. This observation is likely 









Figure 3.2.4 – The few infiltrating T cells in cutaneous tumors probably retain their 
functionality. 
In a few cutaneous tumors, infiltrating T cells were observed. In order to determine 
the functionality of these infiltrated T cells, several cutaneous tumors were collected, 
weighed, and T cell infiltration and T cell effector molecules were measured by flow 
cytometry and qRT-PCR respectively. (A) Cutaneous tumor weights were compared 
between tumors with different T cell densities. The percentages of CD3+, CD4+ and 
CD8+ T cells were inversely correlated with cutaneous tumor weight (n=12). Pearson 
correlation, one-tailed. (B) The ratios of expression of T effector molecules were 
compared between cutaneous (n=8) and visceral (n=16) tumors. No difference was 
observed between cutaneous and visceral tumors. Unpaired t-test, two-tailed. 
Statistical significance between groups is represented by * p<0.05; ** p<0.01; *** 
p<0.001; Cut – Cutaneous; Vis – Visceral. 
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3.2.3 RETAAD T cells infiltrate exogenous skin tumors 
To determine whether the poor infiltration of T cells into cutaneous tumors 
was due to an intrinsic defect in endogenous T cell migration to the skin or to 
the tumors themselves, autochthonous RETAAD cutaneous tumors were 
compared to transplanted B16 cutaneous tumors within the RETAAD mice for 
the ability of the endogenous T cells to infiltrate into each tumor.  
 
In this transplantation experiment, 200,000 B16 mouse melanoma cells were 
injected subcutaneously into both flanks of tumor-bearing RETAAD mice. 
Fourteen days after tumor cell injection, the transplanted B16 and 
autochthonous RETAAD cutaneous tumors were excised and compared for 
intra-tumor T cell infiltration by flow cytometry. As shown in Figure 3.2.5, the 
percentages of CD3+, CD4+ and CD8+ T cells were respectively 11-fold, 9-fold 
and 11-fold more abundant in B16 than in RETAAD tumors within the same 
mouse (two-tailed Mann-Whitney p-values < 0.01).  
 
These data show that T cells from RETAAD mice have the capacity to migrate 
to the skin and to infiltrate cutaneous tumors. Therefore, the paucity of T cells 
in RETAAD cutaneous tumors is most likely due to the tumor environment 







Figure 3.2.5 – RETAAD T cells infiltrate exogenous skin tumors.  
B16 cells were injected subcutaneously into both flanks of tumor-bearing RETAAD 
mice. Fourteen days after injection, transplanted B16 and autochthonous RETAAD 
skin tumors from the same mice were analyzed for T cell infiltration. Results 
demonstrate the flow cytometric comparison of T cell infiltrates in transplanted B16 
(n=4) and autochthonous RETAAD (n=6) skin tumors from the same mice. Data 
show the percentages of CD3+, CD4+ and CD8+ T cells within total live cells. Mann-
Whitney U test, two-tailed. Statistical significance between groups is represented by 
** p < 0.01.   
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3.2.4 T cell infiltration of exogenous tumors correlates with high 
chemokine expression 
Chemokines present in the tumors are likely to play a major role in T cell 
recruitment. Therefore, the repertoire of chemokine expression was compared 
between autochthonous RETAAD skin tumors and transplanted B16 skin 
tumors grown in RETAAD mice using low density PCR arrays. Thirty-nine 
genes including 26 chemokines and 13 chemokine receptors involved in 
inflammation were analyzed by qRT-PCR. As shown in Figure 3.2.6A, 14 out 
of 26 chemokine genes analyzed were differentially expressed in transplanted 
B16 compared to autochthonous RETAAD tumors (open squares; p-value < 
0.05, fold-change > 2), with the vast majority of these chemokines (12 out of 
14) being more highly expressed in B16 tumors. Among the list of differentially 
expressed chemokines, Cxcl9 and Cxcl10 were the two most differentially 
expressed chemokines, with 105- and 42-fold greater expression in B16 
tumors, respectively. Five additional chemokines, Ccl2, Ccl3, Ccl4, Ccl7 and 
Cxcl5 were at least 10-fold more highly expressed in B16 tumors than in 
autochthonous RETAAD tumors.  
 
To gain further insight into the possible roles of these differentially expressed 
chemokines in T cell recruitment, the expression of the corresponding 
chemokine receptors on peripheral blood T cells from RETAAD mice were 
analyzed by flow cytometry. The surface expression of the chemokine 
receptors CCR1, CCR2, CCR3, CCR5 and CXCR3 was analyzed on naïve, 
central memory and effector memory T cells subsets for both CD4+ and CD8+ 
T cells. The chemokine receptor CXCR3 was highly expressed by several 
subsets of circulating T cells while CCR1, CCR3 and CCR5 were only 
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expressed at marginal levels (Figure 3.2.6B). CCR2 was expressed by 25 ± 2% 
of effector memory CD4+ T cells (Figure 3.2.6B). Within the CD4+ T cells, 4 ± 
1.9% of the central memory and 58 ± 10% of the effector memory cells 
expressed CXCR3, while among the CD8+ T cell population, 93 ± 3.6% of the 
central memory and 75 ± 5.7% of the effector memory cells expressed 
CXCR3 (Figure 3.2.6C). CXCR3 has only 3 known ligands, CXCL9, CXCL10 
and CXCL11. Therefore, these results strongly suggest a role for CXCL9 and 
CXCL10 in T cell recruitment into cutaneous melanoma tumors.  
 
Having demonstrated a critical role of chemokines in T cell recruitment into 
cutaneous tumors, it was of interest to understand whether differential T cell 
recruitment between autochthonous cutaneous and visceral tumors could also 
be explained by inherent differences in local chemokine expression. Therefore, 
the profile of chemokine expression was compared by qRT-PCR between 
cutaneous tumors [n=9] and visceral tumors [n=7] collected from RETAAD 
mice [n=3]. As shown in Figure 3.2.6D, 4 chemokine genes and 5 chemokine 
receptor genes were more than 2-fold differentially expressed between 
cutaneous and visceral tumors, with all of the genes having greater 
expression in visceral tumors. This includes the chemokines Ccl20, Ccl22, 
Ccl24 and Ccl5, as well as the chemokine receptors Cxcr5, Ccr6, Ccr7, Ccr8, 
and Xcr1. Interestingly, a distinct panel of chemokines and chemokine 




Taken together, these results demonstrate that chemokines are critical local 
factors that determine effective T cell recruitment into cutaneous melanoma 
and suggest that different chemokines might dictate T cell recruitment into 













































































Figure 3.2.6 – T cell infiltration into tumors correlates with intra-tumoral chemokine 
expression.  
(A) Intra-tumoral expression of chemokine and chemokine receptor genes in 
autochthonous and transplanted skin tumors. Volcano plot shows fold-change in 
gene expression in B16 skin tumors grown in RETAAD mice [n=3] compared to 
autochthonous RETAAD skin tumors [n=5]. Open square represent chemokine 
genes with > 2-fold differential expression and p-value < 0.05. Horizontal line shows 
p-value = 0.05. Vertical line represents 10-fold increase in B16 compared to 
RETAAD tumors. L2, L3, L4, L7, X5, X9 and X10 indicates the chemokine genes 
Ccl2, Ccl3, Ccl4, Ccl7, Cxcl5, Cxcl9, and Cxcl10 respectively. (B) Surface expression 
of chemokine receptors on CD4+ and CD8+ T cells was analyzed in peripheral blood 
collected from RETAAD mice. Data are representative of 8 mice analyzed. Grey filled 
histogram – Isotype control; Black solid line – Naïve (CD44- CD62L+); Red solid line 
– Effector memory (CD44+ CD62L-); Green solid line – Central memory (CD44+ 
CD62L+). (C) Percentages of CXCR3+ cells within CD4+ and CD8+ T cell subsets of 
RETAAD mice (n=8). CM – Central Memory; EM – Effector Memory. (D) Intra-
tumoral expression of chemokine and chemokine receptor genes in autochthonous 
cutaneous and visceral tumors. Volcano plot shows fold-change in gene expression 
in visceral tumors [n=7] compared to cutaneous tumors [n=9] in RETAAD mice. Open 
square and solid circles represent chemokine genes and chemokine receptor genes 
respectively, with > 2-fold differential expression and p-value < 0.05. Horizontal line 
shows p-value = 0.05. Vertical line represents 2-fold increase in visceral tumors 
compared to cutaneous tumors. The symbols L5, L20, L22 and L24 represents the 
chemokines genes Ccl5, Ccl20, Ccl22 and Ccl24 respectively while X1, XR5, R6, R7 
and R8 represents the chemokine receptor genes Xcr1, Cxcr5, Ccr6, Ccr7 and Ccr8 
respectively. 
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3.2.5 Transfection of RETAAD skin tumors with Cxcl9 induces T cell 
infiltration 
To directly demonstrate the role of CXCR3 ligands in T cell recruitment, 
established RETAAD autochthonous tumors were transfected with a plasmid 
encoding CXCL9. RETAAD mice bearing multiple cutaneous metastases 
(median weight = 60mg) were selected for this experiment. Three intra-
tumoral injections were performed on alternate days. In each mouse, one or 
two tumors were injected with the CXCL9-encoding plasmid and one or two 
tumors were injected with a control plasmid. On day 6, tumors were excised, 
weighed and T cell infiltration was assessed by flow cytometry. The 
expression of Cxcl9 in situ in tumor beds was confirmed by qRT-PCR (Figure 
3.2.7A). The expression of Cxcl10 was included as a negative control (Figure 
3.2.7A). As shown in Figure 3.2.7B, CXCL9 transfection resulted in a 6-fold 
increase in both CD4+ and CD8+ T cell infiltration into RETAAD cutaneous 
tumors (one-tail Mann-Whitney p-value = 0.0026 and 0.0025 respectively). 
Injection of the control plasmid did not significantly alter the T cell infiltrate 
(Figure 3.2.7C).  
 
To further characterize CXCL9-recruited T cells, the percentage of CD44+ 
cells (a marker of memory T cells) among the CD4+ and CD8+ TIL were 
measured by flow cytometry. As shown in Figure 3.2.7D, the mean 
percentages of CD44-expressing CD4+ and CD8+ T cells were 99.2 ± 0.6% 
and 92.8 ± 9.9%, respectively. In addition, the expression of several effector 
molecules was measured by qRT-PCR. The expression of Ifng, Gzma and 
Gzmb was increased in CXCL9-treated tumors compared to control tumors by 
7-, 5- and 5-fold, respectively (one-tailed t test p-values = 0.006, 0.01 and 
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0.02, respectively) (Figure 3.2.7E). Moreover, using flow cytometry, there was 
a 43% increase in tumor cell death (one-tailed Mann-Whitney p-value = 0.03) 
in treated tumors compared to control tumors (Figure 3.2.7F).  
 
Taken together, these observations show that CXCL9 attracts effector T cells 




































Figure 3.2.7 – Transfection of Cxcl9 induces T cell infiltration in RETAAD cutaneous 
tumors. 
Cxcl9-encoding or control plasmids (5μg) were injected into established RETAAD 
cutaneous tumors three times on alternate days. On day 6, tumors were analyzed for 
T cell infiltration. (A) Relative expression of Cxcl9 to Gadph in tumors after Cxcl9-
transfection [n=5] was confirmed by qRT-PCR. Relative expression of Cxcl10 was 
shown as a negative control. Unpaired t-test, one-tailed. (B) The percentages of 
CD4+ and CD8+ T cells among total live cells in Cxcl9-treated tumors [n=5] and 
control tumors [n=7] were determined using flow cytometry. Mann-Whitney U test, 
one-tailed. (C) The relative expression of Cd3g to Gapdh measured by qRT-PCR 
between non-injected tumors [n=5] and tumors injected with control plasmid. [n=7]. 
NI = Non-Injected; I = Injected. Unpaired t-test, one-tailed. (D) Percentages of CD44+ 
cells among CD4+ and CD8+ tumor-infiltrating T cells in Cxcl9-transfected tumors 
[n=5]. (E) Relative expression of several effector molecules, i.e. Ifng, Gzma, and 
Gzmb in Cxcl9-treated [n=8] and control tumors [n=5]. Unpaired t-test, one-tailed. (F) 
Percentage of dead tumor cells (CD45-DAPI+/CD45-) in Cxcl9-treated [n=5] and 
control [n=5] tumors. Mann-Whitney U test, one-tailed. Data shown are 
representative of three different experiments. Statistical significance between treated 
and control groups is represented by *** p<0.001, ** p<0.01, * p<0.05. C – Control, Tr 
– Transfected.   
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3.2.6 Cxcl9 expression inhibits exogenous tumor growth in a T cell-
dependent manner 
To investigate whether ectopic expression of Cxcl9 could control tumor growth 
in vivo, Cxcl9 transfection was performed on Melan-ret cells, a tumor cell line 
derived from a RETAAD cutaneous tumor. In this experiment, Cxcl9-
transfected cells were injected subcutaneously into syngeneic C57BL/6 mice 
and tumor growth was monitored every two to three days for 16 days. The 
results showed that Cxcl9-expressing tumor cells demonstrated severely 
impaired tumor growth compared to control cells and tumor formation was 
even abolished in two out of five mice (Figure 3.2.8A). Mice were euthanized 
at day 16, and tumors were collected and weighed, and T cell infiltration was 
analyzed by qRT-PCR. As shown in Figure 3.2.8B, Cxcl9-expressing Melan-
ret tumors were on average 10 times smaller (one-tailed Mann-Whitney p-
value = 0.004; mean weight = 0.14g vs 0.014g) than control tumors, and this 
was associated with a 4-fold increase in Cxcl9 expression and a 3-fold 
increase in Cd3g expression within the transfected tumors (Figure 3.2.8C). 
When the same experiment was repeated in Rag1-/- mice, there was no 
significant difference in the growth of Cxcl9-transfected and control Melan-ret 
tumors (Figure 3.2.8D). These data demonstrate that Cxcl9 expression 
inhibits tumor growth and that this inhibition is dependent on a lymphoid cell 
population. 
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Figure 3.2.8 – Ectopic expression of Cxcl9 inhibits tumor growth in a T-cell 
dependent manner.  
Melan-ret cells were transfected with a CXCL9-encoding plasmid and injected 
subcutaneously into both flanks of C57BL/6 mice [n=5]. (A) Tumor size was 
measured every 2-3 days. Statistical analysis was carried out using two-way ANOVA, 
two-tailed. At necropsy on day 16, Cxcl9-transfected tumors [n=3] and control tumors 
[n=5] were collected and weighed. Mann-Whitney U test, one-tailed. (B-C) The 
expression of Cxcl9 and Cd3g was measured by qRT-PCR in Cxcl9-transfected and 
control tumors. Unpaired t-test, two-tailed. (D) Tumor growth curves and tumor 
weights of Cxcl9-transfected [n=5] and control [n=5] tumors in Rag1-/- mice. Two-way 
ANOVA, two-tailed and Mann-Whitney U test, one-tailed. All data shown are from 
three independent experiments. Statistical differences between groups are 
represented by *** p<0.001; ** p<0.01; * p<0.05; ns=non-significant. C – Control; Tf – 
Transfected. 
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3.2.7 Ccl5 synergizes with Cxcl9 to recruit T cells 
Knowing that CXCL9 promotes T cell recruitment and that chemokines often 
act in concert, the next question asked was whether other chemokines that 
were expressed in RETAAD tumors were also involved in T cell infiltration. By 
comparing a set of 33 cutaneous and visceral tumors, Ccl5 expression was 
found to be highly correlated with Cd3g expression (Pearson‟s r coefficient = 
0.65, p-value = 4.75E-6) (Figure 3.2.9A). CCL5 is the most potent T cell 
chemoattractant. However, surprisingly, RETAAD circulating T cells express 
very low levels of the known receptors of CCL5, namely CCR1, -3 and -5 
(Figure 3.2.6B). Therefore, secretion of CCL5 by the T cells and/or tumor cells 
may account for the observed correlation. Alternatively, CCL5 might play an 
indirect role in T cell attraction, for example by synergizing with CXCR3 
ligands.  
 
To test the latter hypothesis, RETAAD cutaneous tumors were transfected 
with a plasmid encoding either CCL5 alone, CXCL9 alone, or a combination of 
both plasmids. Suboptimal doses of the CXCL9 plasmid were used. Three 
injections were performed on alternate days for four days. On day six, the 
mice were euthanized and the tumors were harvested, weighed and Cd3g 
expression was analyzed by qRT-PCR. As shown in Figure 3.2.9B, treatment 
with CCL5 plasmid alone did not lead to a significant enhancement in Cd3g 
expression in the treated tumors compared to control tumors. Similarly, 
treatment with suboptimal doses of CXCL9 plasmid had only a marginal effect. 
However, a combination of both CCL5 and CXCL9 resulted in a synergistic 
increase in Cd3g expression within the tumors (one-way ANOVA p-value < 
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0.0001). At the protein level, similar results were obtained using flow 
cytometry analyses. Specifically, co-transfection of CCL5 and CXCL9 led to a 
significant increase in CD3+ T cells and CD4+ T cells, when compared to 
CXCL9 alone (p=0.03 and 0.015, respectively). A similar trend was observed 
for CD8+ T cells (p=0.051) (Figure 3.2.9C). 
 
This increased infiltration of T cells in tumors co-injected with CCL5 and 
CXCL9 plasmids was not due to CCL5-mediated increase in CXCL9 
production as no difference was observed between the levels of Cxcl9 
expression between the Cxcl9-injected and co-injected tumors (Figure 3.2.9C). 
Conversely, T cells may undergo changes in chemokine receptor expression 
upon infiltration into the tumor. Therefore, surface expression of CCR5 and 
CXCR3 was compared between TIL (n=16) and blood lymphocytes (n=6). As 
shown in Figure 3.2.9D, CXCR3 expression was significantly down-regulated 
on both CD4+ and CD8+ T cells in the tumor compared to the blood by 11% 
and 27.5% respectively. Interestingly, a small but reproducible increase in the 
percentage of CCR5-expressing CD4+ and CD8+ (40% and 80% increase, 
respectively) were detected in TIL compared to blood lymphocytes (Figure 
3.2.9E).  
 
Altogether, these data demonstrate a clear synergy between CXCL9 and 
CCL5 in T cell recruitment and suggest that CCR5 expression on TIL, due to 
either an upregulation of CCR5 or a preferential recruitment of the few CCR5-
expressing T cells in the circulation, into the tumor microenvironment may 
favor T cell retention in CCL5-expressing tumors. 
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Figure 3.2.9 – Ccl5 synergizes with Cxcl9 to recruit T cells. 
(A) A total of 37 cutaneous and visceral tumors were collected from 15 tumor-bearing 
RETAAD mice and analyzed for the expression of Cd3g and Ccl5 by qRT-PCR. 
Cd3g expression was strongly correlated with Ccl5 expression. Pearson correlation, 
one-tailed. (B-E) RETAAD cutaneous tumors were injected with 2.5μg of plasmid 
DNA encoding either CCL5 [n=10], CXCL9 [n=11], a combination of both plasmids 
[n=15], or control plasmid [n=9], on alternate days for 5 days. On day six, the tumors 
were analyzed for T cell infiltration. (B) The mean relative expression of Cd3g to 
Gapdh was compared by ANOVA and Bonferroni‟s multiple comparison post test. (C) 
The mean percentages of CD3+, CD4+ and CD8+ T cells over live immune cells 
(CD45+ DAPI-) were compared between Cxcl9-injected and co-injected tumors. 
Mann-Whitney U test, one-tailed. (D) Relative expression of Cxcl9 to Gapdh 
measured by qRT-PCR in Cxcl9-injected and co-injected tumors. Unpaired t-test, 
one-tailed. Surface expression of CXCR3 (E) and CCR5 (F) on CD4+ and CD8+ T 
cells in peripheral blood [n=6] and TIL [n=16] by flow cytometry. Mann-Whitney U test, 
one-tailed. All data are representative of three independent experiments. Statistical 
significance is shown by *** p<0.001; ** p < 0.01; * p<0.05. 
 142 
3.3 Chemokines and intra-tumoral T cell trafficking in cutaneous 
human melanoma 
3.3.1 Chemotherapeutic drugs induces chemokine production in 
human melanoma cell lines 
Chemotherapy is known to alter the transcriptome of cancer cells and has 
been reported to modify their profile of chemokine secretion (Levina et al., 
2008). Therefore, three chemotherapeutic drugs commonly used to treat 
stage IV melanoma (temozolomide, cisplatin and dacarbazine) were tested for 
their ability to induce T cell-attracting chemokines in vitro.  
 
Five human melanoma cell lines (HTB-71, M88, M102, M131 and M134) were 
included in the study. Transcription of the CXCL9, CXCL10 and CCL5 genes 
was measured by qRT-PCR 72h after drug treatment. As shown in Figure 
3.3.1A, each drug and each cell line displayed a unique pattern of chemokine 
expression; at least two T cell-attracting chemokines were actively transcribed 
in all cell lines after treatment with at least one drug. Temozolomide strongly 
induced all three chemokines in M102 and M134, and CXCL10 in HTB-71 and 
M131 (more than 10-fold increase). Cisplatin induced all three chemokines in 
M102 but only the CXCR3 ligands in M134 and CXCL10 in M88. Dacarbazine 
induced all three chemokines in HTB-71.  
 
Dose-response relationships were observed for temozolomide and cisplatin 
(Figure 3.3.1B), but no reproducible dose-response relationships were 
observed for dacarbazine. This is likely due to the fact that dacarbazine 
requires conversion into the active metabolite 5-(3-methyltriazen-1-
yl)imidazole-4-carboxamide (MTIC), which relies on spontaneous catalytic 
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reaction in vitro while liver enzymatic activity carries out this step in vivo. 
Therefore, the subsequent experiments focused on temozolomide (which 
shares the same active metabolite as dacarbazine) and cisplatin.  
 
Time course experiments were performed to determine the kinetics of 
chemokine expression after drug treatment. Figure 3.1.1C shows the kinetics 
of CCL5, CXCL9 and CXCL10 induction in M102 cells following treatment with 
100μg/ml temozolomide. Transcription of CXCL10 was detectable as soon as 
24h after treatment, while CCL5 and CXCL9 transcription was only detected 
at 48h and 72h respectively. Under these experimental conditions, cell death 
was not observed before 48h (Figure 3.3.1D), showing that CXCL10 
transcription preceded cell death. In fact, for lower concentrations of 
temozolomide that does not result in obvious cell death 72h after drug 
treatment (i.e. < 60ug/mL), the expression of CCL5 and CXCL9 were already 
detected (Figure 3.3.1B). This data demonstrates that drug-induced 
chemokine expression indeed precedes cell death.  
 
The production of CCL5, CXCL9 and CXCL10 at the protein level was 
confirmed by analyzing supernatants of M102 cells 72h after treatment with 
temozolomide (100ug/mL) or cisplatin (10ug/mL). Using ELISA and Luminex-
based Bio-Plex suspension arrays, the cell culture supernatants were tested 
for a variety of secreted proteins, including 24 cytokines (IL-1α, IL-1β, IL-1ra, 
IL-2, IL-2ra, IL-3, IL-4, IL-5, IL-6, IL-7, IL-9, IL-10, IL-12p40, IL-12p70, IL-13, 
IL-15, IL-16, IL-17, IL-18, IFN-α2, IFN-γ, TNF-α, TNF-β and TRAIL), 10 
additional chemokines (CCL2, CCL3, CCL4, CCL7, CXCL1, CXCL8, CXCL12, 
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MIF, Eotaxin, CTACK), and 11 angiogenic and growth factors (VEGF, basic 
FGF, GM-CSF, HGF, M-CSF, PDGF, SCF, SCGFβ, LIF, b-NGF, G-CSF). 
 
As shown in Figure 3.3.1E, temozolomide induced a more than 9-fold 
increase in the secretion of 5 chemokines (including CCL2, CCL5, CXCL8, 
CXCL9 and CXCL10), and one chemokine-like factor (MIF), while cisplatin 
induced a 5-fold or more increase in the secretion of CXCL8, CXCL10, and 
MIF. Importantly, none of the 40 other factors were significantly induced by 
chemotherapy (Table 3.3.1). 
 
Altogether, these data demonstrate that the three chemotherapeutic drugs 
commonly used for the treatment of human metastatic melanoma induce 































































Figure 3.3.1 – Chemotherapeutic drugs induce chemokine expression in human 
melanoma cells in vitro. 
Temozolomide, cisplatin, dacarbazine were tested on five different human melanoma 
cell lines (HTB-71, M88, M102, M131, M134) for their effect on CCL5, CXCL9 and 
CXCL10 production. (A) CCL5, CXCL9 and CXCL10 expression was measured by 
qRT-PCR in cells treated with either temozolomide (100μg/ml), cisplatin (10μg/ml), or 
dacarbazine (100μg/ml) for 72h. Data shows the fold-change in chemokine 
expression in drug-treated cells over control cells. (B) M102 cells were treated with 
increasing dose of temozolomide (0, 10, 20, 40, 60, 80, 100μg/ml) or cisplatin (0, 1.3, 
2.5, 5, 10μg/ml) for 72h and the expression of CCL5, CXCL9 and CXCL10 was 
measured by qRT-PCR. Comparisons were performed using two-way ANOVA. (C) 
Kinetics of CCL5, CXCL9 and CXCL10 expression in M102 cells at 6, 12, 24, 48, and 
72h after temozolomide (100μg/ml) and cisplatin (10μg/ml) treatment. Comparisons 
were performed using two-way ANOVA. (D) Total number of live cells were counted 
in drug-treated and control cells via trypan blue staining. Two-way ANOVA. (E) 
Concentrations of 40 different cytokines, chemokines, angiogenic factors, and growth 
factors in the supernatants of drug-treated and control cells were determined using 
multiplex immunobeads technology. (F) Data are presented as fold change in protein 
production from drug-treated cells compared to control cells. Only 
cytokines/chemokines with ≥ 9-fold increase in secretion after drug treatment and p-
value < 0.05 are represented from temozolomide treatment group. Results are 
representative of 3 independent samples analyzed. Mann-Whitney U test, one-tailed.  
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Table 3.3.1 – Production of various cytokines, chemokines, angiogenic and growth 
factors after chemotherapy drug treatment. 
 
 
Table shows the concentration of secreted factors in pg/mL ± SD from the 
supernatant of M102 human melanoma cells treated with chemotherapy drug or 
vehicle control. Secreted factors that were significantly upregulated after drug 
treatment are indicated in bold. ND = Not Detected; NA = Not Available. Data are 
representative of 3 independent samples analyzed. Mann-Whitney U test, one-tailed. 
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3.3.2 Enhanced expression of CCL5, CXCL9 and CXCL10 after 
chemotherapy is associated with tumor control and superior 
survival of melanoma patients 
In a recent study, we showed increased T cell infiltration in chemotherapy-
sensitive tumors of melanoma patients treated with dacarbazine (Nardin et al., 
2011). In this previous study, global transcriptome analysis was performed on 
35 cutaneous metastases resected before or after chemotherapy. A total of 13 
melanoma patients with stage III/IV disease were included. For each patient, 
one tumor was collected at inclusion, and one to four tumors from the same 
patient were analyzed after chemotherapy.  
 
Here, we now re-analyzed these data, asking whether there were any 
chemokine genes whose expression correlated with T cell infiltration. Among 
all the genes coding for chemokines, CCL5, CXCL9 and CXCL10 were the 
most significantly correlated with CD3z and CD8A expression, and were 
among the most significantly correlated with CD4 (Figure 3.3.2A; Appendix 2a 
and 2b). For genes coding for chemokine receptors, CXCR3 was the most 
significantly correlated with CD4 and CD8A expression. Next, the levels of 
expression of CD4 and CD8A were compared in three categories of tumor 
samples: those that expressed low levels of the three chemokines, those that 
expressed high levels of CCL5 or high levels of CXCR3 ligands, and those 
that expressed high levels of CCL5 and high levels of at least one CXCR3 
ligand. This comparison revealed a clear synergy between CCL5 and CXCR3 
ligands for T cell infiltration (Figure 3.3.2B).  
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To determine whether chemotherapy had any impact on chemokine 
expression, the expression of CCL5, CXCL9, CXCL10 and CXCR3 was 
compared in tumors before and after chemotherapy. As shown in Figure 
3.3.2C, while dacarbazine did not induce any significant changes in 
chemotherapy-resistant tumors, i.e. progressing lesions, an increase in CCL5, 
CXCL9 and CXCR3 expression was observed after treatment in 
chemotherapy-sensitive tumors (p-values = 0.018, 0.045 and 0.028, 
respectively). A similar trend was observed for CXCL10 (p-value = 0.08). This 
increase in chemokine expression was associated with enhanced T cell 
infiltration, as demonstrated by a significant increase in CD4 and CD8A 
expression in chemotherapy-sensitive tumors (p-values = 0.036 and 0.020, 
respectively; Figure 3.2.2D) Finally, Kaplan-Meier analysis showed that 
patients exhibiting enhanced chemokine expression after chemotherapy 
survived longer (p-value = 0.0002; HR = 35; Figure 3.2.2E). 
 
Taken together, these data show that chemotherapy induces enhanced 
expression of CXCR3 ligands and CCL5 in chemotherapy-sensitive tumors. 
Furthermore, increased expression of these chemokines translates into 
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Figure 3.3.2 – Enhanced chemokine expression in human melanoma skin tumors 
after chemotherapy correlates with increased T cell infiltration, tumor control and 
patient survival.  
A total of 35 cutaneous melanoma tumors from 13 stage III or IV patients were 
collected before and after chemotherapy and analyzed by gene expression 
microarray. (A) CD4 or CD8A expression correlates with CCL5, CXCL9, CXCL10 and 
CXCR3 expression in the tumors. Spearman correlation, one-tailed with Bonferroni’s 
correction for multiple testing. (B) The expression of CD4 and CD8A was compared 
between tumors with high or low expression of CCL5 and CXCR3 ligands. 0 – CCL5lo 
CXCR3 ligandslo; 1 – CCL5hi or CXCR3 ligandshi; 2 – CCL5hi and CXCR3 ligandshi. 
One-way ANOVA. (C and D) Intra-tumoral expression of CCL5, CXCL9 and CXCR3 
as well as CD4 and CD8A was compared between cutaneous tumors before (pre; 
n=13) and after chemotherapy (post; n=22). Tumors collected after treatment were 
divided into chemotherapy-resistant (CT-R) [n=12] or chemotherapy-sensitive (CT-S) 
[n=10]. Differential gene expression between tumor samples collected before 
treatment and chemotherapy-sensitive tumors was assessed by one-tailed t test on 
Log-transformed expression values. (E) Kaplan-Meier analysis of patient survival with 





































4.1 Development of a new spontaneous bioluminescent mouse 
melanoma model to monitor tumor growth and treatment 
responses  
4.1.1 Generation of a ret+/- luc+/- transgenic mouse  
 Most preclinical studies of potential therapies for melanoma are done using 
transplanted tumor models. While these models are relatively appropriate for 
imaging tumor growth, they fail to recapitulate the natural clinical course of 
melanoma in humans. Over the past decade, many attempts have been made 
to use transgenic approaches to generate mouse models of spontaneous 
melanoma [reviewed in (Larue and Beermann, 2007)]. These models are 
often clinically relevant, however, they are limited in the ability to monitor 
tumor burden in animals accurately, especially for microscopic, non-palpable 
tumors. For longitudinal monitoring of cutaneous tumors, central necrosis, 
ulceration, or treatment-induced apoptosis may not be fully accounted for by 
gross tumor measurements (Craft et al., 2005). To circumvent these issues, 
we now report the development of a new genetically driven mouse model that 
allows non-invasive monitoring of spontaneous primary melanoma tumor 
growth and metastases in vivo by bioluminescence imaging (BLI). This novel 
mouse model, to our knowledge, is the only spontaneous model of metastatic 
melanoma that allows monitoring of metastasis development in vivo.  
 
The use of optical imaging techniques for monitoring endogenous tumors can 
be achieved by the expression of a foreign gene in the tumors themselves. 
This is rather time-consuming and the feasibility of this technique has been 
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questioned primarily due to the immunogenicity of the foreign gene (Craft et 
al., 2005). Comparison of optical imaging techniques including BLI and FLI 
demonstrated that BLI is more sensitive than FLI in the detection of 
microscopic tumors due to lower tissue attenuation in BLI than in FLI. For FLI, 
tissues can absorb and scatter fluorescent light at both the excitation and 
emission level; while for BLI only the emission is subjected to attenuation 
since there is no excitation involved (Puaux et al., 2011). The effect of tissue 
attenuation is expected to be magnified for the imaging of visceral tumors 
compared to subcutaneous tumors due to the increased optical path through 
the tissues. Nevertheless, FLI has numerous other applications beyond the 
scope of this study, including fluorescent imaging of tumor cell mobility, 
invasion and angiogenesis (Puaux et al., 2011). In addition, FLI is the only 
imaging technology to give single cell resolution or even sub-cellular 
resolution in vivo (Puaux et al., 2011). In general, even though the resolution 
of optical imaging is not comparable to nuclear imaging techniques, recent 
advances have been made to enable signal collection in a three-dimensional 
plane. 
 
In the case of melanoma, the use of BLI to monitor transplanted tumor growth 
has been extensively reported over the past few decades. This includes the 
widely used B16 syngeneic mouse melanoma model (Craft et al., 2005) and 
the A375 xenograft human melanoma model, among others (Craft et al., 
2005). The method involves transfection in vitro and transplantation of cells in 
vivo, which are relatively simple procedures to perform. On the other hand, 
the use of BLI for monitoring spontaneous melanoma tumor growth and 
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metastases has not been reported. However, the development of 
spontaneous bioluminescent tumor model has been demonstrated for other 
types of cancers, including pituitary tumor (Vooijs et al., 2002), prostate 
adenocarcinoma (Liao et al., 2007), pancreatic cancer (Zhang et al., 2009), 
and mammary tumors (Goldman et al., 2011), indicating the feasibility of this 
approach in following autochthonous tumor growth. In these spontaneous 
bioluminescent tumor models, BLI effectively detected primary tumor 
development. Spontaneous metastases is absent in all the spontaneous 
models described, except for pancreatic cancer. In this model, primary 
pancreatic tumors metastasized to the intestines, liver and abdomen, but only 
a fraction of these metastatic tumors were detected by BLI (Zhang et al., 
2009). Here, by showing that the BLI is able to detect both primary tumors 
and spontaneous metastases in vivo, the Melucie model represents a major 
step forward in the refinement of transgenic melanoma models and provides a 
valuable tool for evaluating novel anti-melanoma therapies, especially those 
targeting the metastatic cascade.  
 
4.1.2 Bioluminescence imaging of spontaneous melanoma tumor 
development in ret+/- luc+/- mice 
We have shown that in the Melucie, BLI successfully detected primary eye 
tumors and spontaneous metastases with sensitivity and positive predictive 
values that were comparable to nuclear imaging techniques such as MRI or 
18FDG-PET. In vivo BLI permitted sensitive and quantitative assessment of 
cutaneous metastases, but it was less than ideal for the detection of visceral 
metastases. It, nevertheless, still provides a means to highlight and localize 
visceral metastases at necropsy.  
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For cutaneous tumors, it should be noted that not all of the tumors were 
visible by in vivo luciferase imaging. This observation could not be explained 
by the loss of Dct promoter activity which drives luciferase expression as 
down-regulation of Dct enzyme was not observed for both cutaneous and 
visceral metastases from RETAAD mice (Lengagne et al., 2008). Other 
possible explanations include quenching of the luciferase signal due to 
hypoxia or necrosis which limits the availability of ATP required for the 
luciferase enzymatic activity. Alternatively, these tumors could harbor 
mutations within the luciferase gene which affects the functionality of the 
luciferase enzyme. Currently, it remains to be investigated what is the lower 
limit of detection for cutaneous tumors in vivo. Others have reported detection 
of as few as 500 cells in C57BL/6 mice (Craft et al., 2005) and a single tumor 
cell in nude mice in vivo (Kim et al., 2010). However, no such details have 
been demonstrated for spontaneous bioluminescent tumor models. 
 
The strong correlation between detected photons and tumor weight both in 
vivo and ex vivo over a large dynamic range strongly support the notion that 
Melucie mice enables sensitive detection of tumor growth, stasis, regression 
or relapse. Although there was a remarkable correlation between BLI signal 
and tumor weight, the relationship was not linear. Low signal to mass ratios 
were observed for some tumors and this could be due to the presence of 
stromal cells or accumulated fluid in the tumors that contribute to the tumor 
mass, but not the signal. Alternatively, it could be due to quenching of the 
luciferase signal by hypoxia or necrosis. On the other hand, we have 
observed a few tumors with a higher signal to mass ratio, which possibly 
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reflects the rapid lost of fluid from these tumors after being harvested for ex 
vivo imaging. It is important to note that BLI detects only live tumors cells, and 
therefore, this technique is particularly suited to test the efficacy of various 
tumor therapies. 
 
Ex vivo imaging of selected organs from Melucie mice demonstrated tumor-
specific BLI signals with little or minimal background expression in control 
organs. Comparatively, the eyes displayed a higher luciferase signal 
compared to other organs in the Melucie and the same phenomenon was 
observed in control mice. This was most likely due to the presence of 
melanocytes in the choroid layer of the eyes. Since luciferase expression is 
driven by the Dct promoter and the Dct protein is present within melanocytes, 
we expected to detect background luciferase expression from the eyes of 
these mice. Interestingly, despite this, we were able to detect early, 
microscopic primary eye tumors in young mice by in vivo and ex vivo BLI 
before clinical detection of the primary tumor, highlighting the sensitivity of BLI 
in the detection of primary tumor onset in our model.  
 
For future studies, it will be interesting to investigate whether the luciferase 
signal correlate with the number of tumor cells and whether we are able to 
measure the proliferation rate of tumors in vivo by longitudinal measurements 
of the tumor BLI signals. In addition, a proof-of-principle experiment needs to 
be performed to demonstrate the feasibility of this model to monitor tumor 
responses to therapies.  
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Taken together, our data demonstrates the feasibility of this new model for 
non-invasive monitoring of spontaneous melanoma tumor development and 
metastasis in living mice. The ability to detect early primary tumors, to track 
the stochastic onset of metastatic tumors, and to perform longitudinal 
monitoring of spontaneous tumor progression in live mice permit matching of 
animals on the basis of tumor burden, thus circumventing the inter-animal 
variation caused by the stochastic nature of spontaneous tumor formation 
(Vooijs et al., 2002), and ultimately reducing the number of animals required. 
Furthermore, it provides both temporal and spatial information throughout 
experiments, instead of just providing endpoint data obtained by more 
conventional approaches. Therefore, we strongly believe that our Melucie 
model will serve as an invaluable tool for the in vivo evaluation of the efficacy 






4.2 Chemokines and T cell trafficking in mouse and human cutaneous 
melanoma 
In the second part of this work, we show that CCL5 and CXCR3 ligands are 
the main determinants of T cell infiltration into cutaneous melanoma tumors. 
Moreover, we show that chemotherapy induces expression of these 
chemokines in several human melanoma cell lines and that chemotherapy-
induced chemokine expression in human melanoma tumors correlates with T 
cell infiltration, tumor control and prolonged patients‟ survival (refer proposed 
























































































































































































































































































































































































































































































































































































































































































































































































































































































































4.2.1 Intra-tumoral T cell trafficking and tumor control in vivo 
While anti-tumor T cells are often detected in the blood of melanoma patients, 
this only rarely translates into favorable patient clinical outcome (Salcedo et 
al., 2006). This applies to spontaneous T cell responses and those induced by 
cancer vaccines; the vast majority of cancer patients undergoing therapeutic 
vaccination display enhanced anti-tumor T cell responses, but only a small 
percentage control their tumors (Klebanoff et al., 2011). Several explanations 
have been proposed for this apparent paradox, including local immune-
suppression, tumor immune-editing and escape from immune attack 
[reviewed in (Rabinovich et al., 2007)]. 
 
We addressed this question in the RETAAD model and found that the reason 
why T cells do not control cutaneous tumors in vivo is because they fail to 
traffic to these tumors. We had previously shown that cutaneous tumors are 
not immune edited (Lengagne et al., 2008): even if CD8+ T cells fail to impact 
the growth of cutaneous tumors in vivo, resected cutaneous tumors are 
recognized ex vivo by anti-melanoma T cells (Lengagne et al., 2004). 
Moreover CD8+ T cells retain their functionality in vivo since they control 
visceral metastases (Eyles et al., 2010).  
 
In this present study, we show that very few T cells infiltrate skin tumors in 
comparison to visceral tumors or transplanted B16 skin tumors. The few T 
cells that infiltrate skin tumors probably retain their functionality since their 
number correlates inversely with tumor size. Further support for this 
conclusion comes from the observation that the ratios of expression of T cell 
 163 
effector molecules (Gzmb, Prf1b, Ifng) and T cell markers (Cd3g, Cd4 and 
Cd8a) are not different between cutaneous tumors and visceral tumors. 
Finally, transfection of CXCR3 ligand and CCL5 in established cutaneous 
tumors results in increased T cell infiltration and reduced tumor growth. 
Therefore in this spontaneous model of melanoma, differential T cell 
trafficking is the main reason for the tissue-specific control of metastases. 
Importantly, we extended this finding to tumors from melanoma patients 
undergoing chemotherapy. In these patients, tumor control and prolonged 
survival are associated with increased T cell infiltration and expression of 
CXCR3 ligands and CCL5.  
 
Taken together, our data clearly shows that homing of T cells with effector 
potential to the target tumor tissue is a prerequisite for its control or rejection 
by T cells, and suggests that local factors within the tumor microenvironment 
are major determinants of effective T cell trafficking to the tumors. 
   
4.2.2 Chemokines and T cell recruitment to tumors 
Chemokines play a critical role in determining the fate of the developing tumor 
by regulating the migration of different leukocyte subtypes into tumors. By 
transplanting B16 skin tumors in RETAAD mice, we identified a panel of 6 
chemokines associated with superior T cell infiltration into B16 skin tumors, 
including CCL2, CCL3, CCL4, CCL7, CXCL9 and CXCL10. In fact, the two 
most differentially expressed chemokines, CXCL9 and CXCL10, are both 
ligands for the chemokine receptor CXCR3. As our data clearly demonstrate a 
differential, selective and strong expression of CXCL9 in the tumor, we 
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decided to focus on CXCL9 as a therapeutic target for over-expression in 
RETAAD cutaneous tumors.  
 
Further support for the use of CXCL9 comes from the analysis of chemokine 
receptor expression on peripheral blood T cells, in which the cognate 
chemokine receptor for CXCL9, i.e. CXCR3, was found to be expressed by 
most circulating T cell subsets. Transfection of CXCL9 into cutaneous tumors 
augmented T cell infiltration and increased anti-tumor activity. 
Characterization of the CXCL9-recruited T cells demonstrated that > 90% of 
the infiltrated T cells were of the activated phenotype and T cell effector 
molecules were elevated in treated tumors, suggesting the recruitment of T 
cells with type 1 polarized/cytotoxic functions. Therefore, our results provide 
“proof-of-concept” that over-expression of CXCL9 within the cutaneous tumor 
microenvironment redirects circulating CXCR3+ T cells into the tumors. 
Nevertheless, we cannot exclude that other chemokines with lymphocyte 
attractant properties might be additionally involved in TIL recruitment. 
Exhaustion of tumor-specific CD8+ T cells in metastases of late-stage 
melanoma patients has been reported recently (Baitsch et al., 2011). In our 
study, further experiments should be performed to determine the phenotype 
and antigen-specificity of the infiltrating T cells in cutaneous melanoma after 
treatment. Such studies are technically challenging, since tumor-specific T 
cells are rare and difficult to isolate for ex vivo analysis. However, the 
emergence of „single-cell biology‟ (Bendall et al., 2011) may ultimately lead to 
comprehensive characterization of small cell numbers, even down to the 
single cell level.  
 165 
 
We have shown that CXCL9 promotes T cell infiltration into cutaneous 
melanoma, most probably via interactions with CXCR3 expressed on 
circulating T cells. CXCR3 has two other known ligands, i.e. CXCL10 and 
CXCL11. We postulate that CXCL10 may function in the same way as CXCL9, 
since CXCL10 was also associated with high endogenous T cell infiltration in 
B16 skin tumors. However, the role of CXCL11 is less obvious. Although all 
three chemokines bind to CXCR3, and have been shown to attract activated T 
cells in vitro (Stanford and Issekutz, 2003) and in vivo (Hensbergen et al., 
2005; Pertl et al., 2001; Tannenbaum et al., 1998; Walser et al., 2007), 
chemokine redundancy may not necessarily be operative in vivo (Groom and 
Luster, 2011). For example, several reports have demonstrated that the three 
CXCR3 ligands can collaborate (Yoneyama et al., 2002), and even compete 
or antagonize each other in vivo (Rosenblum et al., 2010). Thus, further 
experiments are required to clarify the exact roles of the other CXCR3 ligands 
in T cell recruitment into cutaneous melanoma in vivo. In addition to the 
ligands, the chemokine receptor CXCR3 is also known to be expressed by 
other immune cells, such as NK cells and dendritic cells. Although NK cells 
are not the focus of this study, it is possible that NK cells are recruited by 
CXCL9, leading to tumor cell killing. 
 
In view of the critical roles of chemokines in mediating T cell recruitment to 
cutaneous melanoma, we were interested to know whether the differential T 
cell trafficking between visceral and cutaneous melanoma could be explained, 
in part, by differences in intra-tumor chemokine milieu. To do this, we 
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compared the chemokine expression profiles of visceral and cutaneous 
metastases using low-density PCR array. Four chemokine genes, Ccl5, Ccl20, 
Ccl22, and Ccl24, and five chemokine receptor genes, Xcr1, Cxcr5, Ccr6, 
Ccr7 and Ccr8, were differentially expressed with greater expression in 
visceral tumors. Indeed, this data concurs with our finding that poor infiltration 
of T cells into cutaneous melanoma is due to lack of expression of T cell 
chemoattractants. Interestingly, the panel of chemokines differentially 
expressed between visceral and cutaneous tumors was distinct from those 
between transplanted and autochthonous cutaneous tumors, showing that 
different chemokines are involved in lymphocyte homing to different target 
tissues. As lymphocyte trafficking to tumor tissues is a tightly regulated 
process mediated by a complex array of adhesion molecules, chemokine 
signals and proper vasculature, it is possible that factors other than 
chemokines could account for the differential T cell trafficking between 
visceral and cutaneous tumors.  
 Several correlation studies have highlighted the importance of CXCR3 
ligands and CCL5 in the progression of cutaneous melanoma. Harlin et al 
identified several chemokines (including CCL2, CCL3, CCL4, CCL5, CXCL9 
and CXCL10) whose expression correlate with CD8+ T cell infiltration, but this 
study did not distinguish between chemokines that attract T cells and those 
that are produced by T cells (Harlin et al., 2009). In primary malignant 
melanoma, marked infiltration of T cells was observed exclusively in areas 
with strong CXCL9 and to a lesser extent CXCL10 expression (Kunz et al., 
1999). In the present study, by transfecting mouse tumors and analyzing the 
expression of the corresponding chemokine receptor in the blood, we could 
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establish a causal relationship between chemokine expression and T cell 
infiltration. 
 
Expression of the chemokine receptor CXCR3 by circulating memory T cells 
in melanoma patients with stage III disease has been shown to correlate with 
prolonged survival (Mullins et al., 2004). IFN-α, a known inducer of CXCL9 
and CXCL10, is approved for the treatment of high risk (stage IIb-III) 
cutaneous melanoma (Hauschild et al., 2008; Stadler et al., 2006). Based on 
the data presented in this study, it is tempting to speculate that CXCR3-ligand 
induction participates in IFN-α anti-melanoma activity. A recent study 
demonstrated increased plasma level of CXCL10 following IFN-α treatment in 
melanoma patients. However, it is not known whether this increase in 
CXCL10 is important for in vivo trafficking of CD8+ effector T cells to tumor 
targets (Mohty et al., 2010). In another study, expression of CXCL10 by 
melanoma patients‟ PBMC was reported to correlate with tumor control 
(Antonicelli et al., 2011). 
 
Interestingly, CXCR3 expression by cancer cells in cutaneous melanoma 
correlates negatively with lymphocyte infiltration (Monteagudo et al., 2007). 
The mechanism underlying this correlation is unclear but the present study 
suggests that cancer cells expressing CXCR3 might escape the immune 
response by competing for chemokines able to attract T cells. Expression of a 
non-functional variant of CCR5 results in decreased survival of melanoma 
patients receiving immunotherapy (Ugurel et al., 2008).  
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In addition to melanoma, CXCR3 ligands have also been involved in other 
types of cancer. For example, in colorectal cancer, expression of CXCL9, 
CXCL10 and CX3CL1 has been shown to correlate with prolonged disease-
free survival (Mlecnik et al., 2010). In Ewing sarcoma, CXCL9, CXCL10 and 
CCL5 expression in the tumor microenvironment correlates with CD8+, but not 
CD4+ T cell infiltration (Berghuis et al., 2011). Expression of CXCL10 and 
CCL5 within the tumors of hepatocellular carcinoma patients correlates 
positively with NK and CD8+ T cell densities and patient survival as well as 
negatively with tumor cell proliferation (Chew et al., 2011). None of these 
studies established a causal relationship between chemokine expression and 
T cell recruitment and most mouse studies addressing this question used 
transplanted tumor models, which as shown here for B16, may behave very 
differently than spontaneous tumors. 
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4.2.3 Chemokine synergy in immune cell recruitment to tumors 
The present study also revealed a striking synergism between CXCR3 ligands 
and CCL5 in attracting T cells into melanoma tumors. Synergistic interaction 
between chemokines has been observed in both human and mouse tumors. 
At this stage, the exact mechanism accounting for this synergy is unclear 
since circulating RETAAD T cells express very low levels of CCL5-receptors, 
i.e. CCR1, CCR3 and CCR5. In fact, less than 2% of the CD8+ T cells in the 
RETAAD mice express CCL5 receptors. Transfection of Ccl5 did not enhance 
Cxcl9 expression in the tumor, and transfection of Ccl5 alone has no effect on 
T cell attraction.  
 
However, we did observe an increased percentage of CD4+ and CD8+ T cells 
expressing CCR5 among the TIL, suggesting either that CCR5-expressing T 
cells are preferentially attracted into the tumor or that upon infiltration, T cells 
upregulate CCR5. We propose that intra-tumoral expression of Ccl5 might 
facilitate the retention of CCR5-expressing T cells, thereby augmenting the 
percentage of CCR5+ TIL. In fact, CCR5 has been reported to play a role in T 
cell retention at the tumor site (Franciszkiewicz et al., 2009). Although we 
could not test this hypothesis in melanoma patients, we did find that intra-
tumoral expression of CXCR3 ligands and CCL5 in chemotherapy-treated 
tumors does lead to a synergistic increase in T cell infiltration. Since the 
chemokine CCL5 is also expressed in RETAAD visceral metastases, we 
postulate that CCL5 could synergize with other chemokines expressed within 
the tumors to mediate T cell recruitment into the tumors. 
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The cooperative action of chemokines in immune cell recruitment has been 
demonstrated mostly in vitro. Examples include neutrophils (Gijsbers et al., 
2005; Gouwy et al., 2004; Gouwy et al., 2002; Struyf et al., 2001), interferon-
producing cells/plasmacytoid dendritic cells (IPCs/pDCs) (Krug et al., 2002; 
Vanbervliet et al., 2003), dendritic cells, B cells and naïve T cells (Paoletti et 
al., 2005), T cells (Sebastiani et al., 2005), monocytes (Gouwy et al., 2008) 
and PBMCs (Mellado et al., 2001b). Synergistic interactions between 
chemokines have also been shown in vivo albeit in limited cases. Two studies 
demonstrated synergistic chemokine interactions in neutrophil recruitment 
(Struyf et al., 2005; Zwijnenburg et al., 2003), while only one such study on T 
cells has been reported (Stanford and Issekutz, 2003) although the combined 
chemotactic effect in this study was rather additive in nature. Chemokine 
synergism in T cell recruitment to tumors in vivo has not been reported thus 
far. 
 
The molecular basis for the synergistic interactions between chemokines has 
been progressively studied in the past few years, although not yet been 
elucidated. Several proposed mechanisms include formation of chemokine 
heterodimers (Paoletti et al., 2005), co-expression of multiple chemokine 
receptors (Gouwy et al., 2004; Krug et al., 2002; Vanbervliet et al., 2003), and 
synergy between mediators at the post-receptor binding level (Mellado et al., 
2001b). Further research is warranted to better understand the molecular 
mechanisms involved in the synergy between chemokines in order to fine 
tune the immune response for tumor therapy. In addition, further studies could 
explore the combination of chemokines and cytokines to recruit T cells and 
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promote local expansion and activation, a term referred to as the “attraction-
expansion paradigm” (Ruffini et al., 2007). 
 
Collectively, our study is the first to demonstrate synergy between 
chemokines in T cell recruitment into tumors in vivo in mice, and possibly in 
humans. Synergy between pro-inflammatory chemokines may be an 
important phenomenon to induce an adequate migratory response in vivo to 
sites of inflammation or tumors. Since multiple chemokines are often co-
produced by various cell types within the tumor microenvironment, synergy 
between chemokines is biologically relevant and physiologically and 
pathologically important in a broad context.  
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4.3 Chemotherapy and the immune response 
Chemotherapeutic drugs have been selected for their capacity to induce 
apoptosis in tumor cell lines, regression of transplanted tumors in animal 
models, and clinical responses in cancer patients (Herr and Debatin, 2001; 
Tiligada, 2006; Zhang and Herlyn, 2009; Zitvogel et al., 2008). 
Chemotherapies are probably acting, in part, through cell autonomous 
mechanisms. In addition, the immune system may contribute to chemotherapy 
efficiency. The concept of immunogenic chemotherapy has been recently 
proposed to describe compounds which rely on enhanced anti-tumor immune 
response to induce tumor regression (Zitvogel et al., 2011). For example, 
anthracyclines and platinum derivatives induce calreticulin exposure and 
release of danger signals such as HMGB1 or ATP, which activate dendritic 
cells, thereby stimulating the anti-tumor immune response (Obeid et al., 2007). 
DNA damaging agents used in cancer chemotherapy activate the DNA 
damage response pathway and trigger tumor cells to upregulate NKG2D 
ligands, which are recognized by innate immune cells (Gasser et al., 2005).  
 
4.3.1 Chemotherapy induces chemokine expression in tumor cells 
The present study provides evidence for a novel (third) mode of action in 
which some chemotherapeutic drugs could work by inducing chemokine 
expression and promoting T cell infiltration into the tumor. We provide direct 
evidence both in vitro using human melanoma cell lines, as well as in vivo in 
melanoma patients treated with chemotherapy. In vitro, we show that 
dacarbazine, cisplatin and temozolomide induce expression of T cell attracting 
chemokines in several melanoma cell lines. Transcription of CCL5, CXCL9 
 173 
and/or CXCL10 was induced in all tested cell lines 72 hours after drug 
treatment, even though each cell line displayed a unique profile of response to 
the chemotherapeutic drugs. Dacarbazine, which is widely used to treat 
advanced melanoma, gave variable results, most likely due to the fact that it 
needs to be metabolized via a reaction that is unable to occur efficiently in 
vitro (unlike in vivo, where it takes place in the liver). We therefore focused on 
cisplatin and temozolomide, which has the same active metabolite as 
dacarbazine and is also used for the treatment of melanoma.  
 
Both cisplatin and temozolomide are able to inhibit DNA replication and 
transcription leading to tumor cell death. In our study, tumor cell death was 
observed 48 hours after cisplatin (10µg/mL) treatment and 48-72 hours after 
temozolomide (100µg/mL) treatment in vitro. To preclude that the expression 
of chemokines was due to an indirect effect of tumor cell death, time course 
experiments were performed. Our results showed that under most 
experimental conditions tested, transcription of the chemokine genes 
preceded cell death, indicating clearly that the increased expression of 
chemokines is a direct effect of chemotherapy drugs. 
 
Secretion of the chemokines in the culture medium was verified for one of the 
cell lines. The effect of chemotherapy drug on chemokine induction was highly 
specific since out of 48 soluble factors analyzed, only 5 chemokines and 1 
chemokine-like factor were significantly induced by temozolomide; while only 
2 chemokines and 1 chemokine-like factor were induced by cisplatin. 
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Production of other soluble factors including growth factors, angiogenic 
factors and cytokines was not affected after drug treatment. 
  
4.3.2 Chemotherapy-induced chemokine expression triggers T cell 
infiltration, improves tumor control, and prolongs patient survival 
Chemotherapy is a standard treatment of metastatic melanoma but it only 
induces clinical responses in about 20% of melanoma patients (Bajetta et al., 
2002). Even in patients who responded to chemotherapy, mixed responses 
are frequently observed (Bajetta et al., 2002), but the reason for this variability 
is not clear.  
 
In our limited cohort, tumor regression or stabilization was observed in 5 out 
of 13 patients and 10 out of 22 tumors resected after chemotherapy. 
Remarkably, enhanced expression of CCL5, CXCL9 and CXCL10 after 
chemotherapy correlated with increased T cell infiltration and tumor response. 
Most importantly, prolonged patient survival was associated with enhanced 
chemokine expression after chemotherapy. Therefore, our data clearly 
demonstrates that human melanoma tumors, in which chemotherapy induces 
chemokine expression and T cell infiltration, are more likely to be controlled. 
These findings could explain the mixed responses frequently observed in 
patients after chemotherapy. 
 
Chemotherapies are known to alter cancer cell transcriptome [reviewed in 
(Hsu et al., 2002)]. By damaging the tumor and stimulating a wound healing 
response, chemotherapies may induce epithelial-mesenchymal transition and 
favor the outgrowth of cells with higher motility and invasiveness (Rosano et 
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al., 2011); it may also select drug-resistant cells with stem cell and 
metastasis-initiating properties (Ahmed et al., 2010). Levina et al previously 
reported that in vitro treatment of some human cancer cell lines with 
doxorubicin or cisplatin induces expression of several cytokines, chemokines 
and growth factors which protect the cancer cells from drug-induced apoptosis 
(Levina et al., 2008). These previous reports identified cancer cell alterations 
that limit chemotherapy-induced cell death. The present study, by showing 
that chemotherapy can alter cancer cell phenotype in a way which favourably 
impact immune cell trafficking to the tumor, reveals a novel mechanism of 
action of chemotherapy.  
 
A limitation of the present study is that a direct functional link could not be 
tested with the available patients‟ material. Several important questions could 
not be addressed. One such example is the inability to perform kinetics 
experiments in humans. Therefore, it is not possible to know the timing at 
which the chemokines are being produced after chemotherapy treatment and 
whether the chemokine production is at an optimal level. In addition, we could 
not address the question of when T cells start to infiltrate into the tumors, i.e. 
before or after chemotherapy.  
 
The use of preclinical models is tremendously beneficial to unequivocally test 
the hypothesis that induction of intra-tumor chemokines in vivo after 
chemotherapy can induce effective T cell infiltration, leading to tumor control. 
The development of a new transgenic Melucie model of spontaneous 
melanoma will serve as an important tool to allow us to provide the direct 
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functional links by investigating whether (1) cisplatin or temozolomide can 
induce CXCR3 ligands and Ccl5 expression from tumor cells in vivo, (2) T cell 
infiltration into tumors and tumor regression are significantly increased in 
chemotherapy-treated mice compared to control mice, and (3) the efficacy of 
chemotherapy can be blocked by antagonists or blocking antibodies against 
the chemokines (i.e. CXCR3 ligands and CCL5) or the chemokine receptors 
(i.e. CXCR3 and CCR5) involved.  
 
4.3.3 Proposed mechanisms of chemotherapy-induced intratumoral 
chemokine expression 
Chemotherapy drugs have been reported to induce chemokine expression in 
tumor cells (Darst et al., 2004; Geller et al., 2010; Lev et al., 2004; Levina et 
al., 2008; Niiya et al., 2003). However, the exact mechanism(s) of 
chemotherapy-induced chemokine expression in cancer cells is not known. 
Levina et al reported activation of various transcription factors including NF-κB, 
AP-1, AP-2, ATF-2, CREB, HIF-1, STAT-1, STAT-3, and STAT-5 after 
doxorubicin treatment on tumor cells, and activation of these transcription 
factors paralleled the upregulation of IL-6, IL-8, bFGF, G-CSF, CCL2 and 
CCL5 gene expression (Levina et al., 2008). However, the authors merely 
demonstrated an association, and not a causal relationship between 
transcription factor activation and induction of chemokine expression. No 
mechanisms were proposed. Moreover, it is unclear whether a less than two-
fold increase in activated transcription factors is sufficient for the induction of 
more than 15-fold expression of some of the cytokines/chemokine genes.   
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In another study, Lev and colleagues proposed that upregulation of Raf-Mek-
Erk pathway was partially responsible for the over-expression of IL-8 and 
VEGF in dacarbazine-resistant tumor cells, and that inhibition of activated 
Mek rendered the cells more sensitive to dacarbazine (Lev et al., 2004). If the 
Raf-Mek-Erk pathway is involved in the upregulation of IL-8 and VEGF 
proposed by the authors, inhibition of pMek should result in downregulation of 
these cytokines. However, the authors did not demonstrate this in their study. 
Based on their results, it is likely that the Raf-Mek-Erk pathway is involved in 
cell proliferation and survival, rather than the induction of 
chemokines/cytokines.  
 
As chemokine production is regulated via the activation of transcription factors 
(Karin, 2006; Richmond, 2002), it is important to first determine which 
transcription factors are involved in driving the expression of these chemokine 
genes. Multiple transcription factor binding sites are present upstream of the 
chemokine genes CCL5, CXCL9 and CXCL10. For example, the promoters of 
CXCL9 and CXCL10 contain the interferon–stimulated response element 
(ISRE) sequences. In fact, CXCL9 and CXCL10 have been shown to be 
produced by a variety of interferons, including IFN-α, IFN-β and IFN-γ 
(Antonelli et al., 2010). IFN-γ, compared to IFN-α and IFN-β, is the most 
potent inducer of CXCL9 and CXCL10 (Antonelli et al., 2010). In addition, NF-
κB binding sites are also present in the promoters of all three chemokine 
genes. Interestingly, a direct binding site for p53 is present in the promoter 
region of CXCL9 (Table 4.3.1). It is, therefore, possible that more than one 
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pathway are simultaneously activated, leading to the induction of chemokine 




Table 4.3.1 – Transcription factor binding sites in the promoters of CCL5, CXCL9 and 
CXCL10 chemokines genes. 
 
Transcription factor CCL5 CXCL9 CXCL10 
AhR  Y Y 
AP-1 Y   
C/EBPβ Y   
c-Jun Y   
c-Rel Y  Y 
IRF-1 Y Y  
IRF-2  Y Y 
IRF-7A Y   
JunB   Y 
NF-κB Y Y Y 
NF-κB1 Y Y Y 
p53  Y  
PPARγ1 Y   
PPARγ2 Y   
STAT1   Y 
STAT1α   Y 
STAT1β   Y 
STAT5A   Y 
 
Table shows the list of transcription factor binding sites identied in the gene promoter 
regions of the chemokines genes CCL5, CXCL9 and CXCL10 as predicted by 
SABiosciences' Text Mining Application and the UCSC Genome Browser. AhR – aryl 
hydrocarbon receptor; AP-1 – activator protein 1; C/EBP – CCAAT-enhancer-binding 
proteins; IRF – interferon regulatory factor; NF-κB – nuclear factor kappa-light-chain-
enhancer of activated B cells; NF-κB1 – encodes a subunit of the transcripton factor, 
NF-κB; PPAR – peroxisome proliferator-activated receptors; STAT – signal 
transducers and activators of transcription. The presence of a transcription factor 
binding site was indicated by the letter “Y”. 
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In our study, we propose that two major mechanisms could explain the 
induction of chemokines in chemotherapy-treated cancer cells (Figure 4.3.1). 
In the first proposed mechanism, we postulate that endogeneous components 
derived from dying cancer cells, termed damage-associated molecular 
patterns (DAMPs), such as RNA and DNA, can lead to type I IFN production. 
RNA released by necrotic or apoptotic cancer cells, could be sensed by TLR3 
(toll-like receptor 3) (Beg, 2002; Cavassani et al., 2008; Lim and Wang, 2011). 
TLR3 signals via the adaptor protein, TRIF, which activates the kinase TBK1 
(tank-binding kinase 1) and IRF3, leading to the production of type I IFNs 
(Takaoka and Taniguchi, 2008; Tow, 2010). In addition, TRIF associates with 
the mitochondria-localized adaptor molecule, RIP1, to activate NF-κB for the 
synthesis of proinflammatory cytokines (Tow, 2010). Chemotherapy drugs 
could also induce cytoplasmic DNA (Sumantran et al., 1995), which can be 
sensed by the cytosolic DNA sensors, DNA-dependent activator of interferon 
regulatory factors (DAI) or as yet an unknown cytosolic DNA receptor, DNA–
RX, which trigger induction of type I IFN genes through TBK1-mediated and 
IRF3-mediated signalling (Trinchieri, 2010).  
 
The second proposed mechanism is that chemotherapy drugs can induce 
DNA damage, leading to the activation of the DNA damage response pathway 
proteins, such as the protein kinases ATM (ataxiatelangiectasia mutated), 
CHK1/CHK2 (checkpoint kinase 1 or 2), and the transcription factor p53 
(Zitvogel et al., 2008). Activated p53 can result in downstream activation of 
NF-κB through H-Ras, MEK1, and IKKa/b (Armstrong et al., 2006) or via the 
JNK (c-Jun NH2-terminal kinase) pathway (Wu, 2004). Activated p53 can also 
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contribute to interferon response via transcriptional activation of IRF-9 and the 
enhancement of IFN signalling (Munoz-Fontela et al., 2008). In addition, IRF-1 
(interferon regulatory factor-1) has also been reported to be induced via the 
ATM signalling pathway in response to genotoxic stress (Pamment et al., 
2002).  
 
Figure 4.3.1 – Proposed models for the induction of chemokine expression from 
tumor cells after chemotherapy. 
Chemotherapy could induce chemokine expression from tumor cells via at least two 
different mechansims that result in the same downstream responses. In the first 
proposed mechanism, endogenous components from dying cells (RNA and/or DNA) 
could be sensed by nucleic sensors (TLR3 or DAI/DNA-RX), leading to downstream 
activation of the transcription factor, NF-κB, and the production of type I IFN. In the 
second proposed model, DNA damage induced by chemotherapy activates the DNA-
damage response pathway, resulting in downstream activation of NF-κB and IFN 
signalling. The corresponding transcription factor binding sites have been identified in 
the promoters of the CCL5, CXCL9 and CXCL10 chemokine genes. 
 
Proposed model 1 Proposed model 2 
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To identify the pathway(s) involved, a multi-pronged approach including gene 
microarray and proteomic analyses will be performed. As we observed 
different kinetics in the induction of expression of these chemokine genes, it 
will be of interest to analyze tumor cells treated with chemotherapy at different 
time points. Activation of signal transduction pathways and transcription 
factors will be evaluated using western blot analyses and validated by 
microarray analyses (by looking at enrichment of transcription factor target 
genes). In addition, microarray analyses will serve to provide a 
comprehensive list of immediate early genes that may be involved in 
triggering the induction of chemokine expression after chemotherapy 
treatment. Furthermore, it provides insights as to whether chemotherapy-
induced production of chemokines is a sequential event (Zitvogel et al., 2008).  
 
Final proof-of-concept experiments should be performed to determine whether 
blocking the activation of pathways in these cells affects the response to 
chemotherapy treatment. It will also be interesting to determine whether these 
findings can be extended to more than one melanoma line. As shown 
previously, not all the melanoma cell lines included in our study respond to 
chemotherapy drug treatments by upregulating chemokine expression. Thus, 
it will be of interest to understand whether the basis of this „non-
responsiveness‟ could be in part due to defects in the activation of certain 
pathway(s). Finally, preliminary data obtained from this proposed study in 
cultured cells will need to be validated in patients by directly studying tumor 
tissues obtained before and after chemotherapy treatment. 
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4.3.4 Implications for the treatment of metastatic melanoma patients 
Melanoma is a highly heterogeneous disease and it has recently become 
clear that indeed, there are many molecular subtypes of melanoma that may 
be associated with clinical responses to defined therapeutic strategies. This 
has led researchers to probe the tumor microenvironment for local factors that 
may determine the clinical outcome to such treatments. The molecular 
markers associated with responses to immunotherapeutic treatments in 
melanoma have been recently reviewed (Gajewski, 2011; Sznol, 2011). 
 
For example, the identification of an „inflamed‟ signature within the tumor 
microenvironment (that includes T cells and chemokines) by gene expression 
profiling is associated with favorable clinical benefit in recent cancer vaccine 
trials in advanced melanoma and non-small cell lung cancer (NSCLC) 
patients (Gajewski et al., 2009; Louahed et al., 2008; NCT00480025, [updated 
02.06.2011]). In addition, the expression of defined tumor antigens is 
associated with improved disease-free interval (DFI) in patients treated with 
antigen-specific vaccines (i.e. MAGE-A3 Phase II vaccine trial in MAGE-A3-
positive NSCLC patients) (Brichard and Lejeune, 2008). Furthermore, 
activating mutations in B-raf or c-kit are associated with clinical responses to 
the specific kinase inhibitors, PLX4032 and imatinib respectively and 
prospective Phase II and/or Phase III clinical trials are ongoing to demonstrate 
overall survival benefit (Gajewski, 2011). 
 
In addition, several emerging molecular markers involved in signal 
transduction pathways have been identified in melanoma patients that may 
 184 
predict clinical responses to specific immunotherapies and thus facilitate 
patient-specific therapy in subsets of melanoma patients harboring such 
biomarkers. This includes active Notch pathway, activating mutations in PI3 
kinase/loss of PTEN suppressor, activating mutations in ErbB4, activating 
mutations in c-met, expression of stabilized β-catenin, and constitutive 
activation of Stat3, which are potential biomarkers for new targeted agents 
[reviewed in (Gajewski, 2011)]. All these observations clearly show that 
melanoma patients are highly heterogeneous in their tumor subtypes and this 
may render them susceptible to the therapeutic effect of one treatment 
modality and not the other.  
 
The fact that clinical responses to immunotherapeutic agents may be 
predicted based on the molecular biomarkers present in the tumors of the 
patients raises the question of whether conventional chemotherapy drugs 
used for the treatment of metastatic melanoma patients might also be 
associated with a predictive biomarker. Chemotherapy drug resistance in 
melanoma is well known and several mechanisms have been postulated 
including dysregulation of apoptotic pathways, defects in drug transport, 
detoxification, and enhanced DNA repair (Lev et al., 2004).  
 
Indeed, responses to the alkylating agents dacarbazine and temozolomide is 
predicted to be inversely correlated with the expression of DNA repair 
enzymes, such as 06-methylguanine methyltransferase (MGMT). While 
silencing of MGMT has been associated with a favourable clinical response of 
glioblastoma to temozolomide plus radiation (Hegi et al., 2005), the addition of 
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MGMT inhibitor 06-benzylguanine in melanoma failed to demonstrate any 
added clinical benefit (Gajewski et al., 2005). 
 
A recent report demonstrated the use of p53 functional status as a biomarker 
to predict response to neoadjuvant chemotherapy in patients with locally 
advanced head and neck squamous cell carcinoma (HNSCC) in the oral 
cavity (Perrone et al., 2010). In this study, 40% of patients with wild-type or 
partially functional p53 showed complete pathologic response to 
chemotherapy, compared to approximately 10% of those having non-
functional p53. While this study represents a step forward in risk stratification 
of patients and towards personalized therapy, many questions remain to be 
addressed (Mroz and Rocco, 2010). For example, it is unclear whether the 
functional/non-functional distinction is clearly superior to the simple 
mutated/nonmutated classification as not all the exons in p53 were screened. 
In addition, it is unknown whether the complete responses in the 
chemotherapy arm were confounded by the better surgical outcome in 
patients carrying wild-type p53. Most importantly, the exact functions of p53 in 
tumor biology and in mediating responses to chemotherapy in HNSCC remain 
unknown. At this moment, it is still too early to focus solely on p53 functional 
status as a biomarker of chemotherapy response and further experiments 
should be performed and followed up in clinical trials before it can be widely 
applied in clinical practice.  
 
Based on these earlier reports, it is imperative in our case to identify the 
pathway(s) in which chemotherapy induces chemokine expression in 
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melanoma, leading to downstream activation of immune defense mechanisms. 
We believe that elucidation of the pathway(s) involved and the identification of 
the pathway proteins could have tremendous advantages for improving the 
therapeutic success for melanoma patients. Firstly, it could potentially serve 
as a novel predictive biomarker for response to chemotherapy agents 
commonly used to treat metastatic melanoma patients. Secondly, it allows 
stratifying patients based on pathway expression and selection of patients 
such that only those most likely to benefit are subjected to chemotherapy 
treatment. Thirdly, it enables identification of patients whom are likely to gain 
from additional treatment with immunotherapy, i.e. combination 
chemoimmunotherapy.  
 
Patients with advanced metastatic melanoma are often treated with a 
combination of chemotherapy and immunotherapy, i.e chemoimmunotherapy. 
Combination treatments have been studied since the early 1990s (Khayat et 
al., 2002). Some reports have suggested that chemotherapeutic agents 
administered in combination with IL-2 or IFN-α, or both, can improve response 
rates (Legha et al., 1998; Richards et al., 1992) and increase the median 
survival of patients (Falkson et al., 1991). Based on these earlier reports, the 
use of chemoimmunotherapy is currently preferred in some institutions as a 
first-line treatment in advanced (stage IV) melanoma patients (Kadison and 
Morton, 2003; Keilholz and Gore, 2002). In contrast, a recent study suggests 
that adding IL-2 and IFN-α to a specific three-drug regimen of cisplatin, 
vinblastine, and dacarbazine did not prolong survival in a phase III trial (Atkins 
et al., 2008). Thus, the role of IL-2 and IFN-α in improving the response to 
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chemotherapy is still unresolved, and there is still lack of evidence to support 
the use of immunotherapy in conjunction with chemotherapy. 
 
Our findings that chemotherapy can directly enhance intra-tumor chemokine 
expression and positively impacts T cell infiltration, tumor control and patient 
survival raises great hope for combination therapies consisting of vaccines or 
adoptive lymphocyte transfer combined with chemotherapy. Therefore, 
identifying the intrinsic characteristics of tumor cells and the immunological 
characteristic of tumors may yield valuable information for the optimal design 
of chemo-immunotherapies for the treatment of melanoma. Furthermore, 
future studies should consider screening for chemotherapeutic products that 
are able to induce specific expression of T cell attracting-chemokines in 


































T cell infiltration is known to impact tumor growth and is associated with 
cancer patient survival. However, the molecular cues that favor T cell 
infiltration remain largely undefined. Therefore, unraveling the signals that 
control T cell infiltration into the tumors is, without doubt, a pre-requisite to 
improve the efficacy of cancer vaccines and adoptive T cell therapies.  
 
In the present study, using a genetically-engineered mouse model of 
melanoma, we identify CXCR3 ligands (CXCL9 and CXCL10) and CCL5 as 
the main determinants of T cell infiltration into cutaneous metastases. CXCR3 
ligands and CCL5 synergize to attract effector T cells into cutaneous tumors 
leading to enhanced anti-tumor activity. In addition, expression of these 
chemokines in tumors inhibits tumor growth.  
 
In melanoma patients, CXCR3 ligands and CCL5 are also up-regulated in 
chemotherapy-sensitive lesions following chemotherapy, and correlate with T 
cell infiltration, tumor control and patient survival. Mechanistically, we found 
that the chemotherapeutic agents commonly used to treat advanced 
melanomas (dacarbazine, temozolomide and cisplatin) induce specific 
expression of these T cell-attracting chemokines in several human melanoma 
cell lines in vitro.  
 
These data unravel a novel mechanism of the action of chemotherapy, in 
which chemotherapy treatment induces intra-tumoral expression of T cell-
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attracting chemokines, leading to anti-tumor immune responses. The 
combination of experiments performed in vitro and in vivo (using both 
spontaneous and transplanted model of melanoma, syngeneic and human 
melanoma cell lines, together with data from melanoma patients), provide a 
solid validation of the findings.  
 
The findings from this study are important as they may provide the basis for 
new therapeutic approaches to treat melanoma by identifying patients with an 
increased chance of response to conventional chemotherapies as well as 
combination chemoimmunotherapies. For future studies, we propose that 
identifying chemotherapeutic drugs that are able to induce the expression of T 
cell-attracting chemokines in cancer cells may represent a novel strategy to 
improve the efficacy of cancer immunotherapy. To this end, the generation of 
a new reporter mouse model of melanoma, Melucie, will serve as a useful tool 
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Appendix 1 – Sequence of the transgene used to generate the Dct-Luc mice. 
 
     1 CCTAGGCTTT TGCAAAAAGC TCGATTCTTC TGACACTAGC GCCACCATGA 
    51 TCGAACAAGA CGGCCTCCAT GCTGGCAGTC CCGCAGCTTG GGTCGAACGC 
   101 TTGTTCGGGT ACGACTGGGC CCAGCAGACC ATCGGATGTA GCGATGCGGC 
   151 CGTGTTCCGT CTAAGCGCTC AAGGCCGGCC CGTGCTGTTC GTGAAGACCG 
   201 ACCTGAGCGG CGCCCTGAAC GAGCTTCAAG ACGAGGCTGC CCGCCTGAGC 
   251 TGGCTGGCCA CCACCGGCGT ACCCTGCGCC GCTGTGTTGG ATGTTGTGAC 
   301 CGAAGCCGGC CGGGACTGGC TGCTGCTGGG CGAGGTCCCT GGCCAGGATC 
   351 TGCTGAGCAG CCACCTTGCC CCCGCTGAGA AGGTTTCTAT CATGGCCGAT 
   401 GCAATGCGGC GCCTGCACAC CCTGGACCCC GCTACCTGCC CCTTCGACCA 
   451 CCAGGCTAAG CATCGGATCG AGCGTGCTCG GACCCGCATG GAGGCCGGCC 
   501 TGGTGGACCA GGACGACCTG GACGAGGAGC ATCAGGGCCT GGCCCCCGCT 
   551 GAACTGTTCG CCCGACTGAA AGCCCGCATG CCGGACGGTG AGGACCTGGT 
   601 TGTCACACAC GGAGATGCCT GCCTCCCTAA CATCATGGTC GAGAATGGCC 
   651 GCTTCTCCGG CTTCATCGAC TGCGGTCGCC TAGGAGTTGC CGACCGCTAC 
   701 CAGGACATCG CCCTGGCCAC CCGCGACATC GCTGAGGAGC TTGGCGGCGA 
   751 GTGGGCCGAC CGCTTCTTAG TCTTGTACGG CATCGCAGCT CCCGACAGCC 
   801 AGCGCATCGC CTTCTACCGC TTGCTCGACG AGTTCTTTTA ATGATCTAGA 
   851 ACCGGTCATG GCCGCAATAA AATATCTTTA TTTTCATTAC ATCTGTGTGT 
   901 TGGTTTTTTG TGTGTTCGAA CTAGATGCTG TCGACCGATG CCCTTGAGAG 
   951 CCTTCAACCC AGTCAGCTCC TTCCGGTGGG CGCGGGGCAT GACTATCGTC 
  1001 GCCGCACTTA TGACTGTCTT CTTTATCATG CAACTCGTAG GACAGGTGCC 
  1051 GGCAGCGCTC TTCCGCTTCC TCGCTCACTG ACTCGCTGCG CTCGGTCGTT 
  1101 CGGCTGCGGC GAGCGGTATC AGCTCACTCA AAGGCGGTAA TACGGTTATC 
  1151 CACAGAATCA GGGGATAACG CAGGAAAGAA CATGTGAGCA AAAGGCCAGC 
  1201 AAAAGGCCAG GAACCGTAAA AAGGCCGCGT TGCTGGCGTT TTTCCATAGG 
  1251 CTCCGCCCCC CTGACGAGCA TCACAAAAAT CGACGCTCAA GTCAGAGGTG 
  1301 GCGAAACCCG ACAGGACTAT AAAGATACCA GGCGTTTCCC CCTGGAAGCT 
  1351 CCCTCGTGCG CTCTCCTGTT CCGACCCTGC CGCTTACCGG ATACCTGTCC 
  1401 GCCTTTCTCC CTTCGGGAAG CGTGGCGCTT TCTCATAGCT CACGCTGTAG 
  1451 GTATCTCAGT TCGGTGTAGG TCGTTCGCTC CAAGCTGGGC TGTGTGCACG 
  1501 AACCCCCCGT TCAGCCCGAC CGCTGCGCCT TATCCGGTAA CTATCGTCTT 
  1551 GAGTCCAACC CGGTAAGACA CGACTTATCG CCACTGGCAG CAGCCACTGG 
  1601 TAACAGGATT AGCAGAGCGA GGTATGTAGG CGGTGCTACA GAGTTCTTGA 
  1651 AGTGGTGGCC TAACTACGGC TACACTAGAA GAACAGTATT TGGTATCTGC 
  1701 GCTCTGCTGA AGCCAGTTAC CTTCGGAAAA AGAGTTGGTA GCTCTTGATC 
  1751 CGGCAAACAA ACCACCGCTG GTAGCGGTGG TTTTTTTGTT TGCAAGCAGC 
 243 
  1801 AGATTACGCG CAGAAAAAAA GGATCTCAAG AAGATCCTTT GATCTTTTCT 
  1851 ACGGGGTCTG ACGCTCAGTG GAACGAAAAC TCACGTTAAG GGATTTTGGT 
  1901 CATGAGATTA TCAAAAAGGA TCTTCACCTA GATCCTTTTA AATTAAAAAT 
  1951 GAAGTTTTAA ATCAATCTAA AGTATATATG AGTAAACTTG GTCTGACAGC 
  2001 GGCCGCAAAT GCTAAACCAC TGCAGTGGTT ACCAGTGCTT GATCAGTGAG 
  2051 GCACCGATCT CAGCGATCTG CCTATTTCGT TCGTCCATAG TGGCCTGACT 
  2101 CCCCGTCGTG TAGATCACTA CGATTCGTGA GGGCTTACCA TCAGGCCCCA 
  2151 GCGCAGCAAT GATGCCGCGA GAGCCGCGTT CACCGGCCCC CGATTTGTCA 
  2201 GCAATGAACC AGCCAGCAGG GAGGGCCGAG CGAAGAAGTG GTCCTGCTAC 
  2251 TTTGTCCGCC TCCATCCAGT CTATGAGCTG CTGTCGTGAT GCTAGAGTAA 
  2301 GAAGTTCGCC AGTGAGTAGT TTCCGAAGAG TTGTGGCCAT TGCTACTGGC 
  2351 ATCGTGGTAT CACGCTCGTC GTTCGGTATG GCTTCGTTCA ACTCTGGTTC 
  2401 CCAGCGGTCA AGCCGGGTCA CATGATCACC CATATTATGA AGAAATGCAG 



































































































































































































































































































































































































































































Appendix 2b – Microarray: Correlation between chemokine genes and CD3 
(Table A), CD4 (Table B), and CD8A (Table C) expression in resected 
cutaneous melanoma lesions from patients before and after chemotherapy. P-
values for multiple comparisons were adjusted using Bonferroni correction. 
 
 Table A Table B Table C 
